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Inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ulcerative colitis, is a chronic 
relapsing inflammatory disorder of the gastrointestinal tract. The current hypothesis suggests that 
IBD results from an exaggerated response of the mucosal immune system toward components of the 
luminal microbiota in genetically susceptible individuals. It is becoming increasingly evident that bile 
acids play an important role in the pathogenesis of IBD. Experimental data provide evidence that the 
intestinal bile acid profile is profoundly altered in IBD patients, which may be particularly important 
given the variable effects of different bile acids on intestinal epithelial cells, immune cells, and the 
gut microbiota. Previous work from our group and others has demonstrated that secondary 
hydrophilic 37-dihydroxy bile acids, such as ursodeoxycholic acid (UDCA) and its taurine conjugate 
tauroursodeoxycholic acid (TUDCA), exert cytoprotective effects in the intestine and protect against 
experimental colitis. The work presented in this doctoral thesis aimed to provide mechanistic insights 
into how secondary hydrophilic 3,7-dihydroxy bile acids (TUDCA and/or UDCA and 
glycoursodeoxycholic acid (GUDCA)) may contribute to inhibition of intestinal inflammation. 
In the first part of this thesis (chapter 3), we focused on the relationship between bile acid 
supplementation, the expression of enteric bile acid transporters and nuclear receptors, and the 
severity of intestinal inflammation. We first showed that CD patients with ileal involvement exhibit 
reduced expression of ileal bile acid transporters (the apical sodium-dependent bile acid transporter 
(ASBT), organic solute transporter (OST), and OST) and bile acid-activated nuclear receptors 
(farnesoid X receptor (FXR), pregnane X receptor (PXR), and vitamin D receptor (VDR)). Using Caco-2 
cells, an in vitro model for human small intestinal enterocytes, we demonstrated that tumor necrosis 
factor (TNF), which plays a central role in IBD, downregulated the mRNA expression of ASBT, OST, 
and OST. Gene expression levels of the nuclear receptors FXR, PXR, and VDR were also reduced 
when Caco-2 cells were exposed to TNF. The aforementioned genes showed a similar expression 
pattern in ileal tissue of TNFARE/WT mice, which spontaneously develop a chronic CD-like ileitis due to 
overexpression of TNF. Notably, these aberrant gene expression signatures closely resembled those 
observed in mucosal ileal biopsies from CD patients. We next demonstrated that co-incubating Caco-
2 cells with TUDCA partly prevented the TNF-induced downregulation of FXR, PXR, ASBT, and OST. 
Similarly, oral administration of TUDCA increased the expression of Fxr, Vdr, Asbt, and Ost in 
TNFARE/WT mice but not in wild-type mice. As TUDCA has been previously reported to exert 
therapeutic effects in murine colitis, these data prompted us to evaluate whether this secondary bile 




bile acid homeostasis. As anticipated, administration of TUDCA significantly reduced the 
inflammatory response in the distal ileum of TNFARE/WT mice. 
Intestinal dysbiosis is a typical hallmark of IBD and bile acids are modulators of the gut microbiota. 
Therefore, in the next part of this thesis (chapter 4), we studied and compared how UDCA and its 
taurine and glycine conjugates (TUDCA and GUDCA, respectively) influence the intestinal microbiota 
composition during experimental colitis in mice. First, we demonstrated that either of these three 
bile acid treatments equally improved clinical symptoms and inflammatory markers in acute colitis 
induced by dextran sodium sulfate. Analysis of the fecal microbiota by Illumina MiSeq sequencing 
revealed that bile acid therapy did not reverse changes in fecal microbial richness, species diversity, 
and bacterial load. However, UDCA and its taurine/glycine conjugates prevented colitis-associated 
dysbiosis at the phylum-level by normalizing the ratio between Firmicutes and Bacteroidetes, which 
was significantly increased in placebo-treated colitic mice. Furthermore, bile acid therapy increased 
the relative abundance of Clostridium cluster XIVa and Akkermansia muciniphila, anti-inflammatory 
bacterial species that are typically depleted in the dysbiotic IBD microbiota. Finally, we showed that 
orally administered UDCA and its taurine/glycine conjugates underwent significant biotransformation 
in vivo, resulting in a similar fecal bile acid pool. 
In conclusion, the results presented in this thesis contribute to the concept that secondary 
hydrophilic 3,7-dihydroxy bile acids represent an attractive treatment option for IBD which 
warrants further clinical investigation. Based on these, we initiated a pilot trial, designed to study the 
efficacy of UDCA (which is approved by the U.S. Food and Drug Administration for the treatment of 
primary biliary cirrhosis) to correct for intestinal microbiome and metabolomic changes and to 
induce remission in IBD patients. Preliminary results (chapter 5) showed that UDCA therapy 
normalized fecal levels of several metabolites that were significantly altered in quiescent IBD. This 






Inflammatoir darmlijden (inflammatory bowel disease, IBD), waaronder de ziekte van Crohn (Crohn’s 
disease, CD) en colitis ulcerosa, is een chronische terugkerende inflammatoire aandoening van het 
gastro-intestinaal stelsel. De huidige hypothese stelt dat IBD resulteert van een overdreven respons 
van het mucosale immuunsysteem tegenover componenten van de luminale microbiota in genetisch 
vatbare individuen. Het wordt steeds duidelijker dat galzouten een belangrijke rol spelen in de 
pathogenese van IBD. Experimentele gegevens tonen aan dat het intestinale galzoutenprofiel sterk is 
gewijzigd in IBD patiënten, wat vooral belangrijk is gezien de diverse effecten van verschillende 
galzouten op intestinale epitheelcellen, immuuncellen en de darmmicrobiota. Eerder onderzoek 
uitgevoerd door onze groep en anderen toonde aan dat secundaire hydrofiele 3,7-dihydroxy 
galzouten, zoals ursodeoxycholzuur (ursodeoxycholic acid, UDCA) en zijn taurine conjugaat 
tauroursodeoxycholzuur (tauroursodeoxycholic acid, TUDCA), een cytoprotectieve werking 
uitoefenen in de darm en bescherming bieden tegen experimentele colitis. Het werk dat wordt 
beschreven in deze doctoraatsthesis had als doel om mechanistische inzichten te verwerven in hoe 
secundaire hydrofiele 3,7-dihydroxy galzouten (TUDCA en/of UDCA en glycoursodeoxycholzuur 
(glycoursodeoxycholic acid, GUDCA)) bijdragen tot onderdrukking van darminflammatie.  
In het eerste deel van deze thesis (hoofdstuk 3) werd gefocust op de relatie tussen galzout 
toediening, de expressie van intestinale galzouttransporters en nucleaire receptoren, en de ernst van 
darminflammatie. Ten eerste toonden we aan dat CD patiënten met ileale aantasting een gedaalde 
expressie vertonen van ileale galzouttransporters (apical sodium-dependent bile acid transporter 
(ASBT), organic solute transporter (OST) en OST) en galzout-geactiveerde nucleaire receptoren 
(farnesoid X receptor (FXR), pregnane X receptor (PXR) en vitamine D receptor (VDR)). Aan de hand 
van Caco-2 cellen, een in vitro model voor humane dunne darm enterocyten, demonstreerden we 
dat tumor necrosis factor (TNF)welke een centrale rol speelt in IBD, de mRNA expressie van ASBT, 
OST en OST onderdrukte. Genexpressie niveaus van de nucleaire receptoren FXR, PXR en VDR 
waren eveneens gedaald wanneer Caco-2 cellen werden blootgesteld aan TNF. Bovengenoemde 
genen vertoonden een gelijkaardig expressiepatroon in dundarmweefsel van TNFARE/WT muizen, 
welke een spontane chronische ileitis ontwikkelen, lijkend op CD, ten gevolge van overexpressie van 
TNF. Interessant was dat deze afwijkende genexpressie sterk leek op deze die werd gezien in 
mucosale ileale biopten van CD patiënten. Vervolgens demonstreerden we dat co-incubatie van 
Caco-2 cellen met TUDCA de TNF-geïnduceerde onderdrukking van FXR, PXR, ASBT en OST 
gedeeltelijk tegenging. Orale toediening van TUDCA verhoogde evenzeer de expressie van Fxr, Vdr, 




TUDCA therapeutische effecten teweeg brengt bij colitis in muizen, evalueerden we vervolgens of dit 
secundaire galzout een gelijkaardige doeltreffendheid vertoont in een muismodel voor CD ileitis, 
geassocieerd met een verstoorde galzout homeostase. Zoals verwacht resulteerde orale toediening 
van TUDCA in een significant verminderde inflammatoire respons in het distale ileum van TNFARE/WT 
muizen.  
Intestinale dysbiose is een typisch kenmerk van IBD en galzouten kunnen de darmmicrobiota 
wijzigen. In het volgende deel van deze thesis (hoofdstuk 4) bestudeerden en vergeleken we daarom 
hoe UDCA en zijn taurine en glycine conjugaten (TUDCA en GUDCA, respectievelijk) de samenstelling 
van de intestinale microbiota beïnvloeden tijdens experimentele colitis in muizen. Ten eerste 
demonstreerden we dat elk van deze drie galzoutbehandelingen de klinische en inflammatoire 
parameters bij acute colitis, geïnduceerd aan de hand van dextran natrium sulfaat, op een 
gelijkaardige manier verbeterde. Analyse van de fecale microbiota door middel van Illumina MiSeq 
sequenering toonde aan dat galzoutbehandeling de veranderingen in fecale microbiële rijkdom, 
species diversiteit en bacteriële lading niet omkeerde. We vonden echter wel dat UDCA en zijn 
taurine/glycine conjugaten colitis-geassocieerde dysbiose verbeterden op phylum-niveau, door de 
verhouding van Firmicutes ten opzichte van Bacteroidetes te normaliseren. Deze verhouding was 
significant verhoogd in placebo-behandelde muizen met colitis. Een andere belangrijke bevinding 
was dat galzout behandeling een toename veroorzaakte in de relatieve abundantie van Clostridium 
cluster XIVa en Akkermansia muciniphila, anti-inflammatoire bacteriële species die typisch 
ondervertegenwoordigd zijn bij IBD. Tenslotte toonden we dat oraal toegediend UDCA and zijn 
taurine/glycine conjugaten een uitgesproken in vivo biotransformatie ondergingen, wat resulteerde 
in een gelijkaardige fecale galzoutenpool.  
De resultaten voorgesteld in deze thesis dragen bij tot het concept dat secundaire hydrofiele 3,7-
dihydroxy galzouten een veelbelovende behandelingsoptie zijn voor IBD. Op basis van deze 
veronderstelling initieerden we recent een pilootstudie, opgezet om de doeltreffendheid van UDCA 
(welke goedgekeurd is door de U.S. Food and Drug Administration voor de behandeling van primaire 
biliaire cirrhose) te bestuderen met betrekking tot het verbeteren van intestinale microbioom en 
metaboloom veranderingen enerzijds en het induceren van remissie anderzijds in IBD patiënten. 
Preliminaire resultaten (hoofdstuk 5) toonden aan dat UDCA therapie de niveaus van een aantal 
fecale metabolieten, die significant gewijzigd waren in IBD patiënten in remissie, normaliseerde. 
Deze pilootstudie kan belangrijke inzichten verschaffen over de therapeutische doeltreffendheid van 






















I.  INFLAMMATORY BOWEL DISEASE 
Inflammatory bowel disease (IBD) represents a group of idiopathic chronic relapsing inflammatory 
conditions of the gastrointestinal tract comprising two major clinical entities: ulcerative colitis (UC) 
and Crohn’s disease (CD).1–3 The incidence of IBD is highest in Western, developed countries and 
continues to rise, particularly in countries with previously lower morbidity rates, such as the 
developing world.1,2 Diagnosis of the disease relies on a combination of clinical, endoscopic, 
radiographic, and histopathological features.4 Patients generally experience intermittent attacks of 
abdominal pain, bloody diarrhea, fever, loss of appetite, and weight loss.2,5 However, extra-intestinal 
manifestations are also common, with possible involvement of the liver, skin, eyes, and joints.6 
Although CD and UC share clinical and pathological features, several important differences exist 
between both subtypes. CD causes a segmental and transmural inflammation which may involve the 
entire gastrointestinal tract, from the mouth to the anus, whereas UC occurs as a continuous and 
more superficial inflammation that is typically restricted to the colon and the rectum.2,3,5 In UC 
patients with pancolitis, the inflammatory process can occasionally extend into the distal ileum 
(termed backwash ileitis) and may lead to misdiagnosis as CD.5 The type of inflammatory response 
occurring in the intestine also differs between both IBD subtypes; in CD there is a predominant T 
helper (Th)1 and Th17 cell response with high levels of interferon (IFN)tumor necrosis factor 
(TNF)and interleukin (IL)-17, as opposed to UC, which is characterized by an atypical Th2 cell 
response mediated by high levels of TNF, IL-5, and IL-13.7–9 Finally, distinctive features can be 
observed at the histopathological level; severe and widespread crypt architectural distortion, a 
frankly irregular surface, mucosal ulcerations and erosions, severe mucin depletion, and a heavy and 
diffuse infiltration of inflammatory cells (neutrophils, eosinophils, and plasma cells) into the mucosa 
are characteristic for UC, while discontinuous crypt architectural changes, mucin preservation, focal 
inflammation (composed of lymphocytes and plasma cells), and epithelioid granulomas are typical 
features of CD.4,10,11 Patients with IBD sometimes develop complications that are potentially life 
threatening; complications of UC include toxic megacolon and colonic perforation, whereas in CD 
focal lesions can progress to deep ulcerations that may extend through the bowel wall, resulting in 
the development of fistulas and abscesses. Moreover, fibrosis can develop in response to 
inflammation and may result in (sub)obstructive strictures.2,5,12  
In the first section of this introduction, we will give a brief summary of the etiology and risk factors of 
IBD and its current therapeutic approaches. Next, we will focus on intestinal barrier dysfunction and 





1. IBD as a multifactorial disease with substantial unmet clinical need 
1.1 Etiology and risk factors 
The etiology of IBD is multifactorial and incompletely understood, but involves a complex interplay 
between genetic, environmental, microbial, and immune factors.3,7,13 There is a general consensus 
that IBD patients are genetically predisposed to pathological interactions between the immune 
system and the intestinal microbiota.7 A meta-analysis combining genome-wide association studies 
with Immunochip data has identified a total of 163 susceptibility loci for IBD. Of these, 110 loci 
conferred risk to both disease phenotypes, whereas 23 and 30 loci were specific to UC and CD, 
respectively.14 More recently, a trans-ethnic analysis identified an additional 38 IBD susceptibility 
loci, emphasizing shared genetic risk across different ethnic populations.15 Many of the risk genes 
associated with IBD are involved in intestinal homeostasis, including innate and adaptive immune 
regulation, gut barrier function, autophagy, endoplasmic reticulum (ER) stress, and microbial 
defense.16 A prime example of a gene that is associated with IBD is nucleotide-binding 
oligomerization domain-containing protein 2 (NOD2), encoding an intracellular pathogen-recognition 
receptor that recognizes muramyl dipeptide derived from bacterial peptidoglycans.17 Mutations in 
the leucin-rich repeat domain of NOD2 lead to impaired microbial clearance and are involved in the 
development of CD.3,16,18 Genome-wide association studies also reported a strong association 
between autophagy related 16-like 1 (ATG16L1) and immunity-related guanosine triphosphatase 
(IRGM) gene polymorphisms and susceptibility to CD. Both genes are crucial in the process of 
autophagy. The CD-associated ATG16L1 variant T300A may affect the interaction of the ATG16L1 
protein with other components of the autophagosome, resulting in functionally altered 
autophagosomes with reduced capacity to kill microbes.19 Moreover, a 20-kb deletion polymorphism 
located immediately upstream of the IRGM gene is associated with reduced IRGM gene expression 
and could also impair the efficacy of autophagy.19 With regard to the regulation of immune 
responses, several single nucleotide polymorphisms (SNPs) within the IL-23 receptor (IL-23R) gene 
have been identified as risk factors for CD and UC. IL-23R interacts with IL-23, a heterodimeric 
cytokine that plays an essential role in the differentiation of Th17 cells. Notably, an uncommon 
coding variant in IL-23R, Arg381Gln (rs11209026), confers strong protection against IBD.20,21 
Functional characterization of IL-23R Arg381Gln revealed that this gene variant exerts its protective 
effect by impairing IL-23-induced Th17 cell effector function without affecting Th17 cell 
differentiation.22 As a final example, genetic studies have identified several genes involved in the ER 
stress response (X-box binding protein 1 (XBP1), anterior gradient protein-2, and orosomucoid-1-like 




XBP1 gene are hypomorphic, which could have significant functional consequences since XBP1 
deletion in intestinal epithelial cells leads to spontaneous enteritis and higher susceptibility to 
experimental colitis.24 Despite the strong evidence for a genetic predisposition to IBD, the disease 
variance explained by the 163 IBD loci identified is only 13.6% and 7.5% for CD and UC, respectively.14 
This “missing heritability” suggests that there are unidentified rare or common genetic variants that 
could contribute to the inherited risk for IBD. Additionally, the concordance rate in monozygotic 
twins is low (between 10 and 15% for UC and between 30 and 35% for CD),16 which underscores the 
importance of additional non-genetic risk factors in the development of IBD. The rising incidence of 
IBD worldwide suggests a strong environmental component in its pathogenesis. Environmental 
factors such as hygiene, diet, stress, surgery, medication use, and smoking can synergistically 
contribute to the increasing incidence of IBD by impacting the immune system, gut barrier integrity, 
and the intestinal microbiota.3,13 One well-known theory, “the hygiene hypothesis”, postulates that a 
lack of exposure to pathogens during early immune development may predispose individuals toward 
disease manifestation. The underlying idea is that early programming of the intestinal immune 
system requires infection in early childhood and prevents subsequent responses to antigenic 
stimuli.13,25 Western diets that are high in fats and proteins and low in fibers may also be involved in 
IBD development by promoting inflammation or gut barrier dysfunction, and/or by altering the 
intestinal microbiome.2,13  
1.2 Therapeutic approaches for IBD management 
In the last few years, the therapeutic goal in IBD has shifted away from simply relieving or controlling 
symptoms (clinical remission) toward complete mucosal healing (endoscopic remission). Mucosal 
healing refers to the resolution of ulcers and inflammatory lesions and results in improved clinical 
outcomes and improved quality of life as compared to conventional treatment approaches.26–29 In 
this paradigm, a “step-up” approach is used, starting with oral aminosalicylates (e.g. sulfasalazine, 
mesalamine) or antibiotics (e.g. metronidazole, ciprofloxacin) and switching to corticosteroids (e.g. 
prednisone, budesonide) if there is no response or if symptoms worsen. Immunosuppressants (e.g. 6-
mercaptopurine, azathioprine) are mostly added to prevent corticosteroid dependance. In 
corticosteroid-resistant patients or in case of flare during immunosuppressive therapy, biologicals are 
started. Surgery is required in case of treatment failure or in patients with serious complications.2,13,26  
To date, biological therapy for IBD is expanding far beyond the classical anti-TNF therapies 
(infliximab, adalimumab, golimumab) which have been successfully used since more than 20 
years.30,31 Novel biological approaches include blockade of other inflammatory mediators 




Approximately two years ago, the monoclonal antibody that selectively inhibits leukocyte adhesion in 
the gastrointestinal mucosa by targeting the 47 integrin (vedolizumab) was approved for use in CD 
and UC and is now widely used in routine clinical practice.32 Janus kinase (JAK) inhibitors represent a 
new and promising class of therapeutic agents for IBD; tofacitinib, which blocks JAK1 and JAK3 (and 
to a lesser extent JAK2) has shown promising clinical effects in UC,32,33 and a recent phase II study 
suggests clinical efficacy of the selective JAK1 inhibitor, filgotinib, for the treatment of active CD.34 
Additionally, a monoclonal antibody directed at the p40 subunit of IL-12/23 (ustekinumab) is 
currently accepted by the European Medicines Agency for the treatment of CD. Other biologicals, e.g. 
directed to IL-23, are currently being tested in clinical trials.35,36 In spite of the recent advances in the 
treatment of IBD, primary non-response and loss of response to biologicals remains a major problem 
in clinical practice. For example, nearly a third of IBD patients never achieve an initial response to 
anti-TNF therapies, whereas another third will lose their initial response over time.32  
Despite the growing number of therapies, no curative treatment is available and surgery is still 
inevitable in many patients; within 10 years of diagnosis, 71% to 83% of CD patients undergo surgical 
intervention for various indications such as intestinal obstruction and fistula formation, and 20% to 
30% of UC patients require colectomy.5 While the current medical treatment modalities mainly exert 
their effect by acting on the immune system, newer agents targeting mucosal barrier function or the 
microbiota are currently under investigation.13 
2. Intestinal barrier dysfunction in IBD 
2.1 The complexity of the intestinal mucosa as a mechanical barrier  
Under normal circumstances, the intestinal mucosa forms a selective barrier that prevents the 
passage of harmful luminal contents such as bacteria and their toxins, yet allowing the uptake of 
nutrients, electrolytes, and water from the intestinal lumen. This mucosal barrier is comprised of a 
single layer of intestinal epithelial cells that are interconnected by junctional protein complexes (tight 
junctions, adherens junctions, and desmosomes) and covered on their apical side by mucus (Figure 
1). Intestinal epithelial cells are generated from stem cells at the crypt base and differentiate into 
distinct subpopulations: absorptive enterocytes or colonocytes (in the small and large intestine, 
respectively), goblet cells, Paneth cells, microfold (M) cells, hormone-producing enteroendocrine 
cells, tuft cells, and cup cells.37–40 Unlike cup cells, whose exact function is still unknown, tuft cells are 
taste-chemosensory epithelial cells that regulate type-2 immune responses during infection with 
intestinal parasites.40,41 Goblet cells continuously produce a variety of mucin glycoproteins to 




stratified layers; a tightly attached inner layer that is devoid of bacteria and that contains large 
concentrations of antimicrobial factors, and a loose outer layer where commensal bacteria reside. 
The mucus layer in the small intestine is thinner and discontinuous. In this tissue environment, direct 
contact between the microbiota and the epithelium is mainly prevented by the secretion of 
antimicrobial peptides, including defensins and C-type lectines, produced by Paneth cells located in 
the bases of small intestinal crypts. Additionally, B cells residing in the intestinal mucosa produce 
secretory immunoglobulin A which further protects the intestinal epithelium from bacterial 
overgrowth. Unlike other epithelial cells, M cells are located in the follicle-associated epithelium 
overlying the Peyer’s patches or isolated lymphoid follicles and are not covered by a mucus coat. 
These cells function as a “guarded gateway” for sampling of antigens, which are rapidly delivered to 
and recognized by the underlying lymphoid aggregates. Additionally, dendritic cells residing in the 
lamina propria are able to directly sample luminal antigens by extending transepithelial dendrites 
into the gut lumen.37–39  
 
Figure 1. Components of the intestinal epithelial barrier. The intestinal epithelium is composed of a single layer of 
enterocytes (in the small intestine) or colonocytes (in the large intestine), interspersed by specialized cells. Goblet cells 
produce mucins that form a dense inner mucus layer and a loose outer mucus layer, whereas Paneth cells enriched in the 
bases of small intestinal crypts produce antimicrobial peptides (AMP). Antigen sampling across the intestinal barrier is 
mediated by microfold (M) cells and dendritic cells (DC) extending their dendrites into the lumen. IgA, immunoglobulin A; 








The intestinal immune system has the ability to distinguish between inducing either immune 
responses against harmful antigens or tolerogenic responses towards antigens derived from 
nutrients and beneficial bacteria. Mechanisms involved in oral tolerance, i.e. the absence of local and 
systemic immune responses towards innocuous antigens, include clonal deletion and clonal anergy of 
T cells, as well as active regulation by regulatory T cells. Differentiation of antigen-specific T cells into 
regulatory T cells and their subsequent expansion are driven by retinoic acid and regulatory cytokines 
such as transforming growth factor beta and IL-10. Under conditions in which high levels of 
proinflammatory cytokines are produced, however, immune tolerance may be broken, thereby 
enhancing inflammatory immune responses.39,42  
Intraepithelial lymphocytes reside in close proximity to intestinal epithelial cells. They display an 
activated phenotype and are primed to respond rapidly to microbial invasion.39 Intraepithelial 
lymphocytes contribute to the maintenance of the intestinal mucosal barrier by promoting epithelial 
repair following mucosal injury. Moreover, they protect against bacterial translocation across injured 
mucosal surfaces by producing antibacterial factors and chemotactic cytokines that recruit additional 
immune cells.43 
When the mucosal barrier becomes disrupted, bacteria and/or bacterial products can invade the 
adjacent tissues and are sensed by antigen-presenting cells, such as dendritic cells and macrophages. 
These cells migrate to the lymphoid follicles in the Peyer’s patches or to gut-draining mesenteric 
lymph nodes, where they present the antigens to naive T cells leading to their activation and 
expansion. The resulting effector T cells eventually exit the mesenteric lymph nodes and home to the 
gut interstitium. Once in the intestinal lamina propria, they re-encounter their specific antigen 
presented by antigen-presenting cells, which initiates a rapid inflammatory response with excessive 
production of proinflammatory cytokines. These cytokines induce a variety of effects, such as 
activation of antigen-presenting cells, macrophages, and endothelial cells, upregulation of 
endothelial cell adhesion molecules, promoting clonal T cell expansion, and enhancing Th cell 
function. Consequently, additional T cells, as well as B cells and myeloid cells, are recruited to the 
intestine and become activated to produce large amounts of proinflammatory cytokines. Such 
immune responses may further increase epithelial barrier dysfunction, thereby creating a vicious 





2.2 Intestinal barrier dysfunction in IBD 
Loss of barrier function is regarded as an important event in the pathogenesis of IBD, although it is 
unclear whether it is a primary cause or merely a consequence of chronic inflammation. Increased 
intestinal permeability has been reported in both CD and UC, even in patients in remission, and is 
related to disease activity.46,47 Ex vivo studies in Ussing chambers using biopsy specimens of sigmoid 
colon demonstrated reduced epithelial resistance in mild to moderately active CD and UC.48,49 Data 
from animal models of IBD suggest that increased permeability may be a primary defect that drives 
mucosal inflammation; SAMP1/YitFc mice (a spontaneous model of chronic ileitis) exhibit severe 
intestinal barrier dysfunction at an age when the inflammation has not yet developed.50 In addition, 
increased intestinal permeability can be detected in Il-10-/- mice before they develop colitis and 
restoring this barrier defect ameliorates the disease.51  
Perturbations in intestinal barrier function may be due to a combination of defects in each 
component of the mucosal barrier. Changes in the intestinal mucus layer, including reduced 
thickness and continuity, as well as altered composition, and lower numbers of mucin-producing 
goblet cells have been reported in IBD, particularly UC.52,53 Furthermore, CD patients show Paneth 
cell dysfunction and structural defects in Paneth cell granules, resulting in reduced secretion of 
antimicrobial peptides.37 Additional defects have also been described at the tight junction level, such 
as decreased expression and redistribution of tight junction proteins.53 In addition, the intestinal 
epithelium of both CD and UC patients exhibits increased levels of cell death.54 The exact role of 
these features in the pathogenesis of IBD is, however, unclear since these defects can also be 
attributed to the cytokines produced in the mucosa. For example, TNFwhich is highly produced by 
immune cells (such as dendritic cells, macrophages, and effector T cells) and stromal cells (such as 
fibroblasts and adipocytes) in mucosal tissue of IBD patients,8 alters tight junction protein expression 
and distribution and induces intestinal epithelial cell death.53 Nevertheless, even when loss of barrier 
integrity occurs as a consequence of inflammation, these defects will sustain inflammation, induce 
additional epithelial damage and impair proper tissue healing.54,55 
2.3 Targeting gut barrier function as a promising treatment option for IBD? 
Although its causative role in IBD pathogenesis is still controversial, it is obvious that mucosal barrier 
dysfunction may further promote the underlying inflammatory process leading to severe and chronic 
inflammation. Anti-TNF therapy, which remains the cornerstone in the treatment of IBD, exerts 
different effects, with apoptosis of lamina propria T cells being the main mechanism of action.56 In 




reduce intestinal epithelial cell death and restore gut barrier function in CD patients.57,58 Several new 
agents involved in maintaining intestinal barrier function are under investigation. One example is 
related to the restoration of the colonic mucus layer in UC patients; administration of 
phosphatidylcholine, a constituent of mucus that is substantially reduced in UC patients, was shown 
to suppress the inflammatory activity.13,28,59 Because of their barrier protective actions on intestinal 
epithelial cells, the hydrophilic bile acids ursodeoxycholic acid and tauroursodeoxycholic acid also 
represent attractive candidates for restoring intestinal mucosal barrier integrity.
60,61
 In the last 
section of this introduction, we summarize the enteroprotective effects of these cytoprotective bile 
acids (see Chapter 1.III. 3).  
3. Dysbiosis in IBD 
Perturbations of the gut microbial equilibrium have been linked to IBD and are characterized by 
structural and functional imbalances, termed dysbiosis.62,63 Studies in animal models have 
demonstrated that germ-free breeding or antibiotic treatment protects from intestinal inflammation 
and that transmission of a dysbiotic flora from colitic mice increases susceptibility to colitis in healthy 
recipient mice.64–67 In addition, transfer of a disease-related, but not a healthy, microbiota was 
shown to trigger ileitis in genetically susceptible TNFARE/WT mice.67 Furthermore, loss of T-bet in 
immunodeficient Rag2-/- mice (TRUC mice) leads to spontaneous colitis, which is directly 
transmissible to wild-type hosts upon cross-fostering or co-housing with TRUC mice.66 These data 
strongly support the notion that the intestinal microbiota plays a critical role in driving the 
inflammatory process in IBD.  
3.1 Introduction to the intestinal microbiota 
The human gastrointestinal tract is colonized by a diverse and complex community of 
microorganisms, collectively known as the gut microbiota. This microbiota comprises mainly bacteria 
but also harbors viruses, fungi, and protozoans.68 In this thesis we will focus on bacteria, since the 
bacterial component of the intestinal microbiome has been extensively studied in IBD patients and is 
thought to be closely involved in IBD pathogenesis.62,63 However, it should be mentioned that some 
recent data suggest that alterations in the viral and fungal components of the gut microbiome, the 
so-called virome and mycobiome, respectively, might also contribute to IBD.69,70 
It is generally accepted that about 10 to 100 trillion bacterial cells are present throughout the 
gastrointestinal tract, all of which belong to more than 1000 bacterial species.71–74 The most 




Proteobacteria, and Verrucomicrobia being present in lower proportions.75 Both microbial density 
and community structure significantly change along the length of the gastrointestinal tract. This 
spatial heterogeneity is associated with host factors (e.g. pH, oxygen availability, and presence of 
host-derived bile acids and antimicrobial peptides), bacterial factors (e.g. adhesion capacity, 
metabolic capacity, and microbial competition), and other factors such as nutrients. As compared to 
the cecum and colon, the small intestine is more alkaline and contains higher levels of antimicrobial 
factors, thereby inhibiting bacterial growth. Consequently, the upper gastrointestinal tract usually 
comprises a sparse microbiota (101-103 cells/ml in the duodenum) with bacterial density rising to 
1011-1012 cells/ml in the colon.71,73,74 Complex carbohydrates in the cecum and colon favor the growth 
of fermentative polysaccharide-degrading species, such as Bacteroidaceae, Lachnospiraceae, and 
Ruminococcaceae, while simple sugars and amino acids present in the small intestine support the 
growth of Lactobacillaceae and Enterobacteriaceae.73,74 Besides differences in the microbiota along 
the longitudinal axis of the intestine, additional differences can be found between the luminal and 
mucosa-associated microbiota. First, the overall microbial diversity is higher in the luminal 
microbiota. Second, genera within the Firmicutes, Bacteroidetes, and Proteobacteria are more 
abundant in the mucosa-associated microbiota, whereas genera within the Actinobacteria are more 
abundant in the luminal microbiota. While all of the dominant genera present in the luminal 
microbiota are also found in the mucosa-associated microbiota, the latter also contains unique 
genera which are not represented by the luminal niche.76 Fecal samples are often used to study the 
gut microbiota because they are easily sampled. However, the fecal microbiota mainly represents the 
microbial populations within the gut lumen and does not reflect the mucosa-associated bacteria.76 
The infant’s gut is believed to be sterile in utero, but is rapidly colonized after birth. During the 
colonization process, facultative anaerobes are progressively replaced by strictly anaerobic 
organisms.77 This microbial community converges over time and evolves towards an adult-like 
configuration within one to three years.78 Apart from age-associated changes, numerous other 
factors can intervene with the gut microbiota composition, including host genetics, diet, and 
antibiotic use.63,79 Consequently, gut microbial communities are highly dynamic over a human 
lifetime and exhibit significant variation, both taxonomic and functional, between healthy 
individuals.75,78,80 Nevertheless, this “variable microbiota” surrounds a subset of gut bacterial species 
that are shared among individuals, the so-called “core microbiota” which is important for the 
maintenance of general health.72,81,82 It has been estimated that the combined genomes of our gut 
microbiota encode about 100-fold more genes than the human genome.80 Unlike gut microbiota 
structure, the functional composition of the intestinal microbiota is extremely stable between 




interchangeable and that, after a certain microbial disturbance, the functional status of a given 
microbiota may be recovered by the presence of species performing similar functions.83  
The intestinal microbiome is involved in numerous metabolic processes, such as vitamin biosynthesis, 
carbohydrate metabolism, and bile acid biotransformation (see Chapter 1.II. 1.2),84,85 and is integral 
to the development and function of the mucosal immune system.86,87 Furthermore, commensal 
bacteria directly prevent colonization by pathogenic bacteria, which is achieved by competition for 
nutrients and attachment sites, as well as through the production of antimicrobial factors.71 Since the 
indigenous microbiome assures crucial functions that humans cannot exert themselves but are 
indispensable for host health, it is not surprising that impaired host-microbe interactions may 
contribute to various chronic disorders such as IBD.88  
3.2 Factors influencing microbiome composition in IBD  
Although it seems increasingly evident that IBD patients are highly susceptible to alterations in the 
gut microbiome, it is difficult to distinguish whether the observed dysbiosis directly results from the 
intestinal inflammation or whether it represents a causative factor in IBD pathogenesis. 
Nevertheless, host genetics as well as environmental factors may directly impact the gut 
microbiome, thereby disrupting host-microbe cross-talk and predisposing the host to intestinal 
inflammation.62  
3.2.1 Host genetic factors 
Host genetics appear to be crucial in the development and shaping of the gut microbiome. Twin 
pairs, especially monozygotic twins, share more similar fecal microbial community profiles compared 
to unrelated individuals.89 Although intestinal dysbiosis in IBD is largely associated with disease 
phenotype rather than genetic factors,90,91 the finding that numerous IBD susceptibility genes are 
involved in microbial assemblage or host responses to microbes highlights a fundamental 
relationship between host genetics and the gut microbiome in IBD.14,62 One of the genes known to be 
highly associated with CD susceptibility is NOD2.18 Activation of NOD2 by intracellular pathogens 
induces the release of antimicrobial peptides and directs autophagy by the recruitment of ATG16L1 
to the bacterial entry site at the cell membrane.17,92 Mutations in either NOD2 or ATG16L1, which 
have also been associated with CD,93 can therefore impair the autophagic clearance of bacterial 
pathogens.92,94,95 Patients with IBD carrying polymorphisms in ATG16L1 show substantial alterations 
in their gut microbial communities.96–98 Similarly, significant shifts in the microbial composition of UC 




deficient for Nod2 also exhibit severe alterations in their ileal, colonic, and fecal microbial community 
structure, such as increased bacterial loads of Firmicutes and Bacteroidetes, along with the impaired 
ability to suppress colonization with the pathogen Helicobacter hepaticus.99–101 Notably, using 
reciprocal microbiota transplantation experiments, Couturier-Maillard and co-workers showed that 
the dysbiotic bacterial flora from Nod2-deficient mice sensitizes wild-type mice to experimental 
colitis, whereas recolonizing Nod2-deficient mice with fecal microbiota of wild-type mice reduces 
disease risk.64 These observations underscore the importance of the interaction between genetics 
and the microbiome in the pathogenesis of IBD. 
3.2.2 Environmental factors 
Besides genetics, a broad range of environmental factors may also affect the stability and/or 
complexity of the gut microbiome. In fact, modern changes in lifestyle (including hygiene, mode of 
birth, medication use, and dietary patterns) are associated with detrimental changes in the gut 
microbiome that may predispose individuals to develop IBD.62,63  
Compared to the intestinal microbiota of vaginally delivered neonates, gut microbial communities of 
babies born by cesarean section are characterized by reduced diversity and lack of Bifidobacteria 
species.102 Although a recent study reported conflicting results,103 IBD rates in children at age 0-14 
years are moderately increased after delivery via cesarean section.104 Antibiotics also have a 
tremendous influence on the composition of the gut microbiome that may impact host metabolism 
on the longer-term.105–107 Exposure to antibiotics in childhood is associated with increased risk for 
development of IBD,108–110 which appears to be age-dependent; the use of antibiotics in the first year 
of life was shown to be associated with a 5.5-fold increased IBD risk, decreasing to 2.62-fold and 
1.57-fold when children were exposed to antibiotics by the age of 5 and 15 years, respectively.110 
Together, these findings emphasize the importance of environmental factors in the “early” 
development of the intestinal microbial community. Within this context, breast feeding also has a 
crucial role in shaping the infant gut microbiome and may confer protection against the development 
of early-onset IBD.111,112  
Beyond the postnatal period, dietary components continue to regulate the diversity of the gut 
microbial community throughout life. The central role of diet in gut microbiome assembly became 
particularly evident with the recent popularization of Western diets.62 Comparison of the fecal 
microbiota of European children on a Western diet (rich in sugar, fat, starch, and protein) and African 
children on a high-fiber, plant-based diet revealed significant differences in gut microbiota 
composition; Bacteroidetes dominated in the gut microbiota of African children, whereas Firmicutes 




studies evaluating the relationship between dietary components and IBD risk concluded that (1) high 
dietary intake of fibers and fruits is associated with a decreased risk for CD; (2) high dietary intake of 
vegetables is associated with a decreased risk for UC; and (3) high dietary intake of total fats, total 
polyunsaturated fatty acids and n-6 polyunsaturated fatty acids, and meat is associated with an 
increased risk for both CD and UC.114 Moreover, a high intake of saturated fats may increase the risk 
for developing IBD, although conflicting results have been reported.114–116 A study conducted by 
Devkota and co-workers, however, supports the idea that saturated fats are associated with an 
increased risk for IBD. Indeed, consumption of a diet high in saturated, milk-derived fat was shown to 
promote the expansion of the sulphite-reducing pathobiont Bilophila wadsworthia in Il-10-/- mice, 
which was associated with increased susceptibility to colitis in these mice.117 This study supports the 
notion that consumption of a high-fat, high-sugar Western diet may predispose individuals to the 
development of IBD by inducing unfavorable alterations in the gut microbial community structure.  
3.3 Intestinal dysbiosis in IBD 
3.3.1 Structural changes in the microbiome 
The rapid advances in sequencing technologies over the past decade have changed our 
understanding of the microbes in the gut and provided the unique opportunity to define the 
intestinal dysbiosis in IBD patients.63 This dysbiosis is characterized by a reduced intestinal microbial 
diversity, which has been related to temporal instability within the dominant taxa.63 Notably, 
decreased diversity in IBD is particularly associated with a decline in the diversity of Firmicutes.118–120 
Bacterial strains falling within Clostridial clusters IV and XIVa are less represented in UC and CD.119 
Atarashi et al. showed that these strains produce short-chain fatty acids (SCFAs), including acetate, 
propionate, butyrate, and isobutyrate, and induce the differentiation, expansion, and colonic homing 
of regulatory T cells. Moreover, oral administration of a combination of bacterial strains falling within 
these Clostridial clusters attenuates colitis in mice.121 Faecalibacterium prausnitzii is a major 
intestinal bacterium belonging to the Clostridial cluster IV that is significantly underrepresented in 
the microbiome of IBD patients.119 F. prausnitzii is an important producer of butyrate, the main 
energy source for colonocytes that promotes colonic mucosal health by regulating intestinal barrier 
function and mucosal immune responses.122 Other butyrate-producing bacterial species were also 
found to be depleted in fecal communities of IBD patients; Blautia faecis, Roseburia inulinivorans, 
Ruminococcus torques, and Bacteroides uniformis are reduced in CD,123 while Roseburia hominis is 
underrepresented in UC.124 Bifidobacterium species, which prevent nuclear factor-kappa B (NF-B) 




strong reduction of Akkermansia muciniphila was demonstrated in both UC and CD.126 A. muciniphila 
is the most abundant mucolytic mucosa-associated bacterium in the healthy gut and its abundance 
appears to be negatively correlated with the severity of appendicitis, obesity, and autism. It is 
suggested that A. muciniphila plays a protective or anti-inflammatory role that may be lost in IBD; as 
a result of mucus degradation, A. muciniphila produces acetate and propionate that trigger a cascade 
of responses from which the host may benefit.126,127 In the colon, A. muciniphila induces several 
pathways involved in the regulation of immune responses, such as pathways playing a role in 
chemotaxis and complement cascade, as well as in innate immunity and maturation of B and T 
cells.128 Studies in genetically and diet-induced obese mice demonstrated that A. muciniphila 
colonization also restores gut barrier function and recent data suggest that a specific protein isolated 
from the outer membrane of A. muciniphila is involved in this barrier protective effect.129,130 
Collectively, these studies show that IBD-associated dysbiosis is characterized by the loss of beneficial 
microbes, which may contribute to the pathogenesis of IBD. Indeed, depletion of F. prausnitzii in ileal 
mucosa of CD patients at the time of surgical resection was shown to be associated with a higher risk 
of postoperative recurrence of ileal CD.131  
Loss of beneficial commensals may allow detrimental, disease-promoting microbes to expand, which 
could potentiate the inflammatory process.62,63 Analysis of the mucosa-associated microbiota in ileal 
and rectal biopsies from a large cohort of treatment-naive pediatric CD patients demonstrated a 
higher abundance of Enterobacteriaceae, Pasteurellaceae, Veillonellaceae, and Fusobacteriaceae.132 
Within Enterobacteriaceae, adherent-invasive Escherichia coli has been isolated from ileal specimens 
of CD patients. This adherent-invasive strain of E. coli invades intestinal epithelial cells, replicates 
uncontrollably in epithelial cells and macrophages, and is able to interact with Peyer’s patches and to 
translocate across M cells.63,133 Fusobacteria represent a second group of adherent-invasive bacteria 
and Fusobacterium species were also found to expand in the colonic mucosa of UC patients.134 
Moreover, Fusobacterium isolates originating from inflamed biopsies from IBD patients exhibit higher 
invasive ability than strains isolated from healthy tissue.135 Patients with UC also have a higher load 
of Desulfovibrio species within the colon.136  
Characterization of the structural changes of the intestinal microbiota can help to identify disease 
state and response to therapy. Gevers et al. initially described a Microbial Dysbiosis Index that is 
calculated as the log10 of the total abundance in organisms increased in CD divided by the total 
abundance of organisms decreased in CD. This index, which “measures” the altered microbiota 
composition, can diagnose CD and characterize disease severity.132 Although originally described for 
CD, a recent prospective cohort study of treatment-naive pediatric IBD subjects showed that the 




with clinical and biochemical measures of disease activity in both CD and UC.137 The ratio of 
Firmicutes to Bacteroidetes has also been used as an indicator of dysbiosis and disease activity in 
colitis. More specifically, in a study of 32 CD patients and 17 UC patients, a lower Firmicutes to 
Bacteroidetes ratio was associated with active disease.119 However, this ratio has been found to 
evolve during different stages of life.138 Thus, inconsistencies in results regarding the Firmicutes to 
Bacteroidetes ratio may exist between different studies due to heterogeneity in the age of patients.  
Besides structural alterations in the bacterial microbiome, few studies have recently demonstrated 
additional perturbations in the intestinal virome and mycobiome of IBD patients. Metagenomic 
sequencing of virus-like particles from fecal samples obtained from IBD patients and healthy subjects 
revealed an increased abundance of Caudovirales bacteriophages in both UC and CD, with each 
disease subtype harboring distinct bacteriophages.69 In addition, Sokol and colleagues identified a 
clear dysbiosis of the fungal microbiome in IBD that is characterized by an increased Basidiomycota 
to Ascomycota ratio. Furthermore, compared with healthy subjects, the abundance of 
Saccharomyces cerevisiae was found to be reduced in IBD patients, while the abundance of Candida 
albicans was significantly increased.70  
3.3.2 Functional changes in the microbiome  
In addition to structural alterations, intestinal dysbiosis in IBD is also associated with important 
changes in metabolic functions of the microbiome. Remarkably, microbial metabolic pathways are 
even more affected in IBD than is microbial community structure; 12% of analyzed metabolic 
pathways were shown to be significantly altered in IBD patients, compared to only 2% of genus-level 
taxa.139 To date, only a limited number of studies have focused on changes in microbial function in 
IBD.  
Consistent with a depletion of SCFA-producing bacteria (e.g. Roseburia and Faecalibacterium), 
metagenomic and metaproteomic studies reported a marked reduction in the metabolic pathways 
involved in carbohydrate metabolism and SCFA production in the microbiome of IBD patients.139–141 
Accordingly, fecal metabolomes of CD and UC patients are depleted in SCFAs, including acetate, 
propionate, and butyrate.142,143 The IBD metagenome also exhibits major alterations in oxidative 
stress pathways; increased cysteine biosynthesis, glutathione transport, and riboflavin metabolism, 
as well as overrepresentation of the pentose phosphate pathway, are associated with IBD and may 
represent a mechanism to protect from oxidative stress induced by inflammation.139 In addition, 
bacterial genes encoding type II secretion systems (involved in the secretion of bacterial toxins and 
cell wall-degrading enzymes) are more abundant in patients with ileal CD, which is suggestive for a 




microbiome that have been associated with IBD include increased amino acid transport and a 
decrease in biosynthesis and metabolism of amino acids.139,140 However, genes related to the 
metabolism of the sulfur-containing amino acids cysteine and methionine are increased, which is 
accompanied by a higher abundance of genes associated with sulfate transport and sulfur 
metabolism.139 This is in line with studies reporting increased numbers of sulfate-reducing bacteria 
(e.g. Desulfovibrio) as well as increased fecal production of hydrogen sulfide in UC patients.136,144 
Hydrogen sulfide exerts several toxic effects on intestinal epithelial cells, such as preventing SCFA 
oxidation and inducing DNA damage in colonocytes.145 Of note, thiosulfate sulfurtransferase, one of 
the enzymes that is required for detoxification of hydrogen sulfide, shows impaired expression and 
activity in UC patients.146 Finally, the intestinal microbiome of IBD patients exhibits altered capacity 
to metabolize bile acids. Ogilvie and Jones reported a reduced abundance of bile salt hydrolase (BSH) 
genes derived from Firmicutes in individuals diagnosed with CD as compared to healthy 
individuals.147 Bacterial BSHs catalyze the deconjugation of bile acids, which is considered as the 
“gateway” reaction in bacterial bile acid metabolism (see Chapter 1.II. 1.2).147 A similar study 
analyzing large metagenomic datasets from IBD patients demonstrated a significant reduction in BSH 
assigned to the Firmicutes phylum in UC patients. Additionally, Firmicutes-derived 7-dehydroxylase 
and hydroxysteroid dehydrogenase, other bacterial enzymes involved in bile acid metabolism, were 
shown to be more abundant in the microbiome of CD patients.148 Hence, bacterial bile acid 
metabolism is significantly affected in IBD patients, resulting in severe alterations in the fecal bile 
acid profile.149,150 These alterations will be described in more detail in the third section of this chapter 





II.  PHYSIOLOGY OF BILE ACIDS  
Bile acids are amphipathic end-products of cholesterol catabolism synthesized in the liver. After 
conjugation to taurine or glycine, primary bile acids are secreted into bile, stored in the gallbladder, 
and released into the duodenum in response to a meal. In the small intestine, bile acids emulsify 
dietary lipids to provide larger surface areas for digestive enzymes. In addition, bile acids form mixed 
micelles with dietary lipids and lipid-soluble vitamins, which facilitates their absorption by the 
intestinal epithelium. Besides a key role in fat digestion and absorption, bile acids also regulate lipid, 
glucose, and energy metabolism, and function as signaling molecules that participate in the 
modulation of immune responses. Most bile acids are reabsorbed via specific transporters in the 
distal ileum and return to the liver via the portal circulation, thereby completing their enterohepatic 
circulation.151,152 Though, approximately 5% of bile acids escapes reabsorption and is excreted into 
the feces.153 In the large intestine, bile acids encounter high concentrations of intestinal bacteria, 
which perform a plethora of biotransformations to secondary bile acids. This results in a chemically 
diverse bile acid pool that exhibits a broad range of biological functions. Bile acids in turn are also 
inherently involved in the regulation of the gut microbiome.151,152  
In this section, we highlight the bidirectional relationship between bile acids and the gut microbiome. 
In addition, a brief overview of intestinal bile acid transport mechanisms will be given. 
1. Intestinal bacteria as modulators of the bile acid pool 
1.1 Hepatic bile acid synthesis is regulated by gut microbes 
The human adult liver converts about 0.5 g of cholesterol to bile acids every day, accounting for a 
major fraction (~90%) of daily cholesterol turnover. The direct products of hepatic bile acid synthesis 
are referred to as primary bile acids. Humans produce only two primary bile acids, cholic acid (CA) 
and chenodeoxycholic acid (CDCA).151,154–156 In mice, the majority of CDCA is further hydroxylated to 
-muricholic acid (-MCA), which undergoes subsequent epimerization to -MCA.157 Hence, CA, -
MCA, and -MCA represent the main primary bile acids in mice.151 Bile acid synthesis is a highly 
complex process that involves a cascade of reactions catalyzed by at least 17 different enzymes. 
These enzymes participate in the modification of the cholesterol steroid ring structure, oxidation and 





The synthesis of primary bile acids occurs via two main pathways, the classic (or neutral) pathway 
and the alternative (or acidic) pathway. The classic pathway accounts for the majority of total bile 
acid synthesis (90% in humans and 75% in mice) and is regulated by cholesterol 7-hydroxylase 
(CYP7A1). CYP7A1 is the rate-limiting enzyme that converts cholesterol to 7-hydroxycholesterol and 
is under negative feedback regulation by bile acids returning to the liver via the enterohepatic 
circulation. In the alternative pathway, contributing to less than 10% of total bile acid synthesis in 
humans (25% in mice), cholesterol is first hydroxylated at C27 via the action of sterol 27-hydroxylase 
(CYP27A1), followed by hydroxylation at C7 by oxysterol 7α-hydroxylase (CYP7B1).151,154–156 Figure 2 
gives an overview of the two pathways involved in hepatic bile acid synthesis.  
 
 
Figure 2. Schematic overview of pathways involved in the hepatic synthesis of primary bile acids in humans and mice. 
Enzymes or reaction steps regulated by the intestinal microbiota are designated in red. CYP7A1, 7-hydroxylase; HSD3B7, 
3-hydroxy-
5
-C27-steroid oxidoreductase; CYP8B1, sterol 12-hydroxylase; AKR1D1, Δ
4
-3-oxosteroid 5β-reductase; 
AKR1C4, 3α-hydroxysteroid dehydrogenase; CYP27A1, sterol 27-hydroxylase; CYP7B1, oxysterol 7α-hydroxylase; BAL, bile 
acid CoA ligase; BAT, bile acid CoA:amino acid N‐acyltransferase; CA, cholic acid; CDCA, chenodeoxycholic acid; TCA, 
taurocholic acid; GCA, glycocholic acid; TCDCA, taurochenodeoxycholic acid; GCDCA, glycochenodeoxycholic acid; -MCA, 





The intestinal microbiota has a strong regulatory role in the synthesis of primary bile acids. Studies in 
germ-free mice have shown that both gene expression and activity of CYP7A1 decrease by the 
presence of a gut microbiota.158–160 Since CYP7A1 determines the overall rate of bile acid synthesis,151 
the total bile acid pool is significantly lower in conventionally raised mice compared to germ-free 
mice.159 Besides their effect on the bile acid pool size, intestinal bacteria also alter the bile acid 
composition by regulating the expression of sterol 12-hydroxylase (Cyp8b1) or Cyp7b1.158,159,161,162 
CYP8B1 specifically catalyzes the conversion of 7-hydroxy-4-cholesten-3-one (C4) to CA,151 whereas 
CYP7B1 participates in the alternative pathway that predominantly generates CDCA (Figure 2).155 
Thus, the CA/CDCA ratio in humans (CA/MCA ratio in mice) is directly controlled by the intestinal 
microbiota. Other enzymes involved in bile acid synthesis that are under microbial regulation include 
Δ4-3-oxosteroid 5β-reductase (Akr1d1) and Cyp27a1, as well as the enzyme(s) involved in the 
synthesis of -MCA and -MCA (Figure 2).155,159,160  
Newly synthesized bile acids are conjugated at position C24 with taurine or glycine, a process that 
increases the aqueous solubility of bile acids and reduces their hepatotoxicity.163,164 In addition, bile 
acids that have lost their amino acid side chain in the intestine by bacterial deconjugation (see 
Chapter 1.II. 1.2) are efficiently reconjugated upon return to the liver.165 Conjugation of bile acids 
involves a two-step reaction (Figure 2). First, the bile acid is converted to its coenzyme A (CoA) 
thioester, which is catalyzed by bile acid CoA ligase (BAL). In the second step, bile acid CoA:amino 
acid N‐acyltransferase (BAT) displaces the CoA moiety by the amino acid.163 In mice, bile acids are 
almost exclusively conjugated with taurine since murine BAT does not use glycine as a substrate.166 In 
contrast, glycine conjugation predominates in humans with a ratio of 3:1 (glycine:taurine).164,167 Sayin 
and colleagues demonstrated that BAL, the hepatic enzyme catalyzing the first step of bile acid 
conjugation, is downregulated in conventionally raised mice compared to germ-free mice. 
Additionally, hepatic enzymes involved in taurine biosynthesis and transport exhibit altered 
expression in the absence of intestinal bacteria.159 Thus, bile acid conjugation also appears to be 
regulated by the gut microbiota.  
1.2 Bile acids are metabolized in the intestine by gut microbes 
In the small and large intestine, conjugated bile acids are rapidly deconjugated by bacterial BSHs.85 
BSH activity is widely distributed among the various bacterial divisions including members of 
Lactobacilli, Bifidobacteria, Clostridium, and Bacteroides, and shows high functional 
redundancy.155,168 BSH enzymes exhibit different affinities for taurine or glycine conjugates with 




Apart from deconjugation, primary bile acids also become substrate for major bile acid modification 
reactions encoded by anaerobic bacteria in the large intestine, giving rise to the so-called secondary 
bile acids.85 The quantitatively most important bacterial biotransformation of bile acids is 7-
dehydroxylation. Removal of the 7-hydroxyl group of CA and CDCA results in the production of 
deoxycholic acid (DCA) and lithocholic acid (LCA), respectively, whereas murideoxycholic acid (MDCA) 
is formed by 7- or 7-dehydroxylation of -MCA and -MCA, respectively. This complex process of 
dehydroxylation requires prior deconjugation and occurs through a multistep pathway that is carried 
out by bacteria with bile acid-inducible genes. However, 7-dehydroxylating activity appears to be 
limited to a very small fraction of the intestinal microbiota, predominantly members of the genera 
Clostridium and Eubacterium. Some intestinal bacteria possess both 7-dehydroxylating activities, 
whereas other 7-dehydroxylating bacteria lack 7-dehydroxylating activity.85,155  
Other major bile acid conversions in the large intestine include oxidation and epimerization of 
hydroxyl groups. Epimerization starts with a stereospecific oxidation to generate a stable oxo-bile 
acid intermediate, followed by a stereospecific reduction. This biotransformation is catalyzed by two 
stereochemically distinct hydroxysteroid dehydrogenase (HSDH) enzymes.85 In humans, CDCA is 
oxidized by a 7-HSDH into 7-oxo-LCA, which is then reduced to ursodeoxycholic acid (UDCA) by a 
7-HSDH.169 7-HSDHs are widely expressed among members of the genera Clostridium, 
Eubacterium, Bacteroides, Bifidobacterium, and Pseudomonas, whereas only selected members of 
Clostridia are known to carry 7-HSDH activity.169 The bile acid pool of germ-free mice contains low 
levels of taurine-conjugated UDCA, indicating that, unlike in humans, UDCA is a primary bile acid in 
mice.159 Another important epimerization reaction performed by intestinal bacteria is 6-
epimerization of murine -MCA generating -MCA. The latter can be further transformed to -MCA 
by 7-epimerization, or to hyodeoxycholic acid (HDCA) by 7-dehydroxylation.155  
Once transported back to the liver (see Chapter 1.II. 3), the resulting secondary bile acids can be 
further processed by conjugation with taurine or glycine.165 Figure 3 gives an overview of the 





Figure 3. Schematic overview of the bacterial conversion of primary bile acids to secondary bile acids in the intestine. 
TCA, taurocholic acid; GCA, glycocholic acid; CA, cholic acid; DCA, deoxycholic acid; TCDCA, taurochenodeoxycholic acid; 
GCDCA, glycochenodeoxycholic acid; CDCA, chenodeoxycholic acid; LCA, lithocholic acid; UDCA, ursodeoxycholic acid; T-
MCA, tauro--muricholic acid; -MCA, -muricholic acid; MDCA, murideoxycholic acid; T-MCA, tauro--muricholic acid; -
MCA, -muricholic acid; -MCA, -muricholic acid; -MCA, -muricholic acid; HDCA, hyodeoxycholic acid. 
 
Due to the extensive metabolism of bile acids, a chemically diverse bile acid pool is generated in 
which each bile acid exerts its specific physicochemical and biological properties. In general, these 
properties depend on the bile acid hydrophobicity, which is dictated by the number, position, and 
orientation of the hydroxyl groups, as well as by conjugation at the C24 position.170 In humans, the 
magnitude of bile acid hydrophobicity decreases in the order LCA > DCA > CDCA > CA > UDCA, with 
unconjugated bile acids > glycine-conjugated bile acids > taurine-conjugated bile acids.170,171 Similar 
to UDCA, MCAs and derivatives produced in mice are generally considered as highly hydrophilic bile 
acids (Figure 4).172  
 
Figure 4. Chemical structure of the most common bile acids, indicating the site and orientation of the hydroxyl groups as 
well as their hydrophobicity indices. Hydrophobicity indices of the ionized forms of taurine-conjugated, glycine-conjugated, 
and unconjugated bile acids are shown (adapted from Heuman et al.
172
). These values were calculated from capacity factors 
determined by reversed phase high performance liquid chromatography, as described previously.
172,173
 Primary bile acids 
are designated in blue. -MCA, -muricholic acid;-MCA, -muricholic acid; -MCA, -muricholic acid; MDCA, 
murideoxycholic acid; UDCA, ursodeoxycholic acid; -MCA, -muricholic acid; HDCA, hyodeoxycholic acid; CA, cholic acid; 
CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; LCA, lithocholic acid; Gly-conj, glycine-conjugated; Tau-conj, taurine-




2. Bile acids as modulators of the gut microbiota 
2.1 Harmful effects of bile acids on bacteria 
Bile acids exert strong antimicrobial actions to which Gram-negative bacteria are generally more 
resistant than Gram-positive bacteria.174 The primary mechanism underlying these antimicrobial 
effects is related to membrane damage. Due to their detergent effects, bile acids can integrate into 
the phospholipid bilayer and increase membrane permeability, resulting in the leakage of ions and 
small metabolites and eventually cell death.175 Although bile acid concentration is a major 
determinant of bile acid-induced membrane damage, the bile acid conjugation state also appears to 
be an important factor. Conjugated bile acids are negatively charged at physiological pH and will 
remain in the outer hemileaflet of the cell membrane. Unconjugated bile acids, on the contrary, will 
easily move across the lipid bilayer (“flip-flop”), making them more harmful to membrane integrity. 
The number of hydroxyl groups also determines the severity of membrane damage as dihydroxy bile 
acids exhibit a higher flip-flop rate than trihydroxy bile acids.174 Bile acids also impair bacterial growth 
by causing unfolding and aggregation of cytosolic proteins. Again, this effect is more pronounced for 
dihydroxy bile acids, which are more hydrophobic and can more easily destabilize hydrophobic 
protein interactions.176 The same study also showed that bile acids trigger disulfide stress (i.e. 
accumulation of disulfides) in the bacterial cytosol, probably by attacking proteins that control 
disulfide bond formation.176 Besides disturbing membrane or protein characteristics, bile acids also 
induce DNA damage and oxidative stress. Bernstein and colleagues studied the effect of four 
different bile acids (CDCA, DCA, UDCA, and glycocholic acid) on the stress response in E. coli. They 
found that dinD, known to be induced by DNA damage as part of the SOS response, as well as micF 
and osmY, which are both induced by oxidative stress, were consistently activated by all of these bile 
acids.179 Finally, it is suggested that bile acids may chelate cellular ions, such as calcium and iron, and 
can induce low pH stress.174 Acidification of the bacterial cytoplasm predominantly occurs when 
conjugated bile acids enter the cell. Unconjugated bile acids are weaker acids than their conjugated 
counterparts, allowing them to recapture the co-transported proton which may counteract the pH 
drop.174  
Bacteria may resist the deleterious effects of bile acids through several mechanisms. The best-
characterized mechanism is the expression of efflux pumps that extrude bile acids from the cell. 
Furthermore, bacterial BSH activity that mediates bile acid deconjugation protects bacteria from 
intracellular acidification. Unconjugated bile acids, however, can more easily enter the cell due to 
their higher hydrophobicity, which argues against the hypothesis of deconjugation being a 




protection from bile acid toxicity include the production of exopolysaccharides and molecular 
chaperones.180,181 
There is convincing evidence that bile acids also exert indirect antimicrobial actions which are 
regulated by a receptor-mediated signaling pathway.182 This mechanism is thought to predominate in 
the ileum where, due to active bile acid reuptake (see Chapter 1.II. 3), bile acid concentrations fall 
too low to directly inhibit bacterial growth by the mechanisms described above.183 The farnesoid X 
receptor (FXR) is a nuclear transcription factor that is activated by bile acids and is highly expressed 
in the ileal epithelium.182 Microarray analysis revealed that activation of FXR by the synthetic agonist 
GW4064 increases the ileal expression of genes with potential roles in antimicrobial defense, such as 
inducible nitric oxide synthase, angiogenin 1, and Il-18. Moreover, bile duct ligation in wild-type mice 
was shown to increase the bacterial content in the ileum and cecum and to stimulate bacterial 
translocation from the intestine to the mesenteric lymph nodes. Interestingly, the effects of bile duct 
ligation were completely abolished by oral administration of GW4064 in wild-type mice but not in 
mice that were genetically deficient in Fxr. These findings indicate that activation of FXR by bile acids 
induces genes involved in mucosal defense which, in turn, protects the ileum from bacterial 
invasion.182  
2.2 Beneficial effects of bile acids on bacteria 
Apart from bile acid toxicity, bile acids may also be useful to the microbiota since intestinal bacteria 
benefit from bile acid metabolism.85 One of the advantages of bile acid biotransformation for 
bacteria is associated with the ability to use bile acids as electron acceptors, which increases ATP 
formation and stimulates bacterial growth.184 This advantage is most important for bacteria with 
7-dehydroxylation activity, which involves a combination of oxidation and reduction reactions 
with a net two-electron reduction.85 Oxidation of bile acids has also been associated with the 
formation of reducing equivalents and generation of energy, for example in Bacteroides 
thetaiotaomicron.185 Furthermore, taurine and glycine obtained by bile acid deconjugation can be 
utilized as a source of carbon, nitrogen, or sulfur for bacterial growth, either directly or through 
metabolic interactions between bacterial species.85,186,187 In this regard, binary culture experiments 
have shown that hydrogen sulfide produced from taurine by the bile acid-deconjugating Bacteroides 





2.3 Gut microbial community dynamics induced by bile acids 
Selection for bile-resistant species or species that are highly favored in the presence of bile is an 
important part of the mechanism by which bile acids alter the bacterial community composition. 
Consumption of a diet high in saturated fats increased taurocholic acid (TCA) levels in mice, resulting 
in dysbiosis and selective expansion of the sulphite-reducing pathobiont B. wadsworthia.117 The 
selective growth of this bacterium could result from the fact that B. wadsworthia is bile-resistant and 
uses bile to its advantage. In addition, possible suppression of commensal bacteria by TCA was also 
thought to provide B. wadsworthia the opportunity for further expansion.117 In another study, CA 
feeding in rats simplified the gut microbial composition and increased the relative abundance of 
Firmicutes, in particular Clostridium cluster XIVa.189 As certain clostridial cluster XIVa members exhibit 
7α-dehydroxylation activity,184 it is likely that CA was used as a substrate by these bacteria, thereby 
favoring their growth. This theory is further strengthened by the observation that administration of 
CA increased cecal concentrations of DCA which was, due to its high bactericidal activity, suggested 
to be the major cause of the reduced microbial density.189 In line with these findings, increased cecal 
levels of 7α-dehydroxylating bacteria have been demonstrated in mice that were fed a chow diet 
supplemented with CA.184 Furthermore, Kakiyama and co-workers revealed a decrease in total fecal 
bile acid concentrations together with a reduced conversion of primary to secondary bile acids in 
cirrhotic patients. The microbiome in cirrhotic patients showed dysbiosis and, of note, it was found 
that reduced fecal concentrations of the secondary bile acids DCA and LCA correlated with a lower 





3. Intestinal transport of bile acids 
Bile acids are efficiently reclaimed from the intestinal lumen and return to the liver for reexcretion 
into bile. Because bile acid molecules are too large to pass through the tight junctions between 
adjacent enterocytes, bile acid uptake from the intestinal lumen is mediated by transcellular 
mechanisms. After entering the cytosolic compartment, bile acids are shuttled to the basolateral 
membrane (which is facilitated by the ileal bile acid binding protein) and finally secreted into the 
portal circulation through a mechanism of facilitated diffusion (Figure 5).191–193  
 
Figure 5. Intestinal transport of bile acids. ASBT, apical sodium-dependent bile acid transporter; OST, organic solute 
transporter ; OST, organic solute transporter ; IBABP, ileal bile acid binding protein; BA, bile acid; Unconj., 
unconjugated; Gly-conj., glycine-conjugated; Tau-conj., taurine-conjugated.  
 
3.1 Apical bile acid transport 
Apical uptake of bile acids occurs through a combination of active and passive bile acid transport 
mechanisms. Passive non-ionic absorption of bile acids occurs along the length of the small and large 
intestine and may be important for unconjugated and some glycine-conjugated bile acids. 
Unconjugated bile acids are usually uncharged at physiological pH and can therefore rapidly enter 
the enterocyte through passive diffusion. Moreover, a fraction of glycine-conjugated bile acids are 
protonated in the proximal intestine, rendering them permeable to cell membranes. Passive bile acid 
absorption may be more significant in humans than in mice, because the human bile acid pool 




almost exclusively with taurine.164,166 Nevertheless, passive diffusion still accounts for only a small 
fraction of bile acid reclamation, since most of the bile acid pool is conjugated.191–193 Due to their 
lower pKa, conjugated bile acids are almost completely ionized at physiological pH, which limits their 
diffusion across cell membranes. Therefore, reabsorption of conjugated bile acids requires the 
presence of bile acid transporters, whose expression is largely restricted to the terminal ileum (up to 
100 cm proximal to the ileocecal valve).194 Carrier mediated bile acid uptake across the apical brush 
border membrane of the ileal enterocyte is mediated by the apical sodium-dependent bile acid 
transporter (ASBT; encoded by SLC10A2). Apart from its expression on ileal enterocytes, other 
epithelial cells such as proximal renal tubular cells and cholangiocytes also express ASBT at their 
apical membrane. Transport by ASBT is specific for bile acids, since no non-bile acid substrates have 
been identified yet.191–193 ASBT operates as an electrogenic sodium-bile acid cotransporter with a 
sodium:bile acid coupling stoichiometry of 2:1. Although it was suggested that ASBT can mediate 
bidirectional bile acid transport, the presence of sodium and electrical gradients across the 
membrane forces this transporter to function exclusively as an uptake mechanism.195 ASBT exhibits 
highest affinity for taurine- and glycine-conjugated bile acids but also efficiently transports 
unconjugated bile acids. Furthermore, ASBT favors dihydroxy bile acids over trihydroxy bile acids and 
shows low affinity for 6-hydroxy bile acids.191–193  
Targeted deletion of Slc10a2 in mice increases fecal bile acid excretion about 10- to 20-fold and 
reduces the bile acid pool size by 80%.196 These findings highlight the fundamental role of ASBT in 
intestinal bile acid absorption and indicate that alternative absorptive mechanisms cannot 
compensate for loss of SLC10A2 function. In addition, genetic polymorphisms in SLC10A2 have been 
identified in patients with primary bile acid malabsorption. Primary bile acid malabsorption is an 
idiopathic intestinal disorder characterized by defects in the enterohepatic circulation of bile acids, 
reduced plasma cholesterol levels, chronic diarrhea, and steatorrhea. Transfection of these genetic 
variants in COS cells revealed that two mutations, L243P and T262M, do not affect ASBT protein 
expression or trafficking to the plasma membrane but abolish bile acid transport activity. These 
dysfunctional mutations are not found in unaffected subjects with normal ileal bile acid absorption 
and may thus play a role in the pathogenesis of primary bile acid malabsorption.197  
At the transcriptional level, ileal ASBT is regulated by sterols, hormones, vitamins, cytokines, and bile 
acids. Bile acid-induced regulation of ASBT, however, varies depending on the species considered; 
unlike rats, in which ileal Asbt expression is not modulated by bile acids, mouse and human ASBT are 
negatively regulated by bile acids.192 Bile acid responsiveness of the human ASBT gene is mediated by 
FXR-dependent induction of the short heterodimer partner (SHP). SHP subsequently reduces the 




gene expression.198 The negative feedback regulation of mouse Asbt is mediated by a similar 
mechanism, yet SHP inhibits the stimulating effect of the liver receptor homologue-1 (LRH-1), instead 
of RAR/RXR, on the Asbt promoter. The finding that the mouse, but not the rat, Asbt promoter 
contains a functional LRH-1 cis-acting element explains why bile acid-induced negative feedback 
regulation of Asbt does not exist in rats.198 Besides the species-specific nature of bile acid-induced 
regulation of ASBT, the nature of the bile acid species is also important to consider. In this context, it 
has been demonstrated that different bile acid species differentially affect Asbt expression, which 
might be related to the different ability of these bile acids to activate FXR.199,200  
3.2 Basolateral bile acid transport 
Several candidates, including the truncated, alternatively spliced form of ASBT (t-ASBT), multidrug 
resistance-associated protein 3 (Mrp3), and organic solute transporter (OST), have been 
suggested to participate in the efflux of bile acids across the basolateral membrane of enterocytes. 
While the specific contribution of t-ASBT and Mrp3 to intestinal basolateral bile acid transport 
remains uncertain, it is clear that the majority of intestinal bile acids are effluxed to the portal blood 
via the heterodimer OST. The human OST gene encodes a 340 amino acid, seven 
transmembrane domain protein, while OST encodes a 128 amino acid, single transmembrane 
domain ancillary protein. Both subunits need to be co-expressed and assembled into a complex in 
order to ensure proper functioning of OST. Unlike ASBT, OSTexhibits broad substrate 
specificity and transports a variety of compounds other than bile acids, such as digoxin and 
prostaglandin E2. Depending on the solute’s electrochemical gradient, OSTcan mediate either 
solute uptake or efflux, which is driven by facilitated diffusion. The intestinal expression of OST is 
highest in the ileum, with detectable levels also in the proximal small intestine, cecum, and colon 
where it may function as a transporter for bile acids that entered the cell by passive diffusion. In 
humans, OST is also expressed at relatively high levels in the liver, kidney, and testis.191–193  
Bile acids are capable to regulate their own efflux by tightly controlling the expression of 
OSTNotably, the promoters for OST and OST contain both FXR and LRH-1 response elements, 
which mediate either positive or negative feedback regulation, respectively.201 Similar to mouse Asbt, 
negative regulation of OSToccurs via SHP-mediated repression of LRH-1. However, the positive 
regulatory pathway, in which bile acid-activated FXR directly induces OST gene expression, is 
believed to dominate over the negative feedback pathway.201 Indeed, a number of studies 
consistently demonstrated increased OSTexpression in human ileal biopsies incubated with bile 




III.  A ROLE FOR BILE ACIDS IN THE PATHOGENESIS OF IBD? 
The last section of this introduction is dedicated to the complex actions of bile acids on intestinal 
physiology and their possible involvement in IBD pathogenesis. In addition, we will elaborate on the 
protective effects of UDCA and its taurine-coupled conjugate tauroursodeoxycholic acid (TUDCA). 
1. A critical role for bile acids in intestinal physiology 
1.1 Bile acids affect gut barrier function 
1.1.1 Role of bile acids in epithelial barrier function 
It is well established that bile acids have the ability to impair intestinal epithelial barrier function, 
leading to increased permeability to macromolecules. Exposing Caco-2 cell monolayers to rat bile 
juice decreases the transepithelial electrical resistance (TEER) and increases lucifer yellow flux across 
the monolayers in a dose-dependent manner.204 A single dosage of 750 mg CDCA acutely damages 
the small intestinal mucosa in healthy subjects leading to increased permeability, as indicated by a 
higher urinary lactulose/rhamnose ratio.205 Endoscopic biopsies from the sigmoid colon of healthy 
subjects mounted in Ussing chambers show reduced TEER as well as increased uptake of E. coli 
following exposure to DCA or CDCA.206 Moreover, these dihydroxy bile acids were shown to 
aggravate the already increased bacterial uptake through the colonic epithelium in collagenous colitis 
patients in remission.207  
Several studies have compared the potency of different bile acids to impair intestinal barrier 
function. Mucosal permeability and bacterial uptake in normal human colonic biopsies increase more 
efficiently by DCA than CDCA, probably due to its higher hydrophobicity.206 Araki and co-workers 
examined epithelial barrier disruption induced by seven different bile acids in Caco-2 cell 
monolayers. In this study, all bile acids (200 µM) rapidly decreased the TEER, irrespective of the bile 
acid hydrophobicity.208 However, the potency of bile acids to increase epithelial permeability appears 
to vary between different bile acid species when using lower concentrations; CA, CDCA, and DCA (50 
µM) reduced the TEER and promoted the apical-to-basolateral passage of dextran, whereas UDCA 
had no effect on Caco-2 cell monolayer integrity.209 An in vivo intestinal perfusion system revealed 
that DCA and CDCA, but not CA and UDCA, increase mucosal permeability in the rabbit colon.210 
Similarly, a more recent in vivo study in mice demonstrated a barrier disrupting effect of a DCA-




Bile acids are thought to be involved in high-fat diet-induced intestinal barrier dysfunction and 
inflammation.204,212,213 High-fat intake increases fecal bile acid hydrophobicity by increasing fecal 
excretion of DCA, LCA, and 12-keto-LCA.212 Of note, fecal bile acid hydrophobicity is correlated with 
the severity of dextran sodium sulfate-induced colitis in mice, probably by disrupting gut barrier 
function and facilitating the translocation of luminal bacterial antigens.214 On the contrary, feeding 
mice a high-fat diet reduces the proportion of UDCA in the feces, which is associated with increased 
permeability. This observation denotes a barrier protective effect of UDCA.213  
1.1.2 Mechanisms by which bile acids impair epithelial barrier function 
Bile acids are capable to interact with the intestinal mucosa through several mechanisms. One theory 
states that bile acids increase epithelial permeability by altering tight junction structure. Protein 
expression of claudin-1, claudin-3, and junctional adhesion molecule-1 decreases in human intestinal 
Caco-2 cells upon incubation with rat bile juice.204 In addition, exposing Caco-2 cell monolayers to 
DCA or CDCA induces a rearrangement of occludin at the tight junction level.209 An in vitro study on 
primary human esophageal epithelial cells demonstrated that CA conjugates disrupt epithelial barrier 
function in part by modulating the levels of claudin-1 and claudin-4.215 Bile acids regulate tight 
junction complexes via different mechanisms, including epithelial growth factor receptor activation 
or reactive oxygen species generation.208,209  
As bile acid concentrations increase, mucosal permeability may be enhanced due to the ability of bile 
acids to induce cell death. Direct epithelial toxicity was originally attributed to the detergent effect of 
bile acids to cell membranes. Early studies have demonstrated that bile acids induce damage to egg 
phosphatidylcholine liposomal bilayers and cause enzyme leakage and membrane lysis from 
hepatocytes.216,217 Experiments using large unilamellar vesicles revealed that, at very low 
concentrations, bile acids bind to membrane components resulting in the formation of bile acid/lipid 
aggregates in the outer vesicle monolayer. Above a critical bile acid concentration, asymmetric bile 
acid binding leads to membrane stress and subsequently to the formation of transient membrane 
holes.218 Bile acid hydrophobicity is a major determinant of the detergent-mediated disruption of cell 
membranes, with the following order of decreasing detergent power: LCA > DCA > CDCA > CA > 
UDCA.219 Apart from non-specific detergent effects, hydrophobic bile acids also promote 
programmed cell death. In contrast to hepatocytes, the extrinsic pathway of apoptosis plays only a 
minor role in intestinal epithelial cell apoptosis induced by bile acids.220 However, bile acid-induced 
apoptosis within the gastrointestinal tract mainly depends on activation of the intrinsic pathway.220 
Hydrophobic bile acids generate reactive oxygen species by activating plasma membrane enzymes, 




stress promotes the mitochondrial membrane permeability transition and the release of pro-
apoptotic factors (e.g. cytochrome c, Smac/Diablo) into the cytoplasm, leading to activation of 
caspase-9 and -3.220,221 Alternatively, bile acids can trigger the intrinsic apoptotic pathway through ER 
stress, although evidence for this pathway in bile acid-induced intestinal epithelial cell death is 
scarce.222–224  
1.1.3 Mechanisms by which bile acids protect epithelial barrier function 
Apart from the damaging effects of bile acids on epithelial barrier function, bile acids may also exert 
barrier promoting actions. In the small intestine, bile acids protect against bacterial overgrowth by 
activating FXR,182 and stimulate mucosal restitution after injury by increasing epithelial cell 
migration.225 Bile acids may also increase the proliferation of both small and large intestinal epithelial 
cells, further promoting intestinal barrier integrity.226 Finally, bile acids contribute to the 
maintenance of the colonic mucus layer by stimulating mucin secretion probably through a direct 
effect on mucus-secreting cells. Hydrophobic bile acids appear to be more potent mucus 
secretagogues than hydrophilic bile acids, and unconjugated bile acids evoke mucus discharge more 
efficiently than their taurine-conjugated counterparts. As such, this might be a mechanism by which 
bile acids protect the underlying mucosa against the detergent action of bile acids.227,228 
1.2 Bile acids promote colorectal carcinogenesis 
Numerous studies in animal models provide evidence for a causal link between bile acids and 
colorectal carcinogenesis.229–232 A prospective study of UC patients undertaken between 1974 and 
1985 revealed increased fecal bile acid concentrations in those patients with colonic dysplasia or 
carcinoma.233 In addition, analysis of the fecal bile acid profile of patients with colorectal cancer 
showed increased proportions of secondary bile acids compared to controls.234 It is believed that 
hydrophobic bile acids, predominantly DCA, are the most toxic bile acids with respect to colorectal 
carcinogenesis.235 In support of this idea, serum levels of DCA correlate with the proliferation rate of 
the colonic mucosa and are increased in colorectal adenoma patients.236,237 Moreover, treatment 
with DCA, alone or in combination with a carcinogen, promotes the development of colon cancer in 
rodents.231,232,235 Although LCA has also been regarded as a tumor promoter, this toxic bile acid is 
almost exclusively sulfated, which decreases its carcinogenicity.235,238 
Bile acids promote the development of colorectal cancer by several mechanisms. First, bile acids can 
induce oxidative/nitrosative DNA damage and disturb the mitotic machinery, resulting in genomic 




1.1.2), repeated exposure of colonocytes to high bile acid concentrations may induce resistance to 
apoptosis, allowing the survival and proliferation of cells with damaged DNA.235,240 Finally, bile acids 
stimulate proliferation of colonic epithelial cells and promote stemness in these cells resulting in the 
generation of cancer stem cells.241,242  
A large body of evidence suggests a novel role for FXR as a tumor suppressor in colorectal cancer. 
Compared with normal intestinal mucosa, FXR expression is severely reduced in intestinal tumors of 
ApcMin/+ mice as well as familial adenomatous polyposis patients.243 A study using mouse models of 
intestinal tumorigenesis demonstrated that loss of FXR increases tumor progression, whereas in a 
xenograft model, reactivation of FXR in intestinal cancer cells blocks tumor growth.243 FXR may 
protect against intestinal tumorigenesis by repressing epithelial cell proliferation and anti-apoptotic 
pathways and by inducing pro-apoptotic genes.243,244  
1.3 Bile acids regulate the mucosal immune system through nuclear bile acid receptors 
Bile acids are anti-inflammatory molecules able to reduce the production of proinflammatory 
cytokines in immune cells, such as monocytes and macrophages, as well as in intestinal epithelial 
cells.149,245–248 In this regard, it has been suggested that decreased intestinal bile acid levels, or an 
altered composition, increases susceptibility to intestinal inflammation in cirrhotic patients,249 or in 
patients with IBD.149 The anti-inflammatory actions of bile acids are mediated through activation of 
several intracellular ligand-activated nuclear hormone receptors and cell surface G protein-coupled 
receptors.151 In this introduction, we will only focus on bile acid-activated nuclear receptors.  
Bile acids directly activate three nuclear receptors, all of which are known to regulate inflammatory 
responses in the intestine: FXR, pregnane X receptor (PXR) and vitamin D receptor (VDR).151 Among 
all bile acids, CDCA is the most potent ligand of FXR, followed by LCA and DCA, while CA, UDCA, and 
MCA do not activate FXR.250 Unlike FXR, the only bile acid ligands for PXR and VDR are LCA and 3-
keto-LCA.251–253 In contrast to unconjugated bile acids, which diffuse passively across the small and 
large intestinal mucosa, conjugated bile acids can only activate these nuclear receptors in tissues that 
express bile acid transporters, such as the terminal ileum.250 
FXR is widely expressed in the small and large intestine with highest expression in the ileum 
(predominantly in the villus epithelium).182,254 Activation of this receptor was shown to improve 
clinical symptoms of chemically-induced colitis in mice, whereas Fxr gene ablation has been 
associated with disease exacerbation.255,256 Notably, FXR activation downregulates the expression of 
proinflammatory cytokines in the mouse colonic mucosa in vivo, which was further supported by in 




et al. demonstrated that activated FXR trans-represses the transcription of proinflammatory 
cytokines by stabilizing a nuclear corepressor complex on the NF-B response element in the 
promoter region of inflammatory genes.256 Apart from its role in the regulation of intestinal innate 
immunity, FXR also improves intestinal barrier integrity and controls bacterial overgrowth and 
translocation.182,255 In addition to FXR, specific bile acids may also activate two other nuclear 
receptors that are abundantly expressed in the intestinal epithelium, PXR and VDR.151,254 
Interestingly, these receptors also appear to be key regulators of intestinal inflammation. While 
activation of PXR in mice reduces the severity of experimental colitis,257 loss of Pxr increases the 
expression of IL-1, IL-6, and TNF, and induces a prominent inflammatory infiltrate in the small 
intestine.258 Similarly, VDR-deficient mice are extremely sensitive to experimental colitis induced by 
dextran sodium sulfate.259 Studies using non-bile acid ligands for PXR (rifampicin) and VDR (1,25-
dihydroxyvitamin D3) clearly demonstrated that, upon activation, both receptors inhibit NF-B-
mediated expression of proinflammatory cytokines.258,260 Additional work performed by Sun and co-
workers showed that LCA negatively regulates the proinflammatory NF-B pathway induced by IL-
1in Caco-2 cells, an effect that is abolished in VDR-/- cells.247 Thus, bile acids may play an important 
role in the intestine by delivering anti-inflammatory signals through activation of nuclear receptors. 
Besides activation of FXR, PXR, and VDR, bile acids also regulate the expression of these receptors. 
For example, removal of the endogenous bile acid pool in rabbits reduces hepatic FXR expression, 
which can be restored by replacing the bile acid pool with DCA, UDCA, or CA.261 Similar to FXR, 
expression levels of Pxr and Vdr are also under direct control of bile acids.262,263 Though, these effects 
vary between different bile acids, as well as between different species and organs.263  
2. Defective bile acid homeostasis as a distinctive feature of IBD 
Intestinal bile acid homeostasis is achieved by a balance between bile acid transport and metabolism, 
and requires proper regulation by nuclear receptors. Defects in either process have been linked to 
IBD and may be of pathophysiological significance. 
2.1 Bile acid malabsorption  
First data provided by studies from as early as the 1960s demonstrated high fecal bile acid excretion 
and a reduced bile acid pool size in CD patients.264,265 These observations have been confirmed in 
more recent studies using the selenium-75-labeled homotaurocholic acid test or serum C4 




is most common in CD patients with a history of ileal resection but has also been reported in 
nonresected ileal CD patients and in animal models of acute and chronic ileitis.266–270  
In ileal-resected CD patients, the severity of bile acid malabsorption is associated with the extent of 
ileal resection.267 This can be easily understood from the fact that the terminal ileum is endowed 
with transporters designed to facilitate reabsorption of conjugated bile acids (see Chapter 1.II. 3). As 
originally reported by Hofmann and Poley, patients with limited ileal resection (< 100 cm) typically 
present with watery diarrhea (bile acid diarrhea), while patients undergoing a more significant 
resection (> 100 cm) develop steatorrhea.271 Indeed, when the length of terminal ileum resected is 
less than 100 cm, the normal feedback repression of bile acid synthesis will be compromised and bile 
acid synthesis increases. This results in the spillover of bile acids into the colon, which induces 
electrolyte and water secretion and manifests clinically as secretory diarrhea. However, when more 
than 100 cm of terminal ileum has been resected, bile acid malabsorption exceeds the hepatic 
capacity to synthesize bile acids. This impairs the micellar solubilization of dietary lipids and 
ultimately contributes to lipid malabsorption and steatorrhea.152,272 
It was previously reported that 76% of unresected ileal CD patients with chronic watery diarrhea 
suffer from mild to severe bile acid malabsorption.273 The exact cause of bile acid malabsorption in 
unresected patients is less well understood but is most likely related to defects in ASBT. A single 
point mutation in the ASBT gene (868C>T) was identified from a patient diagnosed with CD. This 
mutation replaces a serine for a proline at position 290 and diminishes ASBT transport activity.274–276 
In a rabbit model of chronic ileitis induced by inoculation of Eimeria magna oocytes, active bile acid 
uptake is impaired by a decrease in ASBT activity and expression.269 Expression levels of ASBT are also 
reduced in the ileum of CD patients, both during flare and in remission.277–280  
The mechanisms underlying the downregulation of ASBT are in part mediated via increased cytokine 
levels. The proinflammatory cytokines IL-1 and TNF repress ASBT promoter activity in rat intestinal 
epithelial IEC-6 cells and human Caco-2 cells. It was suggested that c-fos is critically involved in this 
repression. The ASBT gene promoter contains two distinct activated protein-1 (AP-1) elements. 
Under normal conditions, homodimeric c-jun binds to the 5’ AP-1 element, resulting in enhanced 
ASBT expression. During inflammation, however, c-fos is upregulated and becomes phosphorylated, 
thereby enhancing its nuclear translocation. A c-fos/c-jun heterodimer is then formed, which binds to 
the 3’ AP-1 element of the ASBT promoter and represses its activity.281,282 In this context, induction of 





2.2 Impaired nuclear receptor signaling 
Evidence from several studies suggests that nuclear receptor signaling, by which bile acids exert anti-
inflammatory effects, is impaired in IBD. Intestinal inflammation in both IBD patients and rodent 
models of colitis has been associated with reduced expression and/or activity of FXR.256,280,283,284 
Notably, FXR expression was shown to be inversely correlated with the severity of inflammation in 
UC patients.285 Furthermore, PXR as well as its target genes are markedly downregulated in colonic 
biopsies of UC patients.286 A recent case-control study in Puerto Rican IBD patients demonstrated a 
negative correlation between colonic VDR expression and the degree of inflammation in colonic 
tissue.287 
Previous studies reported a genetic association between polymorphisms in human nuclear receptor 
genes and IBD. Attinkara et al. studied the association of variants of the FXR encoding gene with IBD. 
While the rs3863377 variant was less prevalent in IBD, the SNP rs56163822 was found more 
frequently in IBD patients compared to controls.288 Due to its location within the 5’ region, the first 
SNP is thought to affect FXR gene expression by changing a binding site for transcription factors. In 
contrast, the variant rs56163822 may result in reduced protein expression, since this variant is 
situated in the base position adjacent to the translation initiation site.288 Other studies have also 
reported genetic variations in the genes encoding VDR and PXR that are associated with IBD. TaqI 
polymorphisms in the VDR gene (genotype “tt”) are more frequent in patients with CD (particularly 
those with the fistulizing and fibrostenotic phenotype) and UC.289,290 However, the exact mechanism 
of how this polymorphism affects disease susceptibility remains elusive. A case-control study in an 
Irish cohort including 422 IBD patients and 350 ethnically matched controls examined several SNPs in 
the PXR encoding gene that were previously associated with reduced PXR activity. Some of these 
SNPs were found to be strongly associated with UC and/or CD susceptibility.291 Later, an independent 
study in Caucasian IBD patients also concluded that several rare PXR haplotypes may contribute to 
CD susceptibility.292  
In addition to genetic factors, the inflammatory response itself also targets nuclear receptor signaling 
by directly repressing nuclear receptor activity. This effect is most likely mediated by NF-B which, 
upon activation, can interfere with the binding of nuclear receptors to their cognate response 
elements.258,284,293 Due to the anti-inflammatory actions of these receptors (see Chapter 1.III. 1.3), it 
can be anticipated that an acute inflammatory response reduces nuclear receptor activity. This, in 
turn, leads to impaired suppression of the inflammatory burden and may contribute to the 




2.3 Intestinal bile acid dysmetabolism 
A study conducted in the early 1980s showed reduced levels of the secondary bile acids LCA and DCA 
in fecal samples of CD patients.294 A few years later, Kruis et al. compared fecal bile acid patterns of 
both CD and UC patients with those of healthy volunteers by capillary gas chromatography. The fecal 
bile acid pool of healthy volunteers largely consisted of secondary bile acids, while primary bile acids 
dominated in CD and UC patients.295 These results have been replicated in a more recent study that 
used high performance liquid chromatography coupled to tandem mass spectrometry to measure 
bile acid levels in the feces and serum of colonic IBD patients and healthy subjects.149 Besides 
reduced secondary bile acid levels, IBD patients also exhibited higher fecal levels of conjugated and 
sulfated bile acids and the observed effects were more prominent during flare than in remission.149  
Reduced secondary bile acid levels in IBD patients were initially thought to result from impaired 
bacterial conversion due to rapid intestinal transit time. However, orocecal transit time is delayed in 
IBD patients,296,297 and it now appears more likely that bile acid dysmetabolism is associated with 
intestinal dysbiosis. Indeed, the fecal microbiota of IBD patients (particularly those with active 
disease) exhibits impaired ability to efficiently metabolize bile acids, as demonstrated by direct 
enzyme activity assays.149 These findings might be due to alterations in the abundance of bile acid 
metabolizing genes in the intestinal microbiome of IBD patients.147,148 However, the observed defects 
in bile acid metabolism can also be attributed to reduced substrate specificity of bile acid 
metabolizing enzymes encoded by the dysbiotic microbiota. As earlier mentioned in this 
introduction, human bile acids are mainly conjugated with glycine rather than taurine.167 Within the 
two most dominant phyla, Firmicutes and Bacteroidetes, only bacterial strains belonging to 
Firmicutes are capable to deconjugate glycine-conjugated bile acids.168 As IBD-associated dysbiosis is 
characterized by a depletion of Firmicutes,149 one could expect reduced bile acid deconjugation and 






Figure 6. Luminal bile acid dysmetabolism in IBD. (Left) Normal microbial enzymatic activity in healthy subjects results in a 
luminal bile acid pool that is mainly composed of secondary bile acids and low levels of primary and sulfated bile acids. 
(Right) The intestinal microbiota of IBD patients exhibits impaired ability to efficiently metabolize luminal bile acids, thereby 
changing the bile acid pool towards increased levels of primary and sulfated bile acids and reduced levels of secondary bile 
acids. This luminal bile acid dysmetabolism is thought to participate in sustaining chronic intestinal inflammation in IBD. BA, 




3. The protective effects of UDCA and its taurine conjugate in the intestine 
An in vitro study evaluating the effects of bile acids on the inflammatory response in Caco-2 cells 
demonstrated anti-inflammatory effects of secondary, but not primary, bile acids.149 Therefore, it 
was suggested that IBD-associated bile acid dysmetabolism, resulting in decreased secondary bile 
acid levels, contributes to the epithelial inflammatory response in IBD.149 Secondary bile acids, 
however, exert diverse physiological effects in the intestine due to their differences in 
hydrophobicity and cytotoxicity.214 For example, feeding mice a diet supplemented with DCA leads to 
the development of colitis, which is associated with increased nitrosative stress, angiogenesis, 
oxidative DNA/RNA damage, and proliferation.298 On the contrary, the hydrophilic 3,7-dihydroxy 
bile acids UDCA and TUDCA attenuate the severity of intestinal inflammation in rodents.299–302  
In humans, UDCA is regarded as a ‘minor’ secondary bile acid because it represents only a small 
fraction of the total bile acid pool (less than 3%). Nevertheless, this bile acid has become extremely 
popular due to its low toxicity and its favorable effects in cholestatic liver diseases.61,303 In 1997, 
UDCA was approved by the U.S. Food and Drug Administration as the first agent to treat primary 
biliary cirrhosis.304 As a primary effect, UDCA changes the balance between cytotoxic (hydrophobic) 
and cytoprotective (hydrophilic) bile acids in favor of the hydrophilic ones, by displacing the more 




taurine or glycine in the liver.306 Conjugates of UDCA are more hydrophilic than the parent molecule; 
the pKa value for UDCA is 5.04, whereas glycoursodeoxycholic acid (GUDCA) and TUDCA have a pKa 
value of 4.47 and 0.94, respectively.307 Hence, unconjugated UDCA can diffuse passively across the 
intestinal epithelium, while its conjugated counterparts are mainly absorbed in the distal ileum via 
active bile acid transport. In the colon, non-absorbed UDCA (either conjugated or unconjugated) is 
converted to LCA by bacterial 7-dehydroxylation.306,308 Rodrigues et al. previously demonstrated that 
orally administered TUDCA undergoes reduced biotransformation to LCA compared to UDCA, 
because 7-dehydroxylation requires prior deconjugation.306 Moreover, TUDCA increases hepatic 
UDCA concentrations more efficiently than UDCA and appears to be at least as effective as UDCA in 
the treatment of primary biliary cirrhosis.309,310 Beyond primary biliary cirrhosis, UDCA and its taurine 
conjugate have also been studied in a wide range of other hepatic and even extrahepatic diseases.311 
In this context, several lines of evidence strongly support a cytoprotective role for these bile acids on 
the intestinal mucosa. 
Preclinical studies in animal models suggest that UDCA could be used as a chemopreventive agent in 
colon carcinogenesis.312,313 In this respect, UDCA therapy has been associated with a decreased 
prevalence of colorectal dysplasia or cancer in patients with UC and primary sclerosing 
cholangitis.314,315 A recent population-based study in a large cohort of mainly patients with chronic 
liver diseases demonstrated a 41% lower risk for development of colorectal cancer in patients who 
received UDCA.316 Apart from its chemopreventive effects, UDCA also attenuates Toll-like receptor-
induced proinflammatory cytokine release from T84 cells and human colonic mucosa.317 In addition, 
pretreatment of colonic HCT-116 with UDCA confers resistance to apoptosis induced by DCA.318 
Similar results were obtained from in vitro experiments conducted in Ussing chambers, showing a 
protective effect of UDCA on DCA-induced colonic barrier dysfunction.211 Notably, counteracting 
intestinal barrier dysfunction has been suggested as a possible mechanism by which UDCA 
ameliorates intestinal inflammation in rats.299 Other studies indicate that TUDCA also exerts 
cytoprotective actions on intestinal epithelial cells. Incubating HT-29 cells with TUDCA markedly 
reduces IL-8 production induced by TNF.248 Moreover, TUDCA protects HT-29 cells from apoptosis 
induced by receptor-dependent (TNF and Fas ligand) and receptor-independent (staurosporine) 
stimuli in vitro.302 The ability of TUDCA to prevent intestinal epithelial cell death was further 
confirmed in two mouse models exhibiting increased rates of enterocyte apoptosis.302 Finally, TUDCA 
exerts additional epithelial-protective effects by acting as a chemical chaperone that decreases ER 
stress signaling in intestinal epithelial cells.301 Both the anti-apoptotic and chaperone properties of 




Despite the growing evidence of a therapeutic effect of UDCA and TUDCA on intestinal inflammation, 
it remains unclear whether they exert comparable anti-inflammatory effects. In addition, a major 
question is whether these bile acids could represent a safe therapeutic strategy in patients with 
chronic intestinal inflammation, mainly because the effects of bile acid therapy on the gut microbial 
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Although IBD has long been considered as a medical problem in industrialized countries, its incidence 
is rising worldwide due to Westernization of developing countries. The symptoms associated with 
IBD, together with (sometimes life-threatening) complications and psychological and social distress, 
can severely affect the patients’ quality of life. Currently available IBD therapies are directed at 
relieving or controlling clinical symptoms by directly repressing immune responses (e.g. using 
corticosteroids, immunosuppressants, anti-TNF, and anti-integrin antibodies). Despite the 
widespread use of these immune-based therapies, nearly a third of the patients remain refractory to 
treatment and, of those who respond in first-line, another third lose response over time. As a 
consequence, the search for novel therapeutic approaches is of particular interest in the 
management of IBD.  
I.  GENERAL AIM 
The exact pathogenesis of IBD is unknown but our current understanding suggests a complex 
interaction between genetic and environmental factors that contribute to the disruption of intestinal 
homeostasis. A dysregulated immune response, intestinal dysbiosis, and gut barrier dysfunction are 
critical for the onset and exacerbation of the disease process. Notably, recent work has highlighted a 
role for bile acids as novel players in the pathogenesis of IBD. Changes in the intestinal bile acid 
profile are characteristic for IBD and may be of great importance given the differences in 
physiological properties between bile acids; our lab and others have shown that secondary 
hydrophilic 3,7-dihydroxy bile acids (such as UDCA and TUDCA) exhibit cytoprotective actions on 
the intestine and alleviate colitis in rodents. The general aim of this doctoral thesis was to gather 
mechanistic insights into how secondary hydrophilic bile acids inhibit intestinal inflammation by 
evaluating their effect on: 
1. Bile acid transporters and nuclear receptors in enterocytes 
2. The gut microbiome composition  
II.  RESEARCH OBJECTIVES 
In the first part of this thesis, we focused on the relationship between bile acid supplementation, 
expression of bile acid transporters and nuclear receptors, and intestinal inflammation (chapter 3). 
Bile acids are potential regulators of intestinal bile acid transporters and nuclear receptors, which are 
dysregulated in IBD patients. Our first objective was to study the impact of TUDCA on defects in 
intestinal bile acid homeostasis associated with IBD. Due to the predominant expression of bile acid 





The specific objectives were to: 
- Evaluate whether TNF, a key cytokine in the pathogenesis of IBD, influences the expression 
of bile acid transporters (ASBT, OST, and OST) and bile acid-activated nuclear receptors 
(FXR, PXR, and VDR) in an in vitro model of human enterocytes; 
- Analyze changes in the expression of the aforementioned genes in vivo in ileal tissue of 
TNFARE/WT mice, which are commonly used as a mouse model of CD-like ileitis, and evaluate 
whether these aberrant gene expression signatures resemble those observed in mucosal 
biopsies from CD patients; 
- Evaluate whether TUDCA prevents changes in bile acid transporter and nuclear receptor 
expression in vitro and in vivo;  
- Evaluate the potential of TUDCA to reduce the inflammatory response in a mouse model of 
CD-like ileitis associated with impaired intestinal bile acid homeostasis. 
 
Since the intestinal microbiota is directly controlled by the presence of bile acids, the second part of 
this thesis focused on the impact of bile acid therapy on the gut microbiome in intestinal 
inflammation (chapter 4). Because the amino acids present in conjugated bile acids serve as distinct 
substrates for intestinal bacteria, we aimed to study and compare the impact of UDCA 
(unconjugated), TUDCA (taurine-coupled), and GUDCA (glycine-coupled) on the intestinal microbiota 
composition. 
The specific objectives were to: 
- Compare the effectiveness of UDCA and its taurine/glycine conjugates to protect against 
experimental colitis;  
- Evaluate and compare the impact of administration of UDCA and its taurine/glycine 
conjugates on the composition of the fecal microbiota in experimental colitis; 
- Evaluate the extent of biotransformation of UDCA and its taurine/glycine conjugates. 
  
The data obtained from these studies raised a strong interest for initiating a clinical trial to study the 
efficacy of UDCA to correct intestinal dysbiosis and associated metabolomic changes and to induce 
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Bile acids regulate the expression of intestinal bile acid transporters and are natural ligands for 
nuclear receptors controlling inflammation. Accumulating evidence suggests that signaling through 
these receptors is impaired in inflammatory bowel disease. We investigated whether 
tauroursodeoxycholic acid (TUDCA), a secondary bile acid with cytoprotective properties, regulates 
ileal nuclear receptor and bile acid transporter expression and assessed its therapeutic potential in 
an experimental model of Crohn’s disease (CD). Gene expression of the nuclear receptors farnesoid X 
receptor, pregnane X receptor and vitamin D receptor and the bile acid transporters apical sodium-
dependent bile acid transporter and organic solute transporter and was analyzed in Caco-2 cell 
monolayers exposed to tumor necrosis factor (TNF)α, in ileal tissue of TNFARE/WT mice and in 
inflamed ileal biopsies from CD patients by quantitative real-time polymerase chain reaction. 
TNFARE/WT mice and wild-type littermates were treated with TUDCA or placebo for 11 weeks and ileal 
histopathology and expression of the aforementioned genes were determined. Exposing Caco-2 cell 
monolayers to TNF impaired the mRNA expression of nuclear receptors and bile acid transporters, 
whereas co-incubation with TUDCA antagonized their downregulation. TNFARE/WT mice displayed 
altered ileal bile acid homeostasis which mimicked the situation in human CD ileitis. Administration 
of TUDCA attenuated ileitis and alleviated the downregulation of nuclear receptors and bile acid 
transporters in these mice. These results show that TUDCA protects bile acid homeostasis under 
inflammatory conditions and suppresses CD-like ileitis. Together with previous observations showing 
similar efficacy in experimental colitis, we conclude that TUDCA could be a promising therapeutic 
agent for inflammatory bowel disease, warranting a clinical trial. 
  




Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are 
chronic relapsing disorders of the gastrointestinal tract with unknown etiology. Increasing evidence 
suggests that the reduced abundance and richness of the gut microbiota plays a pivotal role in the 
pathogenesis of IBD.1 Interestingly, reduced microbial enzymatic activity in the gut lumen of IBD 
patients results in bile acid dysmetabolism, which is characterized by defective bile acid 
deconjugation, desulphation, and transformation to secondary bile acids. Because some of the 
secondary bile acids produced by intestinal bacteria exert anti-inflammatory effects on gut epithelial 
cells, intestinal bile acid dysmetabolism significantly contributes to the pathogenesis and symptoms 
of IBD.2  
Bile acids are cholesterol derivatives that act as signaling molecules by activating nuclear receptors 
and G protein-coupled receptors. Activation of these receptors alters the expression of genes 
involved in different processes, including bile acid homeostasis, lipid metabolism, and 
inflammation.3,4 The immunomodulatory roles of bile acids have been thoroughly investigated over 
the last years. Several studies indicated a role for the bile acid-activated nuclear receptors farnesoid 
X receptor (FXR), pregnane X receptor (PXR), and vitamin D receptor (VDR) in the immunoregulation 
induced by bile acids in innate immune cells and gut epithelial cells.5–8 Moreover, selective FXR, PXR, 
or VDR agonists reduce the inflammatory response in experimental models of intestinal 
inflammation,5,6,8–10 whereas mice deficient for one of these receptors are sensitized to gut 
inflammation.5,9,10 In addition, FXR-/- and PXR-/- mice exhibit a compromised epithelial barrier,10,11 and 
spontaneously develop colitis or ileitis.5,10,12 Thus, changes in nuclear receptor signaling severely 
affect the course of intestinal inflammation.  
Several lines of evidence support the possibility that nuclear receptor signaling is impaired in IBD 
patients. First, genetic variations in genes encoding PXR, FXR, and VDR have been associated with 
IBD.13–19 Furthermore, mRNA expression levels of FXR and VDR are reduced in inflamed intestinal 
mucosa from IBD patients,20 whereas PXR expression is downregulated in inflamed ileum of pediatric 
CD and in both inflamed and noninflamed colon from active UC patients.20–22 Also, the apical sodium-
dependent bile acid transporter (ASBT) that mediates bile acid uptake across the brush-border 
membrane of ileal enterocytes,23 is downregulated in inflamed ileum of CD patients.20,24 This finding 
can be indirectly related to impaired bile acid signaling through nuclear receptors, since disturbed 
intestinal bile acid transport results in aberrant intracellular bile acid levels.25 Importantly, ASBT gene 
expression is also reduced in noninflamed ileal tissue from CD patients in remission and UC patients 
with active colonic disease,20,24 showing that these molecular changes are not per se directly 




regulate the expression of nuclear receptors and bile acid transporters.26–31 Proinflammatory 
cytokine expression therefore induces a vicious cycle leading to the perpetuation of the intestinal 
inflammation. Hence, normalizing the expression of intestinal bile acid transporters and/or nuclear 
receptors could be useful to alleviate chronic inflammation in IBD.  
Selected bile acid species have been shown to regulate the expression of intestinal bile acid 
transporters.32–36 One of the bile acids that has received much attention over the last years is 
tauroursodeoxycholic acid (TUDCA). TUDCA is a secondary bile acid with cytoprotective properties37 
that ameliorates colonic inflammation in mice.38–40 However, as bile acids are primarily reabsorbed in 
the terminal part of the small intestine, with only a small proportion (< 5%) of the intestinal bile acid 
pool passing into the colon,23 it is more reasonable to study bile acid supplementation in a model of 
ileal inflammation. In this study, we investigated whether TUDCA alleviates the disruption of ileal bile 
acid homeostasis upon tumor necrosis factor (TNF) stimulation and evaluated whether this bile acid 
improves CD-like ileitis in mice.  
 
MATERIALS AND METHODS 
Caco-2 cell culture. Caco-2 cells (HTB-37, ATCC Cell Biology Collection, Manassas, VA, USA) were 
seeded on 24-well semipermeable inserts (0.4 µm, translucent ThinCerts™, Greiner Bio-One, 
Vilvoorde, Belgium) at a density of 105 cells per well and cultured for two weeks in Dulbecco’s 
modified Eagle medium supplemented with 10% heat-inactivated fetal calf serum and 10 mM HEPES 
buffer (all Life Technologies, Ghent, Belgium). Developing Caco-2 monolayer integrity was monitored 
by measuring transepithelial electrical resistance (TEER) using a Millicell ERS-2 Voltohmmeter (Merck 
Millipore, Billerica, MA, USA). Two weeks post-seeding, when TEER values of approximately 700 
Ohm.cm2 were obtained, the fully differentiated Caco-2 monolayers were incubated basolaterally 
with 100 ng/ml recombinant human TNFα (Life Technologies) or an equal volume of medium, and 
apically with 250 µM or 500 µM TUDCA (Prodotti Chimici e Alimentari S.p.A., Italy) or an equal 
volume of medium. Each condition was performed in triplicate. After 48 hours, the TEER of the Caco-
2 monolayers was measured, cells were collected, and total RNA was isolated for quantitative real-
time polymerase chain reaction (PCR). Medium from the basolateral compartment was used to 
determine the concentration of interleukin (IL)-8.  
Patient characteristics and sample collection. Mucosal biopsy specimens from actively inflamed 
areas of terminal ileum of CD patients were sampled during endoscopy. As a control group, mucosal 
samples from the terminal ileum of healthy individuals were included. CD was diagnosed based on 
clinical, endoscopic, and histological criteria. All CD patients underwent endoscopy to determine the 
severity of mucosal inflammation. In healthy individuals, endoscopy was performed for reasons other 
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than IBD (screening for colorectal cancer, abdominal pain, or rectal bleeding). In all healthy subjects, 
the ileum appeared normal during endoscopy, which was confirmed by histopathology. Patient 
characteristics are shown in Table 1. All biopsy specimens obtained during endoscopy were 
immediately placed in RNAlater and stored at -80 °C.  
Table 1. Patient characteristics   
 
CD Healthy control 
N 10 10 
Gender (male/female) 5/5 2/8 
Age (yrs, mean (range)) 28.7 (21-38) 46.4 (23-67) 
Age at diagnosis (yrs, mean (range)) 25.6 (17-38) - 




No 7 10 
 
Corticosteroids 2 - 
 
Questran 1 - 
Surgical history   
 Ileal resection 2 - 
 Appendectomy 1 - 
 Hemicolectomy 2 - 
 Cholecystectomy 1 - 
Indication for endoscopy other than IBD 
 Abdominal pain - 2 
 Screening for polyps or cancer - 6 
 Occult blood in feces - 1 
 Gross rectal bleeding - 1 
 
 
Administration of TUDCA to TNFARE/WT mice. C57BL/6J TNFARE/WT mice were kindly provided by Dr. 
George Kollias (Alexander Fleming Biomedical Sciences Research Center, Vari, Greece). Starting at 4 
weeks of age, male TNFARE/WT mice (N=11) and wild-type littermates (N=5) were given TUDCA 
(Calbiochem, Germany) in the drinking water at a concentration of 2 g/l until the end of the study. 
Placebo-treated TNFARE/WT mice (N=7) and wild-type littermates (N=8) received normal drinking 
water during the entire study period. All animals had free access to food and water. Body weight was 
monitored twice a week and mice were sacrificed by cervical dislocation at 15 weeks of age. The 
distal ileum was removed and flushed with phosphate-buffered saline (PBS). Fragments of 5 mm 
were cut and samples were immersed in 4% formaldehyde (Klinipath, Olen, Belgium) or RNAlater 




RNA extraction. Total RNA was extracted from Caco-2 cells and human and mouse distal ileal 
samples using the Qiagen RNeasy Mini Kit (Qiagen, Venlo, The Netherlands) with on-column DNase 
treatment. Concentration and purity of the total RNA was determined using nanodrop technology 
(BioPhotometer Plus, Eppendorf, Rotselaar, Belgium). All samples exhibited an OD260/OD280 ratio 
between 1.8 and 2.1. 
Quantitative real-time PCR. One microgram of total RNA was converted to single-stranded cDNA by 
reverse transcription using the SensiFAST™ cDNA Synthesis Kit (Bioline Reagents, UK) according to 
the manufacturer’s instructions. The cDNA was diluted to a concentration of 5 ng/µl and 15 ng was 
used in real-time PCR with SYBR Green (SensiMix™ SYBR No-ROX Kit, Bioline Reagents) and 250 nM 
of each primer (BioLegio, Nijmegen, The Netherlands). A two-step program was performed on the 
LightCycler 480 (Roche, Belgium). Cycling conditions were 95 °C for 10 min, 45 cycles of 95 °C for 10 s, 
and 60 °C for 1 min. Melting curve analysis confirmed primer specificities. All reactions were 
performed in duplicate. Expression data were calculated relative to the mean of the overall 
expression level and normalized to the stably-expressed housekeeping genes hydroxymethyl-bilane 
synthase (HMBS), succinate dehydrogenase complex A subunit (SDHA), and tyrosine 3-
monooxygenase/tryptophan 5-monooxygenase activation protein zeta isoform (YWHAZ) for the 
Caco-2 cells, to glyceraldehyde-3-phosphate dehydrogenase (GAPDH), HMBS, hypoxanthine-guanine 
phosphoribosyltransferase (HPRT), and SDHA for the human ileal biopsy samples, and to Gapdh, 
Hmbs, and Sdha for mouse ileal tissue. The PCR efficiency of each primer pair was calculated using a 
standard curve of reference cDNA. Amplification efficiency was determined using the formula  
10-1/slope. Sequences of the primer sets and the PCR efficiencies are listed in Table 2. Gene expression 
levels are expressed as normalized relative quantities (NRQ). 
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Table 2. Primers sequences for quantitative real-time PCR analysis 
 Gene 
symbol 
Species Forw (5' - 3') Rev (5' - 3') E (%) 
Asbt Mouse CCCAAATGCAACTGTCTGCG CACCCCATAGAAAACARCACCA 102 
Fxr Mouse CGGCAGGCAGAATAAAAGGG GTGAGCGCGTTGTAGTGGT 101 
Gapdh Mouse CATGGCCTTCCGTGTTCCTA GCGGCACGTCAGATCCA 87 
Hmbs Mouse AAGGGCTTTTCTGAGGCACC AGTTGCCCATCTTTCATCACTG 95 
Ost Mouse TCTGCACCCACGGTGGTAT GGCCATTTCTACAAGTGTGAGG 98 
Ost Mouse AGATGCGGCTCCTTGGAATTA TGGCTGCTTTCGATTTCTG 103 
Pxr Mouse GATGGAGGTCTTCAAATCTGCC CAGCCGGACATTGCGTTTC 98 
Sdha Mouse CTTGAATGAGGCTGACTGTG ATCACATAAGCTGGTCCTGT 103 
Vdr Mouse GTGCAGCGTAAGCGAGAGAT GGATGGCGATAATGTGCTGTTG 100 
ASBT Human GGACAATGCAACAGTTTGCTC CCGTACTTAGGACCACACTTAGG 101 
FXR Human GACTTTGGACCATGAAGACCAG GCCCAGACGGAAGTTTCTTATT 101 
GAPDH Human TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG 91 
HMBS Human GGC AAT GCG GCT GCA A GGG TAC CCA CGC GAA TCA C 101 
HPRT Human TGACACTGGCAAAACAATGCA GGTCCTTTTCACCAGCAAGCT 103 
OST Human TCATTTCCCGTCAAGCCAGG GGCGAACAAGCAATCTGCC 95 
OST Human TCCAGGCAAGCAGAAAAGAAA ACTGACAGCACATCTCTCTCT 99 
PXR Human TTGCCCATCGAGGACCAGAT GTCTCCGCGTTGAACACTGT 93 
SDHA Human TGGGAACAAGAGGGCATCTG CCACCACTGCATCAAATTCATG 92 
VDR Human TCTCCAATCTGGATCTGAGTGAA GGATGCTGTAACTGACCAGGT 101 
YWHAZ Human ACTTTTGGTACATTGTGGCTTCAA CCGCCAGGACAAACCAGTAT 93 
 
 
Luminex. IL-8 secretion by Caco-2 cells into the basolateral medium was measured using the Bio-Plex 
Pro Human Cytokine Assay (Biorad), according to the manufacturer’s protocol. Measurements were 
performed using the Bio-Plex MAGPIX Multiplex Reader and data were analyzed with the Bio-Plex 
Manager 6.1 software (BioRad). 
Histological assessment of intestinal pathology. Ileal tissue sections of 4 µm were stained with 
hematoxylin and eosin and scored in a blinded fashion. Histological sections were evaluated for 
villous destruction and bowel wall influx of inflammatory cells. Villous destruction was scored on a 
scale of 0-3: 0, normal; 1, thickened villi; 2, blunted villi; 3, destructed villi. Bowel wall infiltration was 
scored using the following scoring system: 0, normal; 1, infiltrate into muscular layer of mucosa; 2, 
infiltrate into submucosa with sporadic granulomas; 3, infiltrate through submucosa into muscularis 
propria (and/or confluent granulomas); 4, regional transmural infiltration; 5, diffuse transmural 
infiltration and/or crypt abcedation. The sum of the individual components was expressed as the 




Statistical analysis. Statistical analysis was performed using SPSS Statistics version 22.0 (IBM SPSS, 
Chicago, USA) and GraphPad Prism version 4 (GraphPad, California, USA). NRQ values were log 
transformed for statistical analysis. All data are expressed as mean ± SEM. Body weight changes were 
analyzed using linear mixed models. Data were tested for normality using the Kolmogorov-Smirnov 
test. Comparisons between two groups were performed using the unpaired Student’s t-test for 
normally distributed data, applying the Welch’s correction in case of unequal variances, or the Mann-
Whitney U test for non-normally distributed data. Statistical analysis for multiple comparisons was 
performed using one-way analysis of variance (ANOVA), with subsequent Tukey or Games-Howell 
post hoc tests, depending on the homogeneity of variances. Two-tailed probabilities were calculated 
and P-values of less than or equal to 0.05 were considered statistically significant. Multivariate 
analysis was carried out using SIMCA version 14.0 (Umetrics, Umea, Sweden). Principal component 
analysis was executed on the gene expression data of nuclear receptors and bile acid transporters in 
TNFARE/WT mice.  
Ethical Considerations. The use of patient material was approved by the Ethics Committee of the 
Ghent University Hospital (permit number UZG 2004/242) and all patients provided written informed 
consent. The mice were housed in the laboratory animal facility at Ghent University Hospital 
according to the institutional animal healthcare guidelines. This study was approved by the 








TNF-induced downregulation of nuclear receptors and bile acid transporters in Caco-2 cell 
monolayers is antagonized by TUDCA 
It is well known that the expression of nuclear receptors and bile acid transporters is directly 
controlled by inflammatory cytokines.26–31 We initially examined the effect of TNF on the mRNA 
expression of the nuclear receptors FXR, PXR, and VDR and the bile acid transporters ASBT, organic 
solute transporter (OST) and OST in Caco-2 cell monolayers. The addition of 100 ng/ml TNFα to 
Caco-2 cells for 48 hours resulted in a reduced expression of PXR (P=0.029; Figure 1A), while there 
was a non-significant trend towards a downregulation of FXR and VDR (P=0.127 and P=0.057, 
respectively; Figure 1A). Concerning the bile acid transporter genes, TNFα reduced gene expression 
levels of ASBT, OST, and OST but this decrease was not statistically significant for ASBT and OST 
(P=0.271 and P=0.071, respectively; Figure 1B). Because previous studies reported a role for bile 
acids in the regulation of intestinal bile acid transporter expression,32–36 we next determined if 
TUDCA could inhibit the TNF-induced downregulation of the aforementioned genes. The addition of 
250 µM or 500 µM TUDCA to the apical compartment of the Caco-2 cell monolayers prevented the 
TNF-mediated repression of PXR and OST. In addition, FXR and ASBT gene expression tended to 
increase when 500 µM TUDCA was added to the apical compartment (P=0.075 and P=0.073, 
respectively). However, decreased mRNA levels of VDR and OST remained unaffected upon TUDCA 
co-incubation (Figure 1A and B). In order to evaluate whether the observed effects are associated 
with a possible anti-inflammatory effect of TUDCA, we measured IL-8 secretion into the basolateral 
medium. This cytokine is highly responsive to TNFstimulation via nuclear factor-kappa B (NF-B)-
mediated mechanisms and is most commonly used as a readout of anti-inflammatory efficacy in 
Caco-2 cells.2,41–43 Incubating cells with 100 ng/ml TNFα for 48 hours resulted in a significant 
induction of IL-8 secretion, which was not prevented by the addition of 250 µM or 500 µM TUDCA to 
the apical compartment (Figure 1C). Furthermore, since TNF increases tight junction permeability 
through NF-B activation,44 monolayer integrity was assessed by TEER measurements as another 
indirect measure of NF-B activity. Exposing Caco-2 cell monolayers to TNF alone for 48 hours 
reduced TEER (P=0.055 compared to control monolayers), which decreased even more when 250 µM 
or 500 µM TUDCA was co-administered apically (P=0.088 and P=0.033 compared to TNF alone, 
respectively; Figure 1D). However, TUDCA was not toxic to Caco-2 cells as assessed by lactate 
dehydrogenase release (supplemental figure S1). These data indicate that TUDCA protects from 
disruption of bile acid homeostasis upon TNF stimulation via mechanisms that are likely 







TNFARE/WT mice display altered ileal bile acid homeostasis resembling human CD ileitis 
Because excessive TNF production drives the onset of ileitis in TNFARE/WT mice,45 which is believed 
to closely mimic human CD ileitis,45,46 we determined whether this model carries the aberrant gene 
expression signatures related to intestinal bile acid homeostasis in CD. Therefore, gene expression 
levels of nuclear receptors and bile acid transporters were determined in ileal tissue of 15-week-old 
TNFARE/WT mice (when ileal inflammation is fully established46) and wild-type littermates, as well as in 
ileal tissue of CD patients with active ileal disease (L1 and L3) and healthy subjects. Patient 
Figure 1. Effect of TUDCA incubation on TNF-induced repression of genes involved in bile acid homeostasis. Caco-2 
cell monolayers were simultaneously exposed to 100 ng/ml TNF (basolateral) and 250 µM or 500 µM TUDCA (apical) 
for 48 hours. (A) Normalized mRNA expression levels of the bile acid-activated nuclear receptors. (B) Normalized 
mRNA expression levels of the main bile acid transporters. (C) Secretion of IL-8 into the basolateral medium. (D) TEER 
expressed as a percentage of the initial corresponding TEER values (prior to experiment). Data are represented as the 
mean ± SEM from three replicates in one experiment. Gene expression data were log-transformed. *P≤0.05, **P<0.01, 
***P<0.001. 
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characteristics are shown in Table 1. Regarding the nuclear receptors (Figure 2A), ileal FXR expression 
was decreased by 43% in CD patients (P=0.019, compared to controls) and by 50% in TNFARE/WT mice 
(P<0.001, compared to wild-type mice). Additionally, we also observed a decrease in mRNA levels of 
PXR and VDR in the inflamed ileum of both CD patients and TNFARE/WT mice. Gene expression analysis 
of ileal bile acid transporters (Figure 2B) revealed that ASBT was significantly downregulated in CD 
ileitis (40% of control values, P=0.018). Similarly, ileitis in TNFARE/WT mice was associated with a 
marked decrease in gene expression of the main bile acid uptake transporter Asbt (22% of control 
values, P<0.001). Although CD patients did not exhibit significant differences in the expression levels 
of the basolateral efflux transporters OST and OSTthese transporters were significantly reduced 
in TNFARE/WT mice as compared to their wild-type littermates (P<0.001 and P=0.035, respectively; 
Figure 2B). These results show that TNFARE/WT mice exhibit major changes in ileal bile acid 




Figure 2. Expression of genes involved in ileal bile acid homeostasis in CD patients and TNF
ARE/WT
 mice. Normalized 
mRNA expression levels of (A) bile acid-activated nuclear receptors and (B) the main bile acid transporters in ileal 
biopsies from healthy controls and CD patients (left, N=10 in each group) and 15-week-old TNF
ΔARE/WT
 mice and wild-
type littermates (right, N≥7 in each group). Data are represented as the mean ± SEM. Gene expression data were log-





Administration of TUDCA improves disrupted ileal bile acid homeostasis in TNFARE/WT mice  
Because TNFARE/WT mice displayed major changes in ileal bile acid homeostasis, we used this mouse 
model to further study the effects of TUDCA on the expression of nuclear receptors and bile acid 
receptors in vivo. At 4 weeks of age, male TNFARE/WT mice and their wild-type littermates were 
treated with 2 g/l TUDCA in the drinking water ad libitum (as previously described by Cao et al.38) 
until the age of 15 weeks. Placebo-treated TNFARE/WT mice and wild-type littermates received normal 
drinking water. TUDCA upregulated the expression levels of Fxr and Vdr in the distal ileum of 
TNFARE/WT mice (P=0.001 and P=0.064 compared with placebo-treated TNFARE/WT mice, respectively), 
while Pxr expression did not change (Figure 3A). Furthermore, prolonged administration of TUDCA to 
these mice increased the mRNA expression of the bile acid transporter genes Asbt (P=0.002) and 
OstP=0.008), but not Ost (P=0.756) (Figure 3B). Although the administration of TUDCA to wild-
type mice resulted in a downregulation of Vdr compared to placebo-treated wild-type mice 
(P=0.017), baseline mRNA expression levels of all other genes analyzed remained unaffected in wild-
type mice following TUDCA treatment (Figure 3A and B). Principal component analysis was 
additionally performed to visualize the gene expression data of nuclear receptors and bile acid 
transporters. The corresponding score plot demonstrates a clear separation between placebo-
treated TNFARE/WT mice and wild-type littermates (Figure 3C). Whereas TUDCA-treated and placebo-
treated wild-type mice cluster together, TUDCA-treated TNFARE/WT mice shift towards the wild-type 
mice. The plot also shows that two TNFARE/WT mice responded poorly to the TUDCA treatment, as 
they cluster within the placebo-treated TNFARE/WT group. Taken together, these results correspond to 
the observed effects of TUDCA in Caco-2 cell monolayers and suggest that TUDCA protects bile acid 
homeostasis under inflammatory conditions in vivo.  
 
  





Figure 3. Effect of TUDCA administration on the expression of genes involved in ileal bile acid homeostasis. 
Normalized mRNA expression levels of (A) the bile acid-activated nuclear receptors and (B) the main bile acid 
transporters in ileal tissue of 15-week-old TNF
ARE/WT
 mice and wild-type (WT) littermates treated with TUDCA or 
placebo. (C) Principal component analysis plot showing distinct clusters for placebo-treated TNF
ARE/WT
 mice and wild-
type littermates. Each mouse is represented as a point: circles for wild-type mice and triangles for TNF
ARE/WT
 mice. The 
filled symbols represent TUDCA-treated mice, whereas placebo-treated mice are shown by open symbols. Notice the 
shift of TNF
ARE/WT
 mice towards wild-type mice after prolonged treatment with TUDCA. Data are represented as the 
mean ± SEM from one experiment with at least five mice per group. Gene expression data were log-transformed. 





Administration of TUDCA attenuates chronic ileitis in TNFARE/WT mice  
Finally, we examined whether prolonged administration of TUDCA exerted therapeutic effects in 
TNFARE/WT mice. From 8 weeks onward, these mice spontaneously develop ileitis similar to human 
CD, with lower body weight and histological abnormalities in the distal ileum.46 The body weight of 
placebo-treated wild-type mice continued to increase until the end of the study, while body weight 
gain in placebo-treated TNFARE/WT mice started to decrease at the age of 11 weeks (Figure 4A, 
P=0.026 compared with wild-type littermates). In contrast, body weight gain of TNFARE/WT mice that 
received TUDCA was maintained until 13 weeks of age (Figure 4A, P=0.042 compared with placebo-
treated TNFARE/WT mice). The overall body weight of TUDCA-treated wild-type mice did not differ 
significantly from placebo-treated wild-type mice. Histopathological evaluation of distal ileum 
sections from TNFARE/WT mice showed obvious signs of inflammation, characterized by distortion of 
the villi and severe leukocyte infiltration into the mucosa, submucosa, and muscularis externa (Figure 
4B). The total inflammation score was significantly lower in the TUDCA-treated TNFARE/WT group 
(P=0.009 compared with placebo-treated TNFARE/WT mice; Figure 4C). More specifically, long-term 
administration of TUDCA to TNFARE/WT mice did not prevent alterations in villous architecture 
(P=0.168 compared with placebo-treated TNFARE/WT mice; Figure 4D) but reduced inflammatory cell 
infiltration (P=0.004 compared with placebo-treated TNFARE/WT mice; Figure 4E). We therefore 










Figure 4. Effect of TUDCA administration on the severity of chronic ileitis in 15-week-old TNF
ARE/WT
 mice. (A) 
Progressive body weight gain starting at 8 weeks of age in placebo-treated wild-type (WT) mice (N=8; open circles), 
TUDCA-treated wild-type mice (N=5; filled circles), placebo-treated TNF
ΔARE/WT
 mice (N=7; open triangles), and TUDCA-
treated TNF
ΔARE/WT
 mice (N=11; filled triangles). (B) Representative pictures (200x) of hematoxylin and eosin stained 
sections of the terminal ileum of wild-type mice and TNF
ΔARE/WT
 mice treated with TUDCA or placebo, showing reduced 
inflammatory cell infiltration in the ileum of TNF
ΔARE/WT
 mice that were treated with TUDCA. (C) The total histological 
inflammation score, calculated as the sum of (D) villous damage and (E) leukocyte infiltration scores. Data are 
represented as the mean ± SEM from one experiment with at least five mice per group. *P≤0.05, **P<0.01. Scale bars: 





Bile acids have recently been described as signaling molecules that activate a subset of nuclear 
receptors including FXR, PXR, and VDR.4 These receptors are key regulators of inflammation3 and 
increasing evidence suggests that signaling through these receptors is compromised in human IBD.13–
22 In the present study, we demonstrated that TUDCA, a secondary bile acid with cytoprotective 
effects,37 alleviates the downregulation of nuclear receptors and bile acid transporters under 
inflammatory conditions, both in vitro and in vivo, and alleviates CD-like ileitis in mice. 
TNF is a key cytokine involved in the intestinal inflammation in human and experimental IBD.45,47 
Using both an in vitro and in vivo model, we illustrated the ability of this cytokine to directly impair 
the expression of genes involved in ileal bile acid transport and signaling. Previous studies also 
showed a significant contribution of cytokines such as IL-1 IL-6, and TNF on the regulation of 
intestinal and hepatobiliary transporters and nuclear receptors.26–31  
Because the TNFARE/WT mouse model is widely used as a CD model,45,46 we compared gene expression 
patterns of ileal bile acid transporters and nuclear receptors in TNFARE/WT mice with those observed 
in ileal CD patients with active disease. In line with previous studies,20,22,24,48 we found a consistent 
downregulation of FXR, PXR, and VDR and the bile acid uptake transporter ASBT in active CD. 
Although Jahnel et al. published comparable results, they did not find decreased mRNA expression of 
PXR.20 This discrepancy in outcome cannot be attributed to the location of tissue sampling because 
PXR is expressed at a constant level along the length of the small intestine.22 However, in the study of 
Jahnel et al. most patients were under concomitant therapy, whereas in our cohort, most patients 
were not receiving treatment as they were newly diagnosed for CD. Since gene expression levels of 
PXR are enhanced by drugs such as corticosteroids,49–51 concomitant medication use might account 
for the discrepancy in outcome. Interestingly, we found that the changes in expression levels of 
genes involved in bile acid homeostasis in TNFARE/WT mice closely resemble the alterations observed 
in CD ileitis. Therefore, we believe that the TNFARE/WT mouse model is a suitable model to study 
defects in bile acid homeostasis, which are a major feature in ileal CD.  
The effects of bile acids on the expression of genes involved in intestinal bile acid homeostasis have 
been reported previously.33,34,36,51–53 These results, however, are sometimes contradictory and vary 
between different bile acid species. In the present study, we showed that TUDCA protected against 
dysregulated expression of nuclear receptors and bile acid transporters in response to TNF. Of note, 
prolonged administration of TUDCA enhanced the expression of genes involved in ileal bile acid 
homeostasis during inflammation in TNFARE/WT mice, but not under steady-state conditions in wild-
type mice. This is an important finding given the crucial role of nuclear receptors in the counter-
regulation of intestinal inflammation.3,4 These observations may suggest that TUDCA improves 
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immunomodulatory bile acid signaling through these receptors, either directly (by regulating nuclear 
receptor expression) or indirectly (by regulating cellular bile acid transport).  
Previous studies by both our group and others, have shown that either oral or intraperitoneal 
administration of TUDCA attenuates murine colonic inflammation elicited by dextran sodium 
sulfate.38–40 However, more than 95% of the intestinal bile acid pool does not move down into the 
colon due to efficient reabsorption in the distal ileum,23 which makes it more appropriate to consider 
TUDCA supplementation as a therapeutic approach for small bowel inflammation. The present study 
showed that early and prolonged administration of TUDCA attenuates chronic ileal inflammation in 
mice, as evidenced by reduced histological inflammatory cell infiltration and improved body weight 
gain. To our knowledge, only one other study has previously examined the effect of TUDCA on ileal 
inflammation. In contrast to our results, it was reported that dietary TUDCA treatment exacerbates 
indomethacin-induced ileitis in rats.54 Differences in dosage are unlikely to explain the discrepancy in 
outcome, since the dose of TUDCA in both studies was estimated to be equivalent to 400 mg/kg body 
weight. However, the presence of bile acids is crucial in the pathogenesis of indomethacin-induced 
ileal inflammation,55 making this an inferior model to study the therapeutic effects of exogenously 
administered bile acids in IBD.  
Finally, as TUDCA was previously found to reduce cytokine responses in vitro,56–58 one could 
speculate that the stabilizing effects of TUDCA on the expression of bile acid transporters and nuclear 
receptors are secondary to anti-inflammatory actions. However, in our study, TUDCA partly 
antagonized the TNF-effect on bile acid transporter and nuclear receptor expression in Caco-2 cell 
monolayers, but could not prevent the TNF-induced secretionof IL-8 and decrement in TEER. The 
reason why TUDCA even further reduced TEER is unclear but cannot be related to cytotoxicity. 
Together with the observation that TUDCA affected the expression of genes involved in bile acid 
homeostasis only in the inflamed ileum, this raises the possibility that TUDCA directly regulates the 
expression of bile acid transporters and nuclear receptors during inflammatory conditions which in 
turn could be a crucial mechanism by which an anti-inflammatory effect is obtained in the longer 
term. Further studies are required to address this hypothesis.  
In summary, we showed that TUDCA alleviates the disruption of bile acid homeostasis upon TNF 
stimulation both in vitro and in vivo. In addition, we demonstrated that early and prolonged 
administration of TUDCA dampens CD-like ileitis in mice. Together with earlier promising results in 
experimental colitis,38–40 we strongly believe that TUDCA should be investigated as a therapeutic 
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Supplemental figure S1. TUDCA is not toxic to Caco-2 cells. Caco-2 cells were exposed to 500 µM 
deoxycholic acid (DCA) or 500 µM TUDCA or an equal volume of medium (control) for 48 hours. 
Cytotoxicity was assessed by measuring lactate dehydrogenase (LDH) release in cell culture medium. 
DCA was used as a positive control. Data are represented as the mean ± SEM from three replicates in 
one experiment. Data were analyzed by ANOVA followed by Games-Howell multiple comparisons 
tests. **P<0.01. 
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The promising results with secondary bile acids in experimental colitis suggest that they may 
represent an attractive and safe class of drugs for the treatment of inflammatory bowel diseases 
(IBD). However, the exact mechanism by which bile acid therapy confers protection from 
colitogenesis is currently unknown. Since the gut microbiota plays a crucial role in the pathogenesis 
of IBD, and exogenous bile acid administration may affect the community structure of the 
microbiota, we examined the impact of the secondary bile acid ursodeoxycholic acid (UDCA) and its 
taurine/glycine conjugates on the fecal microbial community structure during experimental colitis. 
Daily oral administration of UDCA, tauroursodeoxycholic acid (TUDCA), or glycoursodeoxycholic acid 
(GUDCA) equally lowered the severity of dextran sodium sulfate-induced colitis in mice, as evidenced 
by reduced body weight loss, colonic shortening, and expression of inflammatory cytokines. Illumina 
sequencing demonstrated that bile acid therapy during colitis did not restore fecal bacterial richness 
and diversity. However, bile acid therapy normalized the colitis-associated increased ratio of 
Firmicutes to Bacteroidetes. Interestingly, administration of bile acids prevented the loss of 
Clostridium cluster XIVa and increased the abundance of Akkermansia muciniphila, bacterial species 
known to be particularly decreased in IBD patients. We conclude that UDCA, which is an FDA-
approved drug for cholestatic liver disorders, could be an attractive treatment option to reduce 
dysbiosis and improve inflammation in human IBD.  
 
IMPORTANCE 
Secondary bile acids are emerging as attractive candidates for the treatment of inflammatory bowel 
disease. Although bile acids may affect the intestinal microbial community structure, which 
significantly contributes to the course of these inflammatory disorders, the impact of bile acid 
therapy on the fecal microbiota during colitis has not yet been considered. Here, we studied the 
alterations in the fecal microbial abundance in colitic mice following the administration of secondary 
bile acids. Our results show that secondary bile acids reduce the severity of colitis and improve 
colitis-associated fecal dysbiosis at the phylum level. This study indicates that secondary bile acids 
might act as a safe and effective drug for inflammatory bowel disease.  
 
  




Inflammatory bowel diseases (IBD) are chronic inflammatory disorders of the gastrointestinal tract 
characterized by intestinal dysbiosis. Restricted bacterial diversity and underrepresentation of anti-
inflammatory microorganisms such as Clostridium cluster XIVa and Akkermansia muciniphila 
represent typical dysbiotic features in IBD.
1–4
 Since the intestinal microbial community performs a 
wide range of bile acid modifications including deconjugation, dehydroxylation, oxidation, and 
epimerization,
5
 shifts in the composition of the gut microbiota are associated with perturbations of 
the fecal bile acid profile.
6,7
 Of particular interest, Duboc and colleagues demonstrated that the 
conversion of primary bile acids (synthesized in the liver from cholesterol) to secondary bile acids 
(generated by bacterial modifications) is impaired in IBD patients.7 Because secondary bile acids 
exhibit immunomodulatory functions,
7–10
 increasing secondary bile acid levels in the intestinal lumen 
could be an efficient therapeutic approach for IBD. In line with this hypothesis, the administration of 
the secondary hydrophilic bile acid ursodeoxycholic acid (UDCA) ameliorates experimental colitis but 
the exact mechanism protecting from colitogenesis is not fully understood.11 
When administered orally, unconjugated UDCA is rapidly conjugated with glycine in humans, and to a 
lesser extent with taurine, on its first pass through the liver.12,13 Based on the observation that fecal 
bile acid hydrophobicity correlates with the severity of colitis,
14
 it is reasonable to assume that 
conjugates of UDCA, which are more hydrophilic than unconjugated UDCA, might be more favorable 
therapeutic agents for intestinal inflammation. In this regard, we and others have shown that 
tauroursodeoxycholic acid (TUDCA) alleviates dextran sodium sulfate (DSS)-induced colitis in 
mice.15,16 The potential beneficial effect of glycoursodeoxycholic acid (GUDCA) in colitis, however, 
has not been addressed so far and studies comparing the therapeutic effectiveness of these different 
bile acid species are lacking. 
While the composition of the luminal bile acid pool is controlled by intestinal bacteria, it is well 
established that bile acids, in turn, also shape the gut microbiota. Bile acids restrict bacterial 
proliferation and overgrowth directly by causing membrane damage, which is positively correlated 
with bile acid hydrophobicity.17–19 Thus, the bactericidal activity of bile acids decreases with 
increasing numbers of hydroxyl groups and by conjugation of the bile acid side chain with taurine or 
glycine.19 In addition to their role as antimicrobial agents, bile acids also stimulate the growth of 
selected bacterial species.5 Similarly, these properties are determined both by the hydroxylation 
pattern and the conjugation status of the bile acid steroid nucleus. For example, increased intestinal 
levels of bile acids carrying a hydroxyl group at position C7 of the steroid core favor the growth of 7α-




acids in conjugated bile acids act as microbial substrates for distinct bacterial groups; glycine is 
metabolized by Clostridium species,
22,23
 while taurine is a source of sulphite from which Bilophila 
wadsworthia derives energy for its growth.24,25 Interestingly, a diet high in saturated fat promotes 
taurine-conjugation of hepatic bile acids, resulting in the outgrowth of B. wadsworthia and 
exacerbation of colitis.26  
Considering that the gut microbial architecture and metabolism contribute to the course of IBD,
27,28
 
we compared the therapeutic effectiveness of UDCA and its taurine/glycine conjugates in DSS-
induced colitis in mice and investigated their impact on the fecal microbial community.  
 
MATERIALS AND METHODS 
Animals. Male 8-week-old C57Bl/6J mice were obtained from Harlan (Harlan Laboratories, Horst, The 
Netherlands) and maintained under standard laboratory conditions with ad libitum access to food 
(mice maintenance chow, Carfil Labofood, Pavan Service, Belgium) and water. Prior to the 
experiment, mice were co-housed to homogenize gut microbiota between experimental groups. 
After a one-week acclimatization, mice were assigned to the treatment groups based on body 
weights. In order to avoid bacterial cross-contamination between groups, mice of different treatment 
groups were housed in separate cages. The study was approved by the Institutional Review Board of 
the Faculty of Medicine and Health Science of Ghent University (ECD 2014-25). 
Bile acid treatment. Mice were divided into five groups (N=8 in each group). Three of them received 
bile acid treatment: UDCA (Tokyo Chemical Industry Co. Ltd, Toshima-Ku, Tokyo, Japan), TUDCA 
(Calbiochem, Darmstadt, Germany), or GUDCA (Sigma-Aldrich, Diegem, Belgium). Bile acids were 
dissolved in phosphate-buffered saline (PBS) or Labrafil® M1944 (Gattefosse, Saint-Priest Cedex, 
France) and administered daily by oral gavage (500 mg/kg/day). Treatments started at day 0 of DSS 
exposure. A non-DSS control group and DSS control group (referred to as placebo-treated group) 
received the vehicle (PBS or Labrafil®) alone.  
Induction and assessment of colitis. Acute colitis was established by adding 4% (w/v) DSS (molecular 
weight 36,000–50,000; MP Biomedicals, Illkirch, France) to the drinking water for 7 days, followed by 
normal water for 3 days. A non-DSS control group received normal drinking water throughout the 
experiment. Body weight and disease activity were recorded daily. A disease activity index (DAI) was 
calculated as the combined score of body weight loss (0, none; 1, 0-10%; 2, 10-20%; 3, >20%), stool 
consistency (0, normal droppings; 1, loose droppings; 2, diarrhea), and fecal blood loss (0, none; 1, 
hemoccult positive; 2, gross bleeding). Occult blood was detected using the Coloscreen Hemoccult kit 
(Helena Laboratories Inc., Beaumont, Texas, USA). Ten days after initiation of the experiment, mice 
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were anesthetized and blood was collected from the retro-orbital sinus. The mice were then 
sacrificed by cervical dislocation, the colons were removed, and their lengths were measured. 
Segments of distal colon were cut, rinsed with PBS, and frozen in liquid nitrogen. The blood was 
centrifuged (10.000 rpm for 10 min at 4°C) and serum was collected. All samples were stored at -80°C 
until further processing.  
Luminex. Colonic tissues were homogenized in PBS containing protease and phosphatase inhibitors 
and total protein concentration was measured using the Bradford method (Bio-Rad, Nazareth, 
Belgium). Protein levels of chemokine (C-X-C motif) ligand 1 (CXCL1), granulocyte colony-stimulating 
factor (G-CSF), and interleukin (IL)-6 were determined in colon homogenates and serum using the 
Bio-Plex Pro Mouse Cytokine Group I multiplex kit (Bio-Rad), according to the manufacturer’s 
instructions. Measurements were performed with the Bio-Plex MAGPIX Multiplex Reader and data 
were analyzed using the Bio-Plex Manager 6.1 software (Bio-Rad). 
DNA extraction from fecal samples. Fresh fecal pellets were collected at day 9 of colitis and 
immediately stored at -80°C. Total DNA was extracted from the fecal samples using the QIAamp DNA 
Stool Mini Kit (Qiagen Benelux, Venlo, The Netherlands). First, 180 to 220 mg of stool was 
resuspended in 1.4 ml buffer ASL. Then, 0.5 g 0.1 mm Zirconia beads (Biospec Products, Bartlesville, 
Oklahoma) and 4 glass beads (Biospec Products) were added and samples were homogenized by 
vortexing. The suspension was then heated at 95°C for 15 min and the manufacturer’s instructions 
were followed.  
Illumina sequencing. The V1-2 region of the 16S rRNA gene was amplified as previously described.29 
Briefly, in a first 20 cycle polymerase chain reaction (PCR) reaction, the 16S rRNA gene target was 
enriched using the well-documented 27F and 338R primers30,31 as previously specified.32 This 
reaction mixture was used as template in a second 15 cycle PCR reaction with primers comprising 
sequences complementary to the Illumina specific adaptors to the 5’-ends.29 The latter reaction 
mixture was then used as template in a third 10 cycle PCR reaction with primers designed to 
integrate both the sequence of the specific Illumina multiplexing sequencing primers and the index 
primers. Libraries prepared by pooling equimolar ratios of amplicons were finally sequenced on a 
MiSeq (Illumina, Hayward, CA, USA). Afterwards, reads were annotated as described by Verstraelen 
et al.33  
Illumina data analysis. Data analysis was performed as previously described.33 After resampling to 
the minimum sequencing depth using the phyloseq package34 from the R program,35 a total of 8,911 
reads were obtained. Rarefaction curves were generated using the vegan package from R.36 All 






 with a threshold of 80%. Relative abundances of all phylotypes were then compared 
between different experimental groups.  
Quantitative real-time PCR (qRT-PCR). Total fecal DNA was diluted 1:2 in water and 3 µl was used in 
qRT-PCR with SYBR Green (SensiMix™ SYBR No-ROX Kit, Bioline Reagents, UK) and 250 nM of each 
primer (BioLegio, Nijmegen, The Netherlands). Primer sequences used for amplification of A. 
muciniphila were 5’-CAGCACGTGAAGGTGGGGAC-3’ and 5’-CCTTGCGGTTGGCTTCAGAT-3’.
38
 A two-
step program was performed on the LightCycler 480 (Roche). Cycling conditions were 95°C for 10 
min, 45 cycles of 95°C for 10 s, and 60°C for 1 min. The amount of A. muciniphila 16S rRNA gene in 
each sample was normalized to the total amount of bacterial 16S rRNA gene. For the quantification 
of total 16S rRNA gene copies, fecal DNA was diluted 1:10 in water and the universal bacterial 16S 
rRNA gene primers PRBA338f 5’-ACTCCTACGGGAGGCAGCAG-3’ and PRUN518r 5’-
ATTACCGCGGCTGCTGG-3’ were used.
39
 Total bacterial load was calculated using the formula 2deltaCt / 
[total DNA concentration]. 
Bile acid quantification.  
Sample preparation. Fresh fecal pellets were collected at day 4 of colitis and immediately stored at -
80°C. Before bile acids were extracted from fecal samples, 20 µl of an internal standard solution 
(TUDCA-d5 (Santa-Cruz Biotechnology, Heidelberg, Germany) at 25 ng/µl in methanol (VWR 
International, Merck Millipore, Darmstadt, Germany)) was added to 25 mg feces. The extraction 
protocol started with the addition of 5 ml ice-cold acetonitrile (VWR International) containing 5% 
ammonium hydroxide (Merck Millipore, Darmstadt, Germany). The solution was homogenized with 
an Ultra-Turrax homogenizer, thoroughly mixed by vortexing for 1 min and then placed in an 
ultrasonic bath for 30 min. The resultant mixture was centrifuged at 9,000 x g for 10 min and 
supernatant was collected. The extraction procedure was repeated once more and the combined 
supernatants were subsequently evaporated under nitrogen at 40°C. Each dry extract was then 
resuspended in 200 µl of a 40:60 mixture of solvent A (7.5 mM ammonium acetate (Merck Millipore) 
in ultrapure water, pH 4.0) and solvent B (5% acetonitrile in methanol), centrifuged at 9,000 x g for 
10 min and supernatant was collected. To compensate for matrix effects, the standard addition 
method was applied for bile acid quantification.40 Briefly, supernatant was divided into two equal 
aliquots and transferred to liquid chromatography-mass spectrometry vials. One aliquot was spiked 
with 20 µl of the 40:60 mixture of solvent A and B. The other aliquot was spiked with 20 µl of bile 
acid solution (a 40:60 mixture of solvent A and B, supplemented with 16.5 ng/µl lithocholic acid (LCA; 
Sigma-Aldrich), 89.4 ng/µl UDCA (Simga-Aldrich), 0.75 ng/µl TUDCA (Calbiochem), and 0.75 ng/µl 
GUDCA (Sigma-Aldrich)). A 10 μl aliquot of each sample was injected into the ultra-high performance 
liquid chromatography with high resolution mass spectrometry (UHPLC-HRMS) system.  
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UHPLC-HRMS analysis. Chromatographic separation of bile acids was carried out on an Accela UHPLC 
system of Thermo Fisher Scientific (San Jos , CA, USA), with an Acquity UPLC HSS C18 column (1.8 
μm, 50 mm × 2.1 mm, Waters). The binary solvent system consisting of two solvents A and B was set 
at a constant flow rate of 300 µl/min at 35°C. For elution, a gradient profile was applied with the 
following proportions (v/v) of solvent A: 0 – 1.0 min at 40%, 1.0 – 6.0 min from 40% to 1%, 6.0 – 8.0 
min at 1%, 8.0 – 8.1 min from 1% to 40%, followed by 3.9 min of re-equilibration.  
HRMS analysis was performed on an ExactiveTM stand-alone benchtop mass spectrometer (Thermo 
Fisher Scientific), equipped with a heated electrospray ionization source (HESI-II), operating in the 
negative ionization mode. Ionization source working parameters were optimized and were set to a 
sheath, auxiliary, and sweep gas of 40, 5, and 1 arbitrary units (au), respectively, heater and capillary 
temperature of 120°C and 375°C and tube lens, skimmer, capillary, and spray voltage of 123 V, 22 V, 
43.5 V and 4 kV (+/-), respectively. A scan range of m/z 300-550 was selected and the resolution was 
set at 100,000 FWHM at 1 Hz (1 scan per second). The automatic gain control (AGC) target was set at 
high dynamic range (3 × E6 ions) and the maximum injection time was 100 ms.  
Data processing. HRMS data processing was performed with Xcalibur™ 3.0 (Thermo Fisher Scientific). 
The concentration of a selected bile acid was calculated using the following formula:40 
     
          
           
 
with Cunk being the unknown concentration of the bile acid in the original fecal sample, CSA being the 
spiked concentration of the bile acid in the fecal sample after standard addition, ARunk being the area 
ratio of the bile acid in the original sample, and ARSA being the area ratio of the bile acid in the fecal 
sample after standard addition. 
Statistical analysis. Statistical analysis was performed using SPSS Statistics version 22.0 (IBM SPSS, 
Chicago, USA) and GraphPad Prism version 4 (GraphPad, California, USA). All data are expressed as 
mean ± SEM. Data were tested for normality using the Kolmogorov-Smirnov test. Statistical 
significant differences between groups were assessed using the unpaired Student’s t-test for 
normally distributed data, applying the Welch’s correction in case of unequal variances, or the Mann-
Whitney U test for non-normally distributed data. Two-tailed probabilities were calculated and P-
values of less than 0.05 were considered statistically significant. 
Nucleotide sequence accession number. The sequence data were submitted to the European 
Nucleotide Archive (ENA) with accession numbers from LT700235 to LT702885 and can be accessed 







Oral administration of UDCA or its taurine/glycine conjugated species is equally protective in acute 
DSS-induced colitis  
To compare the therapeutic effects of UDCA and its taurine/glycine derivatives on DSS-induced 
colitis, C57BL6/J mice were challenged with 4% DSS for 7 days and treated daily with UDCA, TUDCA, 
or GUDCA by oral gavage. Bile acid therapy reduced the rate of body weight loss, with no differences 
in efficacy between the three bile acid treatments (Figure 1A). At day 10 after the initiation of colitis, 
body weight loss was significantly higher in placebo-treated mice than in bile acid-treated mice 
(P=0.027; P=0.021; and P=0.021 for treatment with UDCA, TUDCA, and GUDCA, respectively). 
Accordingly, the clinical disease activity score, colonic shortening, and colonic concentrations of 
CXCL1, G-CSF, and IL-6, which have been reported to show enhanced expression in the acute phase 
of DSS-induced colitis,41,42 were all attenuated following bile acid treatment (Figure 1B-D). At the 
systemic level, lower levels of CXCL1 and G-CSF, but not IL-6, were detected in the serum of bile acid-
treated mice as compared with the placebo-treated group (Figure 1E). Together, these data 
demonstrate that UDCA and its taurine/glycine conjugates decrease the severity of DSS-induced 
colitis with similar effectiveness. 
 








Figure 1. Oral administration of UDCA, TUDCA, and GUDCA improves clinical parameters and inflammatory markers 
in acute DSS-induced colitis. C57BL/6J mice received 4% DSS in the drinking water for 7 days, followed by normal 
water for 3 days. Control mice received water alone. From the start of DSS administration, mice were treated with 
UDCA, TUDCA, or GUDCA (500 mg/kg/d) by oral gavage. (A) Body weight changes during acute DSS-induced colitis. 
Body weights are represented as a percentage of their initial body weight at day 0. Results of a Mann-Whitney U test 
on day 10 are shown. (B) Clinical disease activity score. Results of a Mann-Whitney U test on day 9 are shown. (C) 
Colon lengths were assessed upon euthanasia on day 10. Cytokine levels of CXCL1, G-CSF, and IL-6 in (D) colonic tissue 
and (E) serum collected on day 10. Data are represented as the mean ± SEM from one experiment (N=8 in each 




Bile acid supplementation to mice challenged with DSS prevents colitis-associated dysbiosis at the 
phylum level  
Because bile acids have been recognized as modulators of the intestinal microbiota,
21,26
 which is 
believed to play a critical role in colitis,
1,28
 we questioned whether administration of UDCA or its 
conjugated derivatives prevented dysbiosis during experimental colitis. Fecal samples were collected 
two days after removing DSS from the drinking water (day 9), when colitis was fully established, and 
microbiota profiles were determined by 16S rRNA Illumina MiSeq sequencing. Four out of 40 mice 
were excluded from microbiota analysis because of insufficient amounts of feces available for DNA 
extraction. As expected, administration of DSS resulted in a significant reduction of species richness 
(number of operational taxonomic units; P=0.002; Figure 2A) and microbial diversity (Shannon index; 
takes into account both species abundance and evenness; P=0.002; Figure 2B). In addition, the total 
fecal bacterial load had dropped significantly to 22% of values seen in non-DSS control mice 
(P=0.002; Figure 2C). Compared to the placebo-treated group, microbial richness and diversity were 
slightly declined when colitic mice were treated with UDCA (P=0.086 and P=0.015, respectively), but 
no changes could be observed after the administration of TUDCA or GUDCA. Furthermore, daily 
administration of UDCA or its taurine/glycine conjugates during colitis did not affect the decrease in 
fecal bacterial load (Figure 2A-C).  
We next analyzed the fecal microbial composition at the major taxonomic hierarchy levels to 
determine if particular bacterial phyla were altered following bile acid therapy during active disease. 
Taxonomic assignment of the sequence reads revealed two dominant phyla, Bacteroidetes and 
Firmicutes, accounting for respectively 58.31% and 31.05% in fecal communities of non-DSS control 
mice. Other phyla present with an average relative abundance ranging from 4.50% to 0.09% were 
Proteobacteria, Deferribacteria, Candidatus Saccharibacteria, and Actinobacteria. Administration of 
DSS significantly altered the structure of the fecal microbiome. At day 9 of colitis, the 
Firmicutes/Bacteroidetes ratio increased in mice that were challenged with DSS (Figure 2D). More 
specifically, bacteria of the Bacteroidetes phylum were underrepresented in fecal samples of 
placebo-treated mice while the relative abundance of Firmicutes bacteria tended to increase (Figure 
2E). Interestingly, oral administration of TUDCA or UDCA normalized the Firmicutes/Bacteroidetes 
ratio, while GUDCA treatment showed a slight but non-significant tendency to reduce this ratio 
(P=0.12, Figure 2D). Compared to placebo-treated mice, the fecal microbial community of bile acid-
treated mice with colitis showed a lower abundance of Firmicutes and an increased abundance of 
Bacteroidetes (Figure 2E). These results show that bile acid therapy in DSS-induced colitis neither 
mitigate nor aggravate altered microbial richness and population diversity but corrects fecal 
microbiota dysbiosis at the phylum level.  




Bile acid supplementation to mice challenged with DSS alters the fecal microbiota at lower 
taxonomic levels 
To examine which bacterial populations accounted for the changes at phylum level, we investigated 
the relative abundance of bacteria at lower taxonomic levels. The abundance of unclassified 
Bacteroidetes was reduced upon DSS administration, whereas no changes were noted for Bacteroidia 
levels (Figure 3A). Interestingly, bile acid supplementation did not elicit an effect on unclassified 
Bacteroidetes but was associated with a significant increase in the abundance of Bacteroidia 
compared with placebo-treated mice (Figure 3A). Examination at the family level indicated that upon 
DSS challenge, the relative proportion of Bacteroidaceae and Porphyromonadaceae increased (Figure 
3B and C), while Prevotellaceae family members nearly completely disappeared in fecal samples of 
placebo-treated mice (0.03% vs. 6.64% in non-DSS control mice, Figure 3D). Interestingly, the relative 
abundance of Prevotellaceae increased to 2.24% and 2.61% when mice were treated with UDCA or 
TUDCA, respectively (Figure 3D). Moreover, Bacteroidaceae tended to further increase upon bile acid 
Figure 2. Oral administration of UDCA, TUDCA, and GUDCA during DSS-induced colitis prevents colitis-associated 
dysbiosis at the phylum level. Fecal samples were collected on day 9 of colitis and microbiota profiles were 
characterized by 16S rRNA Illumina MiSeq sequencing. Estimation of (A) species richness (i.e., total number of 
operational taxonomic units), (B) species diversity (i.e., Shannon index), and (C) bacterial load in the fecal microbiota. 
Bacterial load was calculated as 2
deltaCt
 / [total DNA concentration]. (D) Ratio of the percentage of 16S rRNA gene 
sequences belonging to Firmicutes and Bacteroidetes. (E) Composition of the fecal microbial community at the phylum 
level. Data are represented as the mean ± SEM from one experiment (N≥6 in each group). In the box-and-whisker 
plots, the box edges represent the 25th and 75th quartile, the line across the box shows the median, and the whiskers 
represent the minimum to maximum range of the data. *P<0.05, **P<0.01. C = Control; P = Placebo; T = TUDCA; U = 




supplementation, especially when mice were treated with UDCA (Figure 3B). Within Firmicutes, 
Erysipelotrichia expanded in the fecal samples of mice that were challenged with DSS, though bile 
acid therapy did not abrogate nor amplify this increase (Figure 3A). However, the relative abundance 
of Clostridia remained unchanged in the placebo-treated group, but declined in mice that were 
administered UDCA or derivatives (Figure 3A). Comparisons at the genus level further demonstrated 
that DSS-induced colitis was associated with the outgrowth of Clostridium clusters XI and XIVb and 
with a depletion of Clostridium cluster XIVa (Figure 3E; data not shown). As compared to the placebo-
treated group, colitic mice that were treated with UDCA or conjugates exhibited increased numbers 
of Clostridium cluster XIVa bacteria (Figure 3E). Clostridium species belonging to the clusters XI and 
XIVb, however, were not altered upon bile acid treatment (data not shown). Interestingly, sequences 
that were aligned to the Verrucomicrobia phylum were completely absent in the fecal communities 
of non-DSS control mice. Within this phylum, however, one genus (Akkermansia) expanded in the 
fecal samples of mice that were challenged with DSS. Akkermansia accounted for 0.047% of the 
detectable bacteria in the fecal samples of placebo-treated mice and the relative abundance further 
increased upon treatment with UDCA, TUDCA, or GUDCA (0.145%, 0.114% and 0.159%, respectively; 
Figure 3F). Given the importance of these species in IBD,3,4 the bile acid-induced enrichment of A. 
muciniphila was confirmed by qRT-PCR analysis (Figure 3G). 
 








Figure 3. Oral administration of UDCA, TUDCA, and GUDCA during DSS-induced colitis alters the fecal microbiota at 
lower taxonomic levels. Fecal samples were collected on day 9 of colitis and microbiota profiles were characterized by 
16S rRNA Illumina MiSeq sequencing. (A) Composition of the fecal microbial community at the class level. Percentage 
of 16S rRNA gene sequences belonging to (B) Bacteroidaceae, (C) Porphyromonadaceae, (D) Prevotellaceae, (E) 
Clostridium cluster XIVa, and (F) Akkermansia. (G) qRT-PCR results for A. muciniphila. Copy numbers were normalized 
to the 16S rRNA gene copy number in each sample. Data are represented as the mean ± SEM from one experiment 





Oral administration of UDCA, TUDCA, and GUDCA results in a similar fecal bile acid pool 
To compare the extent of biotransformation of orally administered UDCA, TUDCA, and GUDCA, we 
performed UHPLC-HRMS analysis on fecal samples collected at day 4 of colitis. This time point was 
chosen because changes in the bile acid composition have been suggested to reach a steady-state 
already within 4 days of bile acid administration.
43
 Due to insufficient quantities of feces, two mice 
were excluded from UHPLC-HRMS analysis. UDCA concentrations were significantly higher in fecal 
samples of mice administered UDCA or its taurine/glycine conjugates than in those of placebo-
treated mice (Figure 4A). Concomitant with these changes, we observed increased fecal levels of 
TUDCA and LCA in bile acid-treated mice (Figure 4B and C). Of note, these changes occurred 
irrespective of whether animals were treated with UDCA, TUDCA, or GUDCA and without significant 
differences between the three bile acid treatments. In contrast, administration of GUDCA caused a 
substantial increase in fecal GUDCA levels, while no elevation was observed in animals that were 
administered UDCA or TUDCA (Figure 4D). This finding is consistent with the fact that bile acids are 
predominantly conjugated with taurine (>97%), instead of glycine (<0.1%), in mice.44 Together, these 
data indicate that orally administered UDCA, TUDCA, and GUDCA are extensively metabolized in vivo, 







Figure 4. Orally administered UDCA, TUDCA, and GUDCA undergo extensive biotransformation. Fecal samples were 
collected at day 4 of colitis and bile acids were quantified using UHPLC-HRMS. (A) UDCA, (B) TUDCA, (C) LCA, and (D) 
GUDCA. Data are represented as the mean ± SEM from one experiment (N≥7 in each group). *P<0.05, **P<0.01. C = 
Control; P = Placebo; T = TUDCA; U = UDCA; G = GUDCA. 
 




Previous studies have reported the therapeutic potential of the hydrophilic bile acids UDCA and 
TUDCA in experimental colitis,
11,15,16
 albeit without comparing their respective effectiveness. In the 
present study, we showed that daily administration of UDCA and its taurine- and glycine-coupled 
conjugates equally attenuated body weight loss, disease activity, and colonic shortening caused by 
DSS. Moreover, oral bile acid therapy reduced proinflammatory cytokine concentrations in the colon 
and serum to a similar extent.  
Bile acids are important regulators of the intestinal microbiota,21 which plays a crucial role in the 
pathogenesis of IBD.
27
 In order to examine the role of UDCA and its taurine/glycine conjugated 
species in the regulation of the intestinal microbiota during colitis, we orally administered UDCA, 
TUDCA, or GUDCA to mice that were challenged with DSS and determined fecal microbiota profiles 
by 16S rRNA Illumina MiSeq sequencing. Consistent with previous studies, DSS-induced colitis was 
associated with distinct alterations in the population structure of the gut microbiota.45,46 These 
changes were generally characterized by a reduced overall microbial diversity and a decrease in 
species richness and bacterial load, which are also main hallmarks of dysbiosis in IBD patients.47,48 
We showed that oral bile acid administration did not prevent the DSS-induced changes in microbial 
richness, diversity, and bacterial load. Interestingly, species diversity decreased even more when 
colitic mice were treated with UDCA. However, although reduced richness and diversity of the gut 
microbiota have been associated with human disease,49–51 it seems unlikely that this effect is also 
clinically relevant; the clinical outcome in UDCA-treated mice was similar to that of mice that were 
treated with TUDCA or GUDCA. 
At the phylum level, TUDCA, UDCA, and to a lesser extent GUDCA, normalized the 
Firmicutes/Bacteroidetes ratio that was increased in placebo-treated mice with colitis. This ratio is 
often used as a proxy for microbial health status52–57 and, more specifically, to describe the degree of 
dysbiosis in IBD.55–57 Of note, the phylum-level population shifts from Bacteroidetes to Firmicutes 
induced by DSS in our study resemble those observed in obese individuals and in animals on a high-
fat diet, and have been associated with low-grade intestinal and systemic inflammation in 
obesity.58,59 In this context, fecal calprotectin and plasma C-reactive protein levels showed a positive 
correlation with bacteria belonging to the Firmicutes, whereas a negative correlation was found 
between C-reactive protein levels and specific groups within the Bacteroidetes.58 It is therefore likely 
that bile acid therapy counteracts the development of a “proinflammatory” microbiota during colitis. 
This is speculative since it remains unknown if the changes seen in the Firmicutes/Bacteroidetes ratio 




inflammatory effect. However, bile acid therapy did not prevent the DSS-induced decrease in 
unclassified members of the phylum Bacteroidetes but increased the relative abundance of 
Bacteroidia, which was not affected by DSS. Thus, we can speculate that bile acid therapy directly 
interferes with an imbalanced microbial environment. 
We demonstrated that Clostridium cluster XIVa species were significantly underrepresented upon 
DSS challenge, confirming previous observations in both human and experimental IBD.2,60–62 
However, oral administration of UDCA or its taurine/glycine conjugates was able to provoke an 
enrichment of these species compared with placebo-treated mice. It has been shown that selected 
members within the clostridial cluster XIVa possess 7α-dehydroxylation activity,
20
 which is involved 
in a multistep biochemical pathway converting UDCA to LCA.
63,64
 In our experiment, orally 
administered TUDCA and GUDCA were rapidly deconjugated to UDCA, so either bile acid treatment 
created a substrate-rich environment for these species. This may explain the bloom of Clostridium 
cluster XIVa that was observed in colitic mice that were treated with bile acids. Clostridium spp. 
belonging to cluster XIVa are important inducers of regulatory T cells in the colon.65 In addition, 80% 
of the butyrate-producing strains isolated from human fecal samples belong to the clostridial cluster 
XIVa.66 Butyrate is a short-chain fatty acid with distinctive anti-inflammatory properties that has 
already proven its efficacy in Crohn’s disease.
67
 However, butyrate-producing bacteria are depleted 
in the fecal microbiota of IBD patients.61,62,68 Thus, our observation that UDCA or its taurine/glycine 
conjugates increased the abundance of Clostridium cluster XIVa during colonic inflammation is of 
particular interest and may suggest an immunomodulatory role of these bile acids. 
Another finding of this study was the overrepresentation of Bacteroidaceae, Prevotellaceae, and 
Akkermansia in fecal samples of bile acid-treated mice following DSS exposure. These results might 
be related to the stimulatory effect of bile acids on mucin secretion as a defense mechanism to 
protect the gastrointestinal epithelium against potential bile acid toxicity.69–71 Bacterial species 
belonging to the genera Bacteroides, Prevotella, and Akkermansia produce one or more enzymes 
required for mucin degradation,72 which is enhanced during the acute phase of DSS-induced colitis.46 
Therefore, it is reasonable to assume that these bacteria can grow better in an environment that is, 
resulting from exogenous bile acid administration, enriched with mucins. A. muciniphila is a 
commensal bacterium residing in the mucus layer of the intestinal tract and has been shown to be 
reduced in IBD patients.3,4 Although conflicting results were obtained in studies assessing the role of 
Akkermansia in colonic inflammation, these species are thought to play a key role in the regulation of 
gut barrier function and mucosal immune responses toward the commensal microbiota.73,74  
The molecular structure of a bile acid determines its metabolism, physicochemical properties, and 
biological effects.75 In the present study, we used three bile acids sharing the same steroidal 
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hydroxylation pattern but differing in their amino acid conjugation pattern. Neither bile acid species 
tested proved to be more or less efficacious than the other in reducing colonic inflammation. 
Likewise, administration of UDCA induced similar changes in the bacterial community compared with 
its taurine/glycine conjugated species. These observations can be explained by the rapid in vivo 
biotransformation of orally administered bile acids by the liver and by the intestinal microbiota. With 
the exception of fecal GUDCA concentrations, which were only increased following GUDCA therapy, 
there were no differences in fecal concentrations of UDCA, TUDCA, or LCA between mice that were 
administered UDCA or its conjugates. This is in contrast with data from previous studies in patients 




 showing that, compared with UDCA, orally administered 
TUDCA undergoes reduced 7-dehydroxylation to LCA. It is conceivable that interspecies differences in 
intestinal microbiota account for these discrepancies. For example, deconjugation of TUDCA or 
GUDCA is a prerequisite for further 7-dehydroxylation and is catalyzed by bile salt hydrolases.
43
 
Because Lactobacilli, which express bile salt hydrolases, are more abundant in the mouse gut 
microbiota as compared to the human gut microbiota,
76
 it is likely that biotransformation of these 
conjugated bile acids occurs to a larger extent in mice. 
In summary, we report that UDCA and its taurine/glycine conjugated species ameliorate colonic 
inflammation in mice without differing in therapeutic effectiveness, and reduce DSS-induced fecal 
dysbiosis at the phylum level, irrespective of the bile acid conjugation status. As we demonstrated no 
advantage of using either the taurine or glycine conjugate of UDCA, we suggest that UDCA could be a 
safe and readily available treatment option for IBD. This conclusion is further supported by the 
current therapeutic use of UDCA in cholestatic patients77 and by its preventive effects on IBD-
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Inflammatory bowel disease, including Crohn’s disease (CD) and ulcerative colitis, is characterized by 
structural and functional dysbiosis, leading to changes in the host and microbial metabolism. These 
changes include increased levels of conjugated and sulfated bile acids and lower levels of secondary 
bile acids. We recently demonstrated that the secondary bile acid ursodeoxycholic acid (UDCA) 
alleviated murine colitis and associated fecal dysbiosis. In this study, we performed an open-label 
pilot trial to evaluate changes in fecal metabolic fingerprints in response to UDCA therapy in 
quiescent CD patients. Twenty-three CD patients in clinical remission were administered UDCA (12 
mg/kg/day) for four weeks. Fecal samples were collected from these patients, before and after UDCA 
therapy, as well as from healthy subjects, and ultra-high performance liquid chromatography 
hyphenated to hybrid Orbitrap high-resolution mass spectrometry was performed to generate a 
metabolic fingerprint. Orthogonal partial least squares discriminant analysis models revealed 
differentiating metabolic profiles between CD patients before and after UDCA therapy. Based on the 
abundance of those ions with the highest power to discriminate between pretreated and post-
treated CD patients, we were not able to distinguish CD patients from control subjects. However, 
UDCA therapy normalized the abundance of specific ions that exhibited increased abundance in CD 
patients as compared to control subjects. Structural elucidation and identification of these putative 
metabolites will help to identify molecular pathways altered by UDCA treatment and may provide 
important insights into the therapeutic potential of UDCA in IBD.  
 
  




Inflammatory bowel diseases (IBD), comprising Crohn’s disease (CD) and ulcerative colitis (UC), 
represent chronic inflammatory disorders of the gastrointestinal tract that are characterized by 
substantial shifts in the gut microbiota. Although such a dysbiosis is often described in terms of 
phylogenetic composition, profound changes in the functional composition of the microbiota are also 
observed in IBD and may ultimately result in metabolic abnormalities.1 In this context, recent 
metabolomics studies consistently revealed major differences in the fecal metabolic profiles between 
healthy subjects and IBD patients.2–9  
Bile acids are amphipathic molecules that are synthesized in the liver from cholesterol and further 
metabolized by intestinal bacteria.10 The abundances of bacterial genes involved in bile acid 
biotransformation are significantly altered in the gut microbiome of subjects with IBD.11,12 
Consequently, IBD patients exhibit alterations in their fecal bile acid profile, characterized by 
increased levels of conjugated and sulfated bile acids and lower levels of secondary bile acids.13 
Because secondary bile acids produced by the gut microbiota exert anti-inflammatory effects in 
vitro,13 one may suggest that changes in the capacity for microbial bile acid metabolism might 
participate in the onset and/or progression of IBD.  
The secondary bile acid ursodeoxycholic acid (UDCA) is an FDA-approved drug to treat primary biliary 
cirrhosis. Currently, its use has expanded to other cholestatic and non-cholestatic liver diseases and 
is even spreading to non-hepatic diseases.14 For example, patients with primary sclerosing cholangitis 
(PSC), a chronic cholestatic liver disease that is often associated with IBD, are frequently treated with 
UDCA, as it has been associated with improved biochemical and histological outcomes in PSC 
patients.15,16 In addition, we recently demonstrated that oral administration of UDCA markedly 
improved colonic inflammation and associated fecal dysbiosis induced by dextran sodium sulfate in 
mice.17 Extrapolation of these data to IBD patients is, however, complex because of interspecies 
differences in microbiome structure and bile acid metabolism.18,19  
Fecal metabolomics, i.e. the comprehensive study of small-molecule metabolites present in fecal 
samples, is emerging as a novel, non-invasive IBD diagnostic method.2 Moreover, such metabolomics 
approaches could be useful to determine disease progression and hold promise as a tool to evaluate 
the therapeutic efficacy of drugs used for IBD.6,7,20–22 In anticipation of a randomized placebo-
controlled trial to assess the efficacy of UDCA therapy to induce disease remission in IBD patients, we 
first designed and conducted an open-label pilot trial to evaluate the changes in fecal metabolic 






MATERIALS AND METHODS 
Patients and study design. A prospective, open-label cohort study was conducted at the University 
Hospital of Ghent, Belgium. The study cohort consisted of 23 CD patients in clinical remission and 23 
control subjects without gastrointestinal symptoms. Patients were included when following criteria 
were met: diagnosis of CD with a CD activity index (CDAI) of < 150 and age between 18 and 70 years. 
Exclusion criteria for both patients and control subjects were previous cholecystectomy; recent use 
of UDCA or antibiotics in the month prior to enrollment; and use of bile acid sequestrants. Patients 
received UDCA (Ursofalk®) at a dose of 12 mg/kg/day taken orally in divided doses (three times a day) 
for four weeks. Control subjects were not treated with UDCA. Patient characteristics are shown in 
Table 1. This study was approved by the Ethical Committee of the University Hospital of Ghent (n° 
2014/0784) prior to the start of the recruitment and was performed in accordance with the 
Declaration of Helsinki. Written informed consent was obtained from all participants.  
 
Table 1. Patient characteristics 
   
CD Control 
 
Number of subjects 23 23 
 
Gender (male/female) 12/11 12/11 
 
Age, years (mean, range) 38 (19-69) 37 (21-66) 
 
Years with disease (mean, range) 13 (1-33) - 
 
Disease location (L1/L2/L3) 3/8/12 - 
 





Adalimumab 4 - 
  
Infliximab 18 - 
  
Sulfasalazine 1 - 
  
Azathioprine 3 - 
  Methotrexate 1 - 
Abbreviations: IR ileal resection; AP appendectomy 
 
Sample collection and storage. All participants were provided with stool collection vials for at-home 
sampling. In the patient group, two samples were collected, with the first sample being collected 
before the initiation of UDCA treatment (CD-pre) and the second sample after four-week UDCA 
therapy (CD-post). Fecal samples collected from healthy subjects were used as control samples. All 
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samples were kept cold (4°C), delivered to the laboratory within 24 h after collection, and stored at  
-80°C for a maximum of one year until further analysis.  
Sample preparation. Sample preparation for metabolomics fingerprinting was performed according 
to Vanden Bussche et al.7 To prepare the fecal extracts, fecal samples were lyophilized for 48 h. Then, 
4 ml of ultrapure water was added to 200 mg of lyophilized homogenized feces and the suspension 
was vortexed for 1 min. Subsequently, 1 ml of a 80:20 mixture of ice-cold methanol and ultrapure 
water was added and the suspension was vortexed once more for 1 min. After centrifugation of the 
sample for 10 min at 13.300 x g, the supernatant was completely removed and passed over a 
polyamide filter (pore size of 0.45 µm and diameter of 25 mm). The extract was finally diluted 1:3 
with ultrapure water and transferred to a glass HPLC-vial. Quality control (QC) samples were 
prepared by pooling aliquots of random fecal extracts. 
UHPLC-Orbitrap-HRMS analysis. Untargeted metabolomics analysis was performed using a 
previously described ultra-high performance liquid chromatography hyphenated to hybrid Orbitrap 
high-resolution mass spectrometry (UHPLC-Orbitrap-HRMS) method.7 Briefly, the chromatographic 
separation of fecal metabolites was performed on an Accela UHPLC system of Thermo Fisher 
Scientific (San José, CA, USA) using an Acquity HSS T3 C18 column (1.8 µm, 150 mm x 2.1 mm, 
Waters) and a vanguard precolumn (1.8 µm, 5 mm x 2.1 mm, Waters). A binary solvent system was 
used with solvent A, ultrapure water and solvent B, acetonitrile, both acidified with 0.1% formic acid. 
A 10 µL aliquot of each sample was injected into the column and samples were injected in a 
randomized order. HRMS detection was performed on an ExactiveTM stand-alone benchtop Orbitrap 
mass spectrometer (Thermo Fisher Scientific) using a heated electrospray ionization source (HESI) 
operating in polarity switching mode. 
Data analysis. The raw HRMS data files first underwent multistep preprocessing using SieveTM 2.1 
software (Thermo Fisher Scientific). This preprocessing includes automated peak extraction, peak 
alignment, deconvolution, and noise removal and was performed separately for the positive and 
negative ionization mode.7 In order to correct for possible instrumental drift, the dataset was 
normalized using QC samples which were injected twice after every ten samples. The average signal 
of these two QC samples was used for normalizing the ten preceding samples.7 After normalization, 
an unsupervised principal component analysis (PCA-X) and orthogonal partial least squares 
discriminant analysis (OPLS-DA) model was created using Simca 14.0 (Umetrics, Sweden). Statistical 
significance for selected ions between groups was assessed by a one-way analysis of variance 
(ANOVA) with Bonferroni correction by GraphPad Prism 6 software. Data are represented as mean ± 






Untargeted UHPLC-Orbitrap-HRMS metabolomics analysis was performed on fecal samples from 23 
quiescent CD patients before and after UDCA therapy and 23 control subjects. After combining the 
datasets from both ionization modes, a total of 15.831 ions were extrapolated from the raw files 
(11.236 for the positive ionization mode; 4.595 for the negative ionization mode). The dataset was 
filtered in order to retain only the most relevant ions discriminating between before and after UDCA 
therapy (ions with a ratio between average abundance in pretreated CD patients and average 
abundance in post-treated CD patients of <0.66 or >1.5 and a P-value of <0.05). On this dataset of 
187 residual ions, multivariate regression techniques were applied. The resulting PCA-X score plot 
showed a clear separation between samples obtained before and after UDCA therapy (Figure 1A). 
Moreover, a validated OPLS-DA model was obtained (R2 = 0.88; Q2 = 0.70; PCV-ANOVA = 5.59 x 10
-9) and 
the corresponding score plot indicated a distinct clustering of samples based on the treatment, i.e. 
before versus after UDCA therapy (Figure 1B).  
 
We then evaluated whether fecal samples from pretreated CD patients could be separated from 
those from control subjects based on the 187 ions that were retained from the dataset (i.e. those 
ions that were most relevant to discriminate between patients before and after UDCA therapy). A 
PCA-X score plot did not reveal any outliers in the dataset. In addition, it did not show any separation 
between samples from CD patients and those from control subjects. Furthermore, the OPLS-DA 
model was not able to discriminate between samples according to the disease phenotype, as it could 
not be statistically validated (R2 = 0.50; Q2 = -0.11; PCV-ANOVA = 1). 
 
Figure 1. Plots generated by multivariate regression techniques for CD patients before and after UDCA therapy. PCA-
X score plot (A) and OPLS-DA score plot (B) generated from the 187 ions that were retained upon filtering (average 
abundance ratio of pretreated vs. post-treated CD patients of <0.66 or >1.5 and a P-value of <0.05) of the original 
dataset of ions detected in the fecal samples from CD patients before and after UDCA therapy. 
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In order to screen for features contributing most to the separation between CD patients before and 
after UDCA therapy, we created an S-plot from the OPLS-DA model that was generated from the 187 
ions present in fecal samples from pretreated and post-treated CD patients (cfr. Figure 1B). Ions with 
a variable importance to projection value of >1,5 were considered as the most discriminating ions. 
The abundance of these ions was significantly increased in fecal samples from CD patients following 
UDCA therapy, in comparison with those from pretreated CD patients. However, no significant 
differences in abundance were observed between samples from control subjects and pretreated CD 
patients (Figure 2), which was in line with the fact that no statistical valid model could be generated 




We particularly aimed to identify those ions whose abundance was significantly altered in CD 
patients, as compared to control subjects, and normalized following UDCA therapy. To this end, we 
calculated for each ion of the filtered dataset the ratio between the average abundance in pretreated 
CD patients and the average abundance in post-treated CD patients or control subjects. Only those 
ions with a ratio of <0.66 or >1.5 (for both control versus CD-pre and CD-pre versus CD-post) and a P-
value of <0.05 were selected. Using this approach, we retained a total of 12 ions that differed 
between pretreated CD patients on the one hand, and post-treated CD patients and control subjects 
on the other hand. The abundance of four ions increased in samples from pretreated CD patients, 
compared to samples from control subjects, and even further increased when patients were treated 
with UDCA. However, for all other ions, abundances increased in samples from pretreated CD 
patients and normalized to values similar to those observed in control subjects following UDCA 
therapy. Examples are shown in Figure 3. The structural and chemical identity of the corresponding 
putative metabolites remains to be determined. 
Figure 2. Normalized abundance of most discriminating ions between pretreated and post-treated CD patients 
identified in the fecal samples of control subjects and CD patients before and after UDCA therapy. *P<0.05; 
**P<0.01; ***P<0.001. Statistical significance was determined by one-way ANOVA followed by Bonferroni's post hoc 







The naturally-occurring secondary bile acid UDCA is frequently used as a therapeutic agent for 
cholestatic liver diseases, such as primary biliary cirrhosis and PSC.14 Because of its strong hydrophilic 
properties, as well as its cytoprotective and immunoregulatory actions, preclinical studies have 
previously examined the therapeutic potential of UDCA in intestinal inflammation. Collectively, these 
studies reported beneficial effects of UDCA in both colitis and ileitis, providing a rationale to 
investigate its clinical efficacy as add-on therapy in IBD patients.17,23–25 In the present study, we 
applied an untargeted metabolomics approach to evaluate changes in the fecal metabolome of 
quiescent CD patients in response to UDCA therapy. We demonstrated distinct changes in the fecal 
metabolic profile in CD patients administered UDCA. In addition, UDCA therapy normalized the 
abundance of several putative metabolites that were increased in CD patients as compared to 
control subjects.  
To our knowledge, this is the first study exploring fecal metabolomic differences in response to UDCA 
therapy. Fecal metabolomics represents an attractive approach to non-invasively characterize 
inflammation-induced changes in the metabolic profile associated with intestinal dysbiosis and, 
hence, to evaluate the efficacy of potential therapeutic agents in IBD.8 Although we showed that 
certain features appeared to normalize following UDCA treatment, we did not identify these putative 
metabolites. Further identification of these metabolites will be of major importance to better 
understand specific pathways targeted by UDCA therapy in IBD patients, and will require additional 
MS/MS experiments and/or alternative techniques (e.g. nuclear magnetic resonance spectroscopy). 
The gut microbiota produces a broad range of intestinal metabolites.26 Therefore, perturbations in 
the gut microbial community structure, which have been associated with CD,27 result in metabolomic 
Figure 3. Normalized abundance of selected ions that were increased in CD patients and normalized by UDCA 
therapy. *P<0.05; **P<0.01. Statistical significance was determined by one-way ANOVA followed by Bonferroni's post 
hoc test. 
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abnormalities.2,8,28 In our study, UDCA therapy was found to normalize a number of putative 
metabolites that were disturbed in CD patients, suggesting that UDCA potentially improves intestinal 
dysbiosis related to CD. Although this suggestion is supported by our recent observation that UDCA 
reduced colitis and associated fecal dysbiosis in mice,17 this is just a speculation that needs to be 
confirmed by 16S rRNA metagenomic approaches. Interestingly, Sabino et al. recently reported that 
intestinal dysbiosis present in IBD patients (both CD and UC) with concomitant PSC (IBD-PSC) under 
UDCA therapy resembled that of IBD-PSC patients not treated with UDCA.29 However, the microbiota 
of IBD-PSC patients was distinct from that of IBD-only patients, but not from that of PSC-only 
patients,29 implying that the observed dysbiosis in IBD-PSC patients is primarily associated with PSC 
rather than with IBD. Thus, further studies are needed to evaluate changes in microbial communities 
of IBD patients treated with UDCA, and to correlate these changes with fecal metabolomic changes. 
CD and UC are quite different clinical entities with regard to the gut microbial and metabolic 
composition.2,9,27,30,31 Similarly, microbial and metabolic signatures in CD patients correlate with 
disease activity and are more pronounced in patients with active disease.2,9,30–32 In order to ensure a 
homogeneous patient population, we only included patients with quiescent CD. Interestingly, 
medication use and intestinal surgery are also important confounding factors in studies evaluating 
metabolic profiles in IBD patients.8 For example, the ability to distinguish CD and UC patients based 
on their fecal metabolome is significantly influenced by anti-TNF antibody therapy or intestinal 
surgery.8 Therefore, these factors should be taken into consideration when performing studies to 
evaluate how a certain treatment affects the fecal metabolome. In our cohort, all patients, except for 
one, were treated with anti-TNF antibodies and only one patient underwent ileal resection. Based 
on the PCA-X and OPLS-DA models that were used, these patients did not appear to be different from 
the others.  
In summary, we demonstrated that UDCA therapy induced distinct changes in the fecal metabolome 
of CD patients and normalized the abundance of several putative metabolites that were altered in 
CD. Elucidating the structural and chemical identity of these metabolites will improve our 
understanding about pathways that are affected by UDCA therapy, and will provide novel insights 
into the therapeutic potential of UDCA in IBD. The preliminary data presented in this paper might 
pave the way for a randomized placebo-controlled study to evaluate the efficacy of UDCA therapy to 
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Inflammatory bowel disease (IBD) represents a group of chronic relapsing inflammatory disorders of 
the gastrointestinal tract, with two major forms: Crohn’s disease (CD) and ulcerative colitis (UC). 
Although its exact etiology remains poorly understood, bile acids are increasingly being recognized as 
crucial players in the pathogenesis of IBD. Besides perturbations in intestinal bile acid homeostasis, 
IBD patients suffer from profound changes in the fecal bile acid profile. The physiological properties 
of bile acids greatly depend on their chemical structure. Unlike other bile acid species, secondary 
hydrophilic 3,7-dihydroxy bile acids such as ursodeoxycholic acid (UDCA) and 
tauroursodeoxycholic acid (TUDCA) have long been known to possess cytoprotective properties. 
Consequently, these bile acids have been proposed as therapeutic agents in the treatment of IBD. 
The work presented in this thesis aimed to provide mechanistic insights into how secondary 
hydrophilic bile acids inhibit intestinal inflammation. In this chapter, we will discuss the main 
research outcomes described in chapters 3, 4 and 5 and outline some unresolved questions and ideas 
for future research.  
 
I.  TUDCA PROTECTS BILE ACID HOMEOSTASIS IN MODELS OF INTESTINAL INFLAMMATION 
As described in the introduction, a growing body of evidence suggests prominent defects in bile acid 
homeostasis in IBD. These defects include compromised bile acid uptake from the intestinal lumen 
(predominantly in terminal ileum) as well as improper signaling through anti-inflammatory nuclear 
receptors. TNF is a proinflammatory cytokine that plays a major role in the pathogenesis of IBD.1 
Transgenic TNFARE/WT mice overexpressing TNF develop severe CD-like chronic ileitis.2 In chapter 3, 
we demonstrated that bile acid transporters (ASBT, OST, and OST) and bile acid-activated nuclear 
receptors (FXR, PXR, and VDR) are downregulated both in ileal tissue of TNFARE/WT mice and in 
human enterocyte-like Caco-2 cells that were exposed to TNF.Apparently, these changes closely 
resembled those observed in our ileal mucosal biopsies from actively inflamed CD patients. 
Therefore, we believe that these models are suitable to study IBD-associated defects in bile acid 
homeostasis.  
Previous studies have implicated bile acids in the regulation of their own transport and signaling.3 We 
showed that TUDCA partly reverses the downregulation of bile acid transporters and nuclear 
receptors in both TNFARE/WT mice and TNF-stimulated Caco-2 cells. It is likely that TUDCA controls 
intestinal inflammation, at least in part, by augmenting the expression of FXR, PXR, or VDR. Indeed, 
these members of the nuclear hormone receptor superfamily evoke anti-inflammatory responses 
upon activation and agents capable to selectively activate such receptors are being explored as a 




VDR that can be produced from TUDCA by microbial conversion.7,8 We therefore suggest that TUDCA 
also increases anti-inflammatory signaling through these nuclear receptors by (1) providing putative 
ligands (i.e. LCA) for FXR, PXR, and VDR, and (2) by increasing the expression of apical bile acid 
transporters needed for conjugated bile acids to enter the cell and activate their nuclear receptors.  
One of the most interesting findings was that the downregulation of FXR could be antagonized by 
TUDCA. FXR is probably one of the most extensively studied bile acid-activated nuclear receptors 
because it regulates a broad range of metabolic processes. In this context, selective FXR agonists 
have been synthesized and are now being tested for their clinical efficacy in several hepatobiliary and 
gastrointestinal diseases.9 Of these, obeticholic acid, a highly potent semisynthetic FXR agonist 
derived from chenodeoxycholic acid, improves biochemical markers of primary biliary cirrhosis and 
was recently approved by the U.S. Food and Drug Administration for this indication.10 Preclinical 
studies indicate that obeticholic acid also represents a promising treatment option for IBD, as it 
ameliorated experimental colitis in mice and was able to counteract the production of 
proinflammatory cytokines by intestinal epithelial cells and immune cells in vitro.11 Unlike obeticholic 
acid, fexaramine is a synthetic, gut-restricted FXR agonist that is only poorly absorbed into the 
circulation.12 Therefore, fexaramine is thought to exert greater effects in the intestine, making it 
possibly a more promising therapeutic strategy for IBD.13 However, inadequate responses to FXR 
agonists are likely to occur in IBD patients, as they exhibit reduced expression of FXR in the intestinal 
mucosa.14,15 Since TUDCA was found to partly restore intestinal FXR expression, co-administering 
TUDCA with FXR agonists might provide an additional therapeutic benefit in IBD patients. Preclinical 
studies should address the value of such a combination therapy.  
Besides its beneficial effects on intestinal inflammation, accumulating evidence suggests a key role 
for FXR in the regulation of intestinal cell proliferation and colon carcinogenesis.16 Considering that 
IBD patients are at higher risk for developing colorectal cancer,17 and that FXR expression is weak or 
even absent in colonic mucosa from IBD patients,15,18 TUDCA might prevent the development of 
colorectal cancer by restoring FXR expression. These are, however, speculations that call for further 
research in mouse models of colitis and colitis-associated colorectal carcinogenesis.  
Another important finding was that TUDCA alleviates the downregulation of ASBT, the key 
mechanism for active bile acid uptake from the intestinal lumen. Disruption of the gene encoding 
ASBT results in bile acid malabsorption, which can eventually lead to diarrhea and steatorrhea.19 A 
retrospective study on ileal CD patients with chronic watery diarrhea revealed that 76% of CD 
patients who did not undergo ileal resection suffer from mild to severe bile acid malabsorption.20 
Hence, targeting the expression of ASBT may be beneficial in the treatment of IBD in terms of 




We demonstrated, both in vitro and in mice, that TUDCA protects intestinal bile acid homeostasis by 
partially restoring the expression of bile acid transporters and nuclear receptors. However, the 
effects observed in human Caco-2 cells did not completely mimic those observed in TNFARE/WT mice. 
This could be explained by the fact that externally delivered bile acids undergo extensive 
biotransformation in vivo (resulting in bile acid species with other physiological actions) which cannot 
be mimicked in vitro. Another explanation might be due to species-specific differences in the 
regulation of bile acid transporters and/or nuclear receptors. For example, FXR-mediated repression 
of ASBT in humans and mice is mediated through different mechanisms (i.e. through inactivation of 
liver receptor homologue-1 in mice, and retinoic acid receptor/retinoid X receptor in humans).21 
Hence, we are planning to evaluate whether TUDCA also protects intestinal bile acid homeostasis in 
human IBD patients. With regard to the design of such a clinical study, appropriate selection for 
medication use needs to be considered. More specifically, because previous studies have shown 
direct effects of corticosteroids on the expression ASBT, OST, and PXR,22–25 patients with recent or 
concomitant use of corticosteroids cannot be included in this study. 
The work presented in chapter 3 did not elaborate on the mechanistic aspects associated with the 
observed changes in bile acid transporter and nuclear receptor expression induced by TUDCA. Bile 
acids are able to regulate their own transport by modulating gene expression of ASBT, OST, and 
OST through activation of FXR.21,26,27 Though, it is unlikely that the effects demonstrated in our 
study are mediated by this receptor since TUDCA is only a weak FXR agonist.28 Moreover, FXR 
represses ileal ASBT expression,21,26 whereas in our study, TUDCA increased ASBT expression. Other 
receptors that have been implicated in the regulation of bile acid transporters include PXR, VDR, and 
the glucocorticoid receptor, as well as the bile acid-regulated peroxisome proliferator-activated 
receptor alpha.24,29,30 These ligand-activated receptors bind to their response element in the 
promoter region of ASBT, OST, or OST, thereby inducing or repressing gene expression. Besides 
enhancing the expression of bile acid transporters, we showed that TUDCA also increased gene 
expression levels of FXR, PXR, and VDR. Similar effects have been reported for other bile acids, 
however, the mechanisms involved in this regulation are largely unknown.28,31 One possibility is that 
these receptors are upregulated through (positive) autoregulatory loop mechanisms, whereby 
activation of a specific receptor induces its own expression. This has previously been demonstrated 
for VDR, which expression was increased in rat and human ileum slices incubated with 1,25-
dihydroxyvitamin D3.32 Alternatively, it is likely that activation of one nuclear receptor induces the 
expression of other receptors, as demonstrated elsewhere.33 Future studies should address the 




transporters and nuclear receptors. This can be done, for example, by antisense-mediated knock-
down of these receptors in Caco-2 cells, or using mice deficient for one of these receptors. 
Finally, we would like to emphasize that in the experiments presented in chapter 3, we exclusively 
focused on mRNA expression levels. Gene expression levels, however, do not necessarily correlate 
with protein expression levels. This is illustrated by Drozdzik and colleagues, who compared gene 
expression and protein content of several transporters in the intestinal epithelium of healthy donors. 
Although ASBT gene expression levels positively correlated with ASBT protein content, no correlation 
or even a negative correlation was found for other transporters.34 In addition, gene and/or protein 
expression data do not directly reflect protein localization and/or activity. Future studies addressing 
these aspects are required, for example using immunohistochemical techniques, or by ex vivo 
transport experiments on intestinal mucosa mounted in Ussing chambers. In addition, in order to 
understand the impact of TUDCA on nuclear receptor activity, the expression of specific target genes 
could be determined.  
 
II.  UDCA AND ITS TAURINE/GLYCINE CONJUGATES INDUCE BENEFICIAL AND SIMILAR CHANGES 
IN THE FECAL MICROBIOME OF COLITIC MICE 
Bile acids have been identified as regulators of the gut microbiota, which plays an important role in 
the pathogenesis of IBD.35 Given the fact that UDCA and TUDCA have been suggested to be beneficial 
for IBD, we considered it of interest to investigate how these bile acids affect the gut microbial 
community. In chapter 4, we focused on the impact of UDCA and its taurine/glycine conjugates on 
the composition of the fecal microbiome in a mouse model of acute colitis induced by dextran 
sodium sulfate (DSS). We demonstrated that oral administration of either bile acid was able to 
normalize the Firmicutes to Bacteroidetes ratio, which was increased by the induction of colitis. 
Although this ratio has been considered as a measure of dysbiosis and disease activity,36 it would be 
too simplistic to state that bile acid therapy restores the microbial community structure to a “healthy 
state”. This is further supported by the observation that neither bile acid treatment could restore 
microbial diversity and richness. Nevertheless, we showed specific changes in some bacteria known 
to be beneficial to host health. Administration of UDCA or its taurine/glycine conjugates increased 
the abundance of Clostridium cluster XIVa and Akkermansia muciniphila, both of which are depleted 
in IBD patients.37 Clostridium species belonging to cluster XIVa are commonly associated with 
butyrate production and the development of regulatory T cells,38 while A. muciniphila may be 




administration of UDCA or its taurine/glycine conjugates causes beneficial changes in the intestinal 
microbiota.  
It should be mentioned that we used fecal material in order to study gut microbial changes. The fecal 
microbiota generally represents the luminal niche of the intestinal microbiota, which differs 
markedly from the mucosa-associated microbiota, both in its diversity and composition.40 It has been 
postulated that the luminal microbiota is primarily involved in metabolism and nutrient digestion, 
whereas the mucosa-associated microbial community plays a major role in immunomodulation 
because it interacts more closely with host epithelial and immune cells.41 Thus, it should be 
worthwhile to additionally focus on how bile acid therapy influences the composition of the mucosa-
associated microbiota. Furthermore, it would be of interest to study microbial communities from 
different regions of the intestine (proximal, mid, and distal colon) after bile acid treatment because 
(1) different colonic regions exhibit clear differences in microbial composition,42 and (2) bacterial bile 
acid conversion occurs along the length of the intestinal tract and increases bile acid hydrophobicity 
from the proximal to the distal parts of the colon.43 The mucosal simulator of the human intestinal 
microbial ecosystem (M-SHIME) represents an excellent tool for these purposes and will be used in 
future experiments to study the effect of UDCA or its taurine/glycine conjugates on the mucosa-
associated microbiota in different gut regions. This dynamic in vitro gut model was adapted from the 
original SHIME system, which consists of five compartments simulating the stomach, small intestine, 
and the different regions of the large intestine (ascending, transverse, and descending colon). The M-
SHIME provides a niche for both luminal and mucosa-associated bacteria by incorporating an 
additional mucosal compartment using mucin-covered microcosms.44  
Finally, we have investigated the impact of bile acid therapy on the microbiota in a mouse model of 
acute colitis. Future studies should investigate whether prolonged bile acid therapy alters the 
microbial structure in chronic models of colonic, but also ileal, inflammation.  
Although the bile acid species used in this study share a very similar structure, it was surprising to 
observe similar changes in the fecal microbial composition following administration of UDCA or its 
taurine/glycine conjugates. Administration of TUDCA or GUDCA was thought to induce unique 
changes in the microbiome since, after deconjugation, taurine and glycine can be used as a substrate 
by distinct bacterial groups. In addition, conjugation of bile acids increases their hydrophilic character 
and is believed to reduce their conversion to more hydrophobic bile acids (exerting strong 
bactericidal actions).8 Consumption of a diet rich in saturated fat was previously shown to increase 
the proportion of taurocholic acid in bile. Of note, this taurine-conjugated bile acid, but not its 
glycine-conjugated counterpart, promotes the growth of the sulphite-reducing pathobiont Bilophila 




This prompted us to investigate whether administration of TUDCA induces the expansion of B. 
wadsworthia in our model. We found no changes in the relative abundance of B. wadsworthia in 
fecal samples of colitic mice that were treated with TUDCA, compared to placebo-treated mice with 
colitis. As expected, administration of UDCA or GUDCA had also no effect (unpublished data, Figure 
1A). B. wadsworthia uses taurine as an electron acceptor for anaerobic respiration, thereby 
generating hydrogen sulfide.46 We therefore incubated a human colonic microbial community with 
TUDCA or GUDCA to evaluate how these bile acids affect sulfide production in vitro. Microbial 
communities that were incubated with GUDCA produced only negligible amounts of sulfide, while 
sulfide production dose-dependently increased in the presence of TUDCA (unpublished data, Figure 
1B, see Addendum I for Supplementary materials and methods). Our observations parallel those of a 
study showing that cell extracts of B. wadsworthia produced sulfide only when taurine was added to 
the growth medium.47 Considering that sulfide might be involved in the pathogenesis of UC,48 it 
would be interesting to quantify the fecal release of sulfide following TUDCA treatment.  
 
 
Figure 1. (A) Acute colitis was induced in mice by adding 4% DSS to the drinking water and mice were treated daily with 
TUDCA, UDCA, GUDCA (500 mg/kg), or placebo. At day 9, fecal samples were collected and total DNA was extracted. B. 
wadsworthia levels were determined by quantitative real-time polymerase chain reaction and copy numbers were 
normalized to the 16S rRNA gene copy number in each sample. Data are represented as the mean ± SEM from one 
experiment (N≥6 in each group). C = Control (no DSS); P = Placebo; T = TUDCA; U = UDCA; G = GUDCA; (B) Sulfide 
production by a human colonic microbial community during incubation with TUDCA (left) or GUDCA (right) for 48 hours. 
Concentrations of TUDCA and GUDCA are indicated along the x-axis (in mM). Data are represented as the mean ± SEM from 
three replicates in one experiment. Detailed information on materials and methods is provided in Addendum I. *P<0.05; 






III.  ORAL BILE ACID THERAPY ATTENUATES INTESTINAL INFLAMMATION IN MICE 
Chapters 3 and 4 provide clear evidence that 3,7-dihydroxy bile acids exert therapeutic effects in 
preclinical models of IBD. In chapter 3, we studied the clinical effect of TUDCA therapy on the 
development of chronic inflammation in the ileum of TNFARE/WT mice. We found that early and 
prolonged administration of TUDCA to TNFARE/WT mice significantly improved the histological 
inflammation score and body weight gain, indicating that TUDCA therapy suppresses the severity of 
ileitis. The deregulated production of TNF in TNFARE/WT mice not only leads to ileitis but also to 
polyarthritis. Chronic inflammatory polyarthritis in these mice is associated with distortion of front 
and rear paw morphology, joint swelling, reduced grip strength, and impairment in movement.2 At 
15 weeks of age, just before sacrification, clinical symptoms of arthritis were evaluated and we did 
not observe reduced signs of arthritis in TNFARE/WT mice that were treated with TUDCA (unpublished 
data). Thus, TUDCA most likely induces local rather than systemic anti-inflammatory effects.  
The beneficial effect of TUDCA has been repeatedly described in the DSS model of colitis.49–51 
Similarly, administration of UDCA was shown to improve trinitrobenzene sulphonic acid-induced 
colitis in rats.52,53 Despite the increasing number of studies providing evidence for a therapeutic role 
of 3,7-dihydroxy bile acids in IBD, studies comparing their therapeutic efficacy have not yet been 
performed. In chapter 4, we demonstrated that UDCA and its taurine/glycine conjugates reduce in a 
similar way body weight loss, disease activity, and colonic shortening in a UC-like model of colitis 
induced by DSS.54 In addition, all forms of bile acid therapy lowered the colonic expression of CXCL1, 
G-CSF, and IL-6, further supporting the therapeutic potential of these hydrophilic bile acids in DSS-
induced colitis. Hence, we believe that, when moving to clinical testing in human IBD, UDCA should 
be considered, especially since this bile acid is approved by the U.S. Food and Drug Administration for 
the treatment of primary biliary cirrhosis. 
Previous studies suggest that bile acids exert immunomodulatory actions on immune cells and 
intestinal epithelial cells.55–61 Some of our preliminary data showed a strong inhibitory effect of UDCA 
and its taurine/glycine conjugates on macrophage activity in vitro; incubation of THP-1 cells, 
differentiated into macrophages by phorbol 12-myristate 13-acetate, with UDCA or its 
taurine/glycine conjugates induced a marked decrease in the release of proinflammatory cytokines 
and chemokines following stimulation with lipopolysaccharide (LPS) (unpublished data, Figure 2, see 
Addendum I for Supplementary materials and methods). Such actions could help to reduce the 
inflammatory response in the intestinal mucosa because during inflammation, circulating monocytes 
are recruited to the intestine and differentiate into macrophages which may promote chronic 





Figure 2. Phorbol 12-myristate 13-acetate (PMA)-differentiated THP-1 cells were treated with LPS (100 ng/ml) alone or 
simultaneously with TUDCA, UDCA, or GUDCA. After 24 hours, concentrations of (A) TNF, (B) IL-6 and (C) monocyte 
chemoattractant protein (MCP)-1 were measured in cell culture supernatant by Luminex bead assay and (D) lactate 
dehydrogenase (LDH) release was determined spectrophotometrically. Data are represented as the mean ± SEM from three 
replicates in one experiment repeated once with similar results. Detailed information on materials and methods is provided 
in Addendum I. *p<0.05; **p<0.01; ***p<0.001, as compared to LPS-stimulated control. Statistical significance was 
determined by one-way ANOVA followed by Bonferroni's post hoc test.  
 
The observation that UDCA shows similar efficacy as its taurine/glycine conjugates to attenuate 
cytokine/chemokine production from THP-1-derived macrophages corresponds with the finding that 
these bile acids induced a similar clinical effect on DSS-induced colitis. However, the question 
remains of which mechanisms are involved in the immunosuppressive effects of UDCA and its 
conjugates on THP-1 cells. First, bile acid-induced membrane damage and subsequent toxicity are 
unlikely, as demonstrated by a lactate dehydrogenase assay (Figure 2D). In addition, conjugated bile 
acids are more hydrophilic than the unconjugated ones and consequently, they cannot enter the cell 
via passive diffusion. Since monocytes/macrophages do not express bile acid transporters, the 
immunosuppressive effects of TUDCA and GUDCA on THP-1 cells are possibly mediated via 
extracellular mechanisms. A role for the bile acid-activated G protein-coupled receptor TGR5 seems, 




other, yet unknown, membrane bound receptors might be involved, it is possible that TUDCA and 
GUDCA inhibit the specific binding of LPS to its receptor. Similar findings were previously reported by 
Saitoh and colleagues, showing reduced binding of TNF on colonic HT-29 cells in the presence of 
taurine-conjugated bile acids.60 This suggestion should be further investigated, for example, by using 
a biotinylated form of LPS that can be easily detected and localized via fluorescence microscopy. In 
addition, it should be determined whether or not the mechanisms involved in the 
immunosuppressive effects of UDCA are similar to those of its conjugated derivatives. More 
specifically, as unconjugated UDCA might enter the intracellular compartment through passive 
diffusion, it could possibly activate several receptors with reported anti-inflammatory properties, 
such as PXR and the glucocorticoid receptor.64–66 This should be further studied using specific PXR 
and glucocorticoid receptor inhibitors, or by knocking-down these receptors in THP-1 cells. Finally, 
further research is necessary to evaluate whether UDCA and its taurine/glycine conjugates also 
modulate the function of other immune cells, such as dendritic cells and T lymphocytes. 
 
IV.  CHANGES IN THE FECAL BILE ACID POOL FOLLOWING ADMINISTRATION OF UDCA AND ITS 
TAURINE/GLYCINE CONJUGATES 
LCA is a secondary bile acid that may contribute to colon carcinogenesis by suppressing apoptosis of 
colonocytes and promoting their proliferation.67 This carcinogenic bile acid is produced from UDCA 
via direct 7-dehydroxylation or by 7-dehydroxylation of chenodeoxycholic acid, which arises from 
7-epimerization of UDCA.68 Consequently, increased intestinal LCA concentrations resulting from 
UDCA therapy might increase the risk for colorectal cancer. Bile acid deconjugation is an absolute 
requirement before bile acid dehydroxylation can take place. In this regard, it has been suggested 
that conjugation of UDCA protects the bile acid steroid nucleus from bacterial 7-dehydroxylation, 
thereby limiting its biotransformation to LCA.69 Accordingly, studies comparing the metabolic fate of 
orally administered UDCA and TUDCA demonstrated that TUDCA undergoes less biotransformation 
to LCA as compared to its unconjugated counterpart.8,69 
In chapter 4, we compared the extent of biotransformation of UDCA with that of its taurine/glycine 
conjugates. Mice were administered UDCA, TUDCA, or GUDCA for 4 days and fecal excretion of 
selected bile acid species was quantified using ultra-high performance liquid chromatography 
coupled to high-resolution mass spectrometry. Fecal excretion of UDCA, TUDCA, and LCA was higher 
in mice that were administered either UDCA or its taurine/glycine conjugates without any significant 




administered GUDCA exhibited a significant increase in fecal GUDCA levels. Collectively, these results 
indicate that, in mice: 
(i) TUDCA and GUDCA undergo significant deconjugation to UDCA; 
(ii) UDCA undergoes either reconjugation with taurine, but not with glycine, or is converted 
to LCA by 7-dehydroxylation; 
(iii) UDCA and its taurine/glycine conjugates are equally prone to intestinal 
biotransformation to LCA. 
The finding that UDCA is converted to the carcinogenic bile acid LCA suggests that prolonged UDCA 
therapy may contribute to the development of colorectal cancer. This is an important issue since 
UDCA has been widely used in the clinic for the treatment of cholestatic liver diseases. We also 
demonstrated that fecal excretion of LCA is similarly increased during administration of TUDCA or 
GUDCA. Therefore, we believe that, at least in mice, taurine/glycine conjugates of UDCA have no 
advantage over UDCA that may have a positive outcome in the longer term. Our findings are in direct 
contrast to previous studies showing that UDCA is more susceptible to biotransformation than 
TUDCA.8,69 However, the study presented in this doctoral thesis evaluated the metabolic fate of 
UDCA and its taurine/glycine conjugates in a mouse model of colitis, whereas the aforementioned 
studies were performed on rats or patients with primary biliary cirrhosis.8,69 We assume that 
differences in the gut microbiota, either species-specific or related to a disease phenotype, might 
account for changes in bile acid biotransformation.  
The (possible) carcinogenic effect induced by UDCA or its taurine/glycine conjugates can be 
circumvented by synthesizing bile acid homologues that are resistant to modification by the 
intestinal microbiota. For example, UDCA modified through methylation at position C6 or C7 was 
shown to undergo less bacterial 7-dehydroxylation than the normally occurring bile acid.70,71 It would 
be very interesting to study the biological effect of such a synthetic bile acid in preclinical models of 
IBD. Nevertheless, it should be stressed that a recent cohort study in which patients (mainly with 
chronic liver diseases) taking UDCA were followed up for a median of 5 years, showed a 
chemopreventive, rather than a carcinogenic, effect of UDCA on colorectal cancer development.72 
First, it is likely that the carcinogenic effect of LCA is counteracted via several detoxification 
mechanisms; as described in chapter 3, TUDCA enhances the expression of FXR, PXR, and VDR, which 
are activated by LCA to promote the transcription of metabolic phase I and phase II detoxification 
enzymes.73 Second, besides a high fecal excretion of LCA in bile acid treated mice, our study also 




counteracts the cytotoxic effects of hydrophobic bile acids,74 and therefore we strongly believe that 
the potential carcinogenic effect of LCA is neutralized by UDCA.  
Our results further demonstrated that the fecal bile acid pool becomes significantly enriched with 
hydrophilic bile acids (UDCA and its conjugates) following oral bile acid therapy in mice. Increasing 
the hydrophilic character of the intestinal bile acid pool could be a mechanism by which 
administration of UDCA or its taurine/glycine conjugates reduces susceptibility to colitis. Indeed, 
fecal bile acid hydrophobicity is positively correlated with the severity of DSS-induced colitis,75 which 
can be related to the tissue-disrupting effects of hydrophobic bile acids.76 In this context, UDCA 
counteracts barrier disruption induced by hydrophobic bile acids and high-fat diet-induced intestinal 
permeability is associated with a lower proportion of fecal UDCA.77 Enrichment of the bile acid pool 
with hydrophilic bile acids is also thought to be (one of) the mechanism(s) of action of UDCA in the 
treatment of other disorders; the therapeutic use of UDCA in chronic cholestatic liver diseases is 
based, in part, on the replacement of hydrophobic bile acids with UDCA, which reduces the damage 
to hepatocytes and biliary cells.78 Besides cholestatic disorders, it was also suggested that UDCA 
prevents the development of colon cancer by reducing the proportion of the hydrophobic bile acid 
deoxycholic acid.79 
 
V.  FROM BENCH TO BEDSIDE? 
Although mouse models represent a valuable tool to evaluate the efficacy of novel therapeutic 
agents, extrapolation of these data to humans is, however, complex. First, one should be aware that 
the mouse models used for IBD research only partially resemble human IBD. In addition, prominent 
differences exist between humans and mice with respect to bile acid composition and metabolism. 
For example, humans produce only two primary bile acid species whereas mice produce five. 
Furthermore, human bile acids are mainly conjugated with glycine while in mice, bile acids are almost 
exclusively conjugated with taurine.80 Finally, although the intestinal microbiota of humans and mice 
are quite similar at the phylum level, large differences exist at lower taxonomic levels (mainly the 
genus and species level).81 Human flora-associated mice, i.e. germ-free mice colonized with a human 
fecal flora, could therefore provide a better model to study the influence of exogenous bile acid 
therapy on the intestinal microbiota and the fecal bile acid composition. However, although this 
model is frequently used to investigate how dietary components or therapeutics (such as antibiotics, 
probiotics, and prebiotics) affect bacterial composition and metabolism, the established intestinal 





In order to validate our preclinical results in humans, we recently designed and initiated an open-
label pilot study in which we intend to:  
(i) Characterize changes in the fecal microbiome and metabolic profile of IBD patients with 
active disease and in clinical remission following UDCA therapy; 
(ii) Evaluate the effect of UDCA therapy on clinical symptoms and inflammatory markers in 
IBD patients with active disease. 
This study was approved by the Ethical Committee of the University Hospital of Ghent (n° 2014/0784) 
and is still ongoing. The first preliminary results are shown in chapter 5.  
We chose to use UDCA in this study because this bile acid is approved by the U.S. Food and Drug 
Administration for the treatment of primary biliary cirrhosis and, as presented in this thesis, shows 
similar therapeutic effectiveness as its taurine/glycine conjugates in murine colitis. However, 
considering the interspecies differences in intestinal microbial composition and bile acid composition 
and metabolism between humans and mice,80,81 it is still likely that UDCA and its conjugates have 
different therapeutic outcomes in human IBD patients. 
Based on previously published results,51,85 the bile acid doses used in the animal studies presented in 
chapters 3 and 4 were set at 500 mg/kg/d (corresponding to 2 g/l in drinking water86). This dose is 
quite high as it equates to a human dose of about 40 mg/kg/d,87 thereby exceeding the 
recommended UDCA dose for primary biliary cirrhosis (approximately 12 mg/kg/d).88 Interestingly, 
this recommended dose corresponds to 160 mg/kg/d in mice, which is still much higher than other 
UDCA doses found to be effective in reducing intestinal inflammation.52,89–91 Therefore, the UDCA 
dose used in the pilot study presented in this thesis was set at 12 mg/kg/d.  
For many years, UDCA is a commonly used drug for primary sclerosing cholangitis (PSC), a cholestatic 
liver disorder that is closely linked to IBD.92,93 Since PSC patients with co-existing IBD are at high risk 
for developing colorectal cancer,94 several studies have investigated the efficacy of UDCA in the 
prevention of colorectal cancer in those patients.95–97 Though, these studies did never focus on a 
potential effect of this bile acid towards the co-existing intestinal inflammation. One recent study 
focused on the intestinal microbiota but did not demonstrate any effect of UDCA therapy on 
microbial dysbiosis in PSC patients with co-existing IBD.98 These findings are in direct contrast with 
our observation that UDCA reduced colitis-associated fecal dysbiosis in mice. However, the microbial 
signature of IBD patients with concomitant PSC is primarily associated with PSC, and not with IBD.98 
Our preliminary results presented in chapter 5 showed that UDCA therapy normalized fecal levels of 
several putative metabolites that were significantly altered in quiescent CD. These metabolomic 




work is planned in order to identify these metabolites. In addition, metagenomics approaches will be 
applied to study how UDCA therapy influences microbial community composition and function. A 
final integration of the metabolomics and metagenomics data may provide important insights into 
pathways that are affected by UDCA therapy. As a second part of this study, we will focus on patients 
with active disease, as they exhibit a higher degree of intestinal dysbiosis compared to quiescent IBD 
patients.100,101 Moreover, we will assess whether these patients show clinical improvement following 
UDCA therapy by measuring clinical and biochemical parameters of disease activity. The results 
obtained in this pilot study will hopefully pave the way for a large-scale randomized placebo-
controlled trial designed to evaluate the efficacy of UDCA therapy in achieving disease remission in 





VI.  GENERAL CONCLUSION 
The work described in this thesis aimed to further explore the beneficial role of secondary 
hydrophilic bile acids in IBD (Figure 3). We showed that the expression of anti-inflammatory nuclear 
receptors and bile acid transporters are reduced in ileal biopsy specimens from CD patients and that 
these changes are mimicked by in vitro and mouse models of intestinal inflammation. Using these 
models, we demonstrated that the observed defects in bile acid homeostasis were reversed by 
TUDCA. It is known from the literature that bile acids exert bactericidal activity and may alter the 
composition of the intestinal microbiome. We showed that administration of TUDCA and two 
derivatives (UDCA and GUDCA) partly prevented colitis-associated dysbiosis and increased the 
abundance of Clostridium cluster XIVa and Akkermansia muciniphila, which are beneficial to 
intestinal health. These effects were associated with attenuation of the inflammatory responses in 
ileal and colonic inflammation in mice. In addition, either bile acid treatment resulted in a 
comparable increase in fecal TUDCA, UDCA, and LCA levels. Together with previously published data, 
our findings suggest that secondary hydrophilic 3,7-dihydroxy bile acids warrant clinical 
investigation for the treatment of IBD. Based on this, we initiated a pilot trial in IBD patients in order 
to study the efficacy of UDCA to correct fecal dysbiosis and metabolomic alterations and to induce 
disease remission. This study may provide novel insights into the therapeutic potential of UDCA in 
human IBD. 
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ADDENDUM I: SUPPLEMENTARY MATERIALS AND METHODS  
1. Batch incubation of an in vitro cultivated colon suspension and sulfide measurement.  
Batch incubations were performed as described previously.1,2 Briefly, an in vitro cultivated colon 
suspension was obtained from the Mucosal Simulator of the Human Intestinal Microbial Ecosystem 
(M-SHIME),3,4 which was incubated with a fecal sample from a healthy volunteer. Suspensions taken 
from the colon ascendens were diluted 1:5 in sugar-depleted SHIME nutritional medium (0.1 M 
potassium phosphate buffer pH 5.9, supplemented with 3 g/l yeast extract (Oxoid, Aalst, Belgium), 3 
g/l proteose peptone (Oxoid), 1 g/l mucin type II from porcine stomach (Sigma-Aldrich, Diegem, 
Belgium) and 0.5 g/l L-cystein) in penicillin bottles, supplemented with 0.1-10 mM TUDCA or GUDCA. 
To obtain anaerobic conditions, the bottles were closed with butyl rubber stops and flushed with N2 
(15 cycles of 2 min each, at 800 mbar overpressure and 900 mbar underpressure). The tubes were 
put on atmospheric pressure and incubated at 37°C. Each condition was performed in triplicate. After 
48 hours, samples were taken and sulfide (S2-) concentrations were determined using Nanocolor® 
Sulfide 3 tube tests (Macherey-Nagel, Düren, Germany). 
 
2. Incubation of THP-1 cells with lipopolysaccharide and bile acids.  
The human monocytic THP-1 cell line was maintained in Roswell Park Memorial Institute (RPMI) 1640 
medium supplemented with 1 mM sodium pyruvate, 10 mM HEPES, and 10% heat-inactivated fetal 
calf serum. Cells were seeded in 24-well plates at a density of 5 x 105 cells/well and treated with 50 
ng/ml phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich, Diegem, Belgium) for 48 hours to 
induce differentiation. After PMA exposure, THP-1 cells typically acquire both functional and 
phenotypic characteristics similar to those of macrophages.5 The differentiated THP-1 cells were then 
washed three times with phosphate-buffered saline and the wells were filled with THP-1 culture 
medium to allow the cells to recover from PMA treatment. The next day, the cells were incubated 
with TUDCA (Calbiochem, Darmstadt, Germany), UDCA (Tokyo Chemical Industry Co. Ltd, Toshima-
Ku, Tokyo, Japan), or GUDCA (Sigma-Aldrich, Diegem, Belgium) at different concentrations (0.01 mM, 
0.1 mM, or 1 mM) and three hours later, lipopolysaccharide (100 ng/ml) was added to the bile acid-
supplemented medium. Each condition was performed in triplicate. After 24 hours, cell culture 
supernatant was collected and the concentrations of tumor necrosis factor (TNF), interleukin (IL)-6, 
and monocyte chemoattractant protein (MCP)-1 were measured by Luminex bead assay (Bio-Plex Pro 
Human Cytokine Assay; Bio-rad, Nazareth, Belgium). Lactate dehydrogenase release into the medium 
was measured spectrophotometrically at 492 nm and 630 nm as reference wavelength using the 
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